



Published 2025
Issue 1, Volume 1

Journal of AI & Disease Dataset

Official Journal of Rawalpindi Medical University



AI-Driven Analysis of
Real-World Disease Data

Disclosure Statement

The Journal of AI & Disease Data Set (JAID) is the official journal of Rawalpindi Medical University (RMU). The articles published in this journal are based on real clinical patient data collected from three RMU-affiliated teaching hospitals: District Headquarters Hospital (DHQ), Holy Family Hospital (HFH), and Benazir Bhutto Hospital (BBH). JAID uses various artificial intelligence (AI) tools to help with writing, data analysis, and presentation of research. While the patient data used in all articles is real and clinically authentic, some parts of the written content or analysis are AI-assisted. RMU does not allow any material published in this journal to be copied, republished, or submitted to another journal or platform without prior written permission.

“And He taught Adam the names of all things.”
(Al-Baqarah 2:31)

“And We taught him the making of armor for you...”
(Al-Anbiya 21:80)

“Say, are those who know equal to those who do not know?”
(Surah Az-Zumar 39:9)



Editorial Policies

The Journal of AI & Disease Data Set (JAID)

Editorial Policies

The journal is dedicated to publishing scholarly articles in the field of Artificial Intelligence, with a particular focus on disease analysis and research using hospital and healthcare datasets. All manuscripts are prepared using various AI tools under careful human supervision and editorial oversight. The editorial team ensures the accuracy, relevance, originality, and academic integrity of the content. AI tools are used solely for content generation and are not recognized as authors of the articles. Each submission is reviewed to meet ethical standards, especially concerning healthcare data and research practices. The journal is committed to transparency and the responsible use of artificial intelligence in medical and health-related research.

Journal aims, scope and indexing

The Journal of AI & Disease Data Set (JAID) aims to promote high-quality research in the field of Artificial Intelligence, with a special focus on disease analysis and healthcare applications using hospital datasets. The journal encourages innovative and interdisciplinary research that applies AI techniques to real-world medical and clinical challenges.

The scope of JAID includes artificial intelligence, machine learning, deep learning, data analytics, medical informatics, and ethical AI practices. It publishes original research articles, review papers, and case studies that contribute to academic and practical advancements in AI.

Submission prerequisites and manuscript preparation

Manuscripts submitted to The Journal of AI & Disease Data Set (JAID) must be original, unpublished, and not under consideration elsewhere. All submissions should align with the journal's aims, particularly research involving Artificial Intelligence, disease analysis, and healthcare or hospital datasets. Authors/editors must ensure that ethical standards are followed, especially in the use of medical data, with proper anonymization and compliance where applicable.

Manuscripts should be prepared in clear and concise English with a logical structure, including title, abstract, keywords, introduction, methodology, results, discussion, and references. Proper citations from credible and verifiable sources are mandatory, and all references must be checked for accuracy. Figures, tables, and datasets should be clearly labeled and relevant to the study.

Authorship, acknowledgements and contributor statements

Authorship in The Journal of AI & Disease Data Set (JAID) is limited to individuals who have made significant intellectual or editorial contributions to the manuscript. Since manuscripts may be generated using AI tools, such tools are not recognized as authors. Human contributors are responsible for the accuracy, originality, ethical compliance, and final approval of the submitted work.

Acknowledgements should be used to recognize individuals, institutions, or organizations that provided support, resources, or guidance but do not meet the criteria for authorship. Any financial, technical, or institutional assistance should be clearly stated.

A contributor statement must be included, specifying the role of each contributor, such as conceptualization, data curation, editorial review, validation, and supervision. The use of various AI tools must be explicitly disclosed in this section to ensure transparency.

Research ethics, patient consent and data handling

The Journal of AI & Disease Data Set (JAID) requires that all research adhere to high ethical standards, particularly studies involving healthcare, disease analysis, and hospital datasets. Authors are responsible for ensuring that research is conducted in accordance with institutional, national, and international ethical guidelines.

For studies involving patient data, informed consent must be obtained where applicable, and the use of data should be approved by the relevant ethics committee or authority. All patient information must be properly anonymized to protect privacy and confidentiality.

Data handling practices must ensure accuracy, security, and responsible use of healthcare data. Authors must clearly state the source of datasets and confirm that data has been used solely for research purposes in compliance with ethical and legal requirements.

Peer review model, reviewer selection and standards

The Journal of AI & Disease Data Set (JAID) follows a **rigorous peer review process** to ensure the quality, accuracy, and integrity of published research. Manuscripts are evaluated based on originality, scientific merit, relevance to AI and healthcare applications, and adherence to ethical standards.

The journal employs a **single-blind editorial review model**, where reviewers remain anonymous to authors to encourage objective and unbiased evaluation. Reviewers are selected based on their expertise in AI, machine learning, healthcare analytics, and related fields, ensuring a thorough assessment of technical and methodological rigor. Reviewers are expected to provide constructive feedback, identify methodological or ethical concerns, and verify the credibility of references and data sources. All reviews are conducted confidentially, and conflicts of interest must be disclosed to maintain transparency and integrity throughout the review process.

Editorial governance, independence and conflicts of interest

The Journal of AI & Disease Data Set (JAID) is governed by an editorial board responsible for maintaining the scientific quality, integrity, and ethical standards of all publications. The board oversees manuscript evaluation, policy enforcement, and strategic direction, ensuring that the journal meets its academic objectives.

The editorial team operates independently of commercial, institutional, or personal influences, making decisions based solely on the scholarly merit and relevance of submitted work. Authors, reviewers, and editors are required to disclose any potential conflicts of interest that could affect impartiality.

Any identified conflicts are carefully managed to maintain transparency and trust in the publication process. The journal prioritizes ethical governance, unbiased editorial decisions, and accountability in all aspects of manuscript handling and publication.

Corrections, expressions of concern, retractions and article removal

JAID is committed to maintaining the integrity and accuracy of the scientific record. If errors, inaccuracies, or ethical issues are identified post-publication, the journal may issue **corrections** to clarify or amend the content.

In cases where concerns arise about the validity, reliability, or ethical compliance of a publication, the journal may publish an **expression of concern** while an investigation is conducted. If serious misconduct, data fabrication, or significant ethical violations are confirmed, the article may be **retracted**, with a clear explanation provided to readers.

Articles may be **removed** in exceptional cases where content poses legal, ethical, or safety risks. All corrections, expressions of concern, retractions, and removals are documented transparently to uphold the trustworthiness of JAID and the scientific community.

Copyright, licensing and reuse

All articles published in JAID are the intellectual property of the authors, with copyright retained by the journal under an open-access licensing model. Authors grant JAID the right to publish, distribute, and archive their work while ensuring proper attribution.

Plagiarism, text recycling and image manipulation

Manipulation of images, figures, or data to misrepresent results is strictly prohibited. Any adjustments to visual material must be clearly described and must not alter the scientific meaning. Violations of these standards may result in rejection, correction, or retraction of the article.

Use of artificial intelligence and similarity thresholds

The Journal of AI & Disease Data Set (JAID) recognizes the use of various artificial intelligence tools to assist in manuscript preparation, data analysis, or literature synthesis. Authors must **fully disclose the use of AI tools** in their work, specifying the role of AI and the extent of human oversight in content creation. AI tools are not considered authors, and human contributors remain responsible for the accuracy, originality, and ethical compliance of the manuscript.

Appeals, complaints and misconduct procedures

The Journal of AI & Disease Data Set (JAID) provides a transparent mechanism for authors, reviewers, and readers to raise **appeals or complaints** regarding editorial decisions, peer review, or publication processes. Appeals should be submitted in writing to the editorial office with clear justification, and they will be reviewed by senior editors or an independent committee. The journal takes **research misconduct** seriously, including plagiarism, data fabrication, ethical violations, or undisclosed conflicts of interest. All allegations are investigated thoroughly, maintaining confidentiality and fairness.

If misconduct is confirmed, appropriate actions may include corrections, retractions, sanctions, or reporting to relevant institutions. The procedures aim to protect the integrity of the scientific record while ensuring fairness and accountability for all parties involved.

Supporting materials, checklists and governance aids

The Journal of AI & Disease Data Set (JAID) provides authors, reviewers, and editors with a range of **supporting materials and checklists** to ensure the quality, transparency, and ethical compliance of submissions. These resources include manuscript preparation guidelines, data reporting templates, ethical compliance checklists, and AI usage disclosure forms.

Governance aids are provided to assist the editorial board in maintaining consistent review standards, managing conflicts of interest, and ensuring adherence to the journal's policies. Authors are encouraged to use these tools to improve manuscript completeness, clarity, and compliance with JAID editorial and ethical standards.

Disclaimer

JAID is a journal that publishes AI-generated reviews of medical research papers, case studies, and related content. The data used in these publications are collected from hospitals and other medical sources.

While JAID aims to provide accurate and reliable information, the content is AI-generated and may not always reflect complete clinical accuracy. JAID and its contributors do not assume responsibility for any medical decisions, treatments, or outcomes based on the content published in the journal.

All content is intended for informational and educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Readers are advised to consult qualified healthcare professionals for any medical concerns.

Editorial Board

Patron

Muhammad Umar
Vice Chancellor

Editor in Chief

Naeem Akhter
Director ORIC and PhD Programs
Riaz Ahmed
Dean of Orthopedic Neurosurgery & Trauma
Mehwish Iqbal
Additional Director ORIC
Mehwish Riaz
Assistant Professor, Community Medicine

Associate Editor

Amna Noor
Additional Director ORIC
Maham Yamin
Manager ORIC

Managing Editors

Muhammad Khurram
Professor and Dean of Medicine and Allied Health Sciences, Principal RMC
Usman Qureshi
Professor of Surgery
Tayyab Saeed Akhter
Senior Registrar, Gastroenterology
Sadiah Ahmed
Assistant Professor, Gastroenterology
Muhammad Mujeeb Khan
Head of the Department, Infectious Unit
Junaid Khan
Senior Registrar, Orthopedics
Saima Ambreen
Professor of Medicine
Khola Noreen
Associate Professor, Community Medicine
Faiza Aslam
Research Coordinator, NIHR-Global Health Research Centre for IMPACT
Rizwana Shahid
Associate Professor, Community Medicine
Farrah Pervaiz
Associate Professor, Community Medicine
Asma Nafisa
Director PhD Biochemistry Program
Fatima Javed Mirza
Manager ORIC

Editorial Board Members

Jehangir Sarwar Khan
Professor of Surgery
Asad Tameez-ud-Din
Professor of Psychiatry
Ifra Saeed
Professor of Anatomy
Ayesha Yousaf
Professor of Anatomy

Section Editors

Humera Noreen
Professor of Gynaecology/Obstetrics
Sadiah Chaudhry
Professor of ENT
Saima Ambreen
Professor of Medicine
Obaid Ur Rehman
Associate Professor of Orthopedic Surgery

International Members

Americas

Muhammad Bilal
Associate Professor of Medicine, University of Colorado, USA
Sohail Aman
Assistant Professor, Mobile Infirmary Medical Center, USA

Australia

Bashir Gondal
Consultant Emergency Physician, Monash Health/Monash University

Asia

Bilal Haider Shamsi
Assoc. Professor, Postgraduate Supervisor Northwest University China
Muhammad Iftikhar Hanif
Professor of Orthopedics, Newcastle University Medicine, Malaysia

National Members

Islamabad Capital Territory

Shahzad Ali Khan
Vice Chancellor, Health Services Academy
Umar Ali Khan
Prof of Physiology, Pro Vice Chancellor, Isra University

Balochistan

Shabir Ahmad Lehari
Vice Chancellor, Bolan University of Health & Medical Sciences, Quetta
Naqib Ullah Achakzai
Bolan University of Medical and Health Sciences Quetta Pakistan

Punjab

Muhammad Waris Farooka
Professor of Surgery, Principal Sargodha Medical College, Sargodha
Parvez Ahmed
Professor of Hematology, Pathwel Center of Hematology and Bone Marrow Transplant

Sindh

Muhammad Sadik Memon
Professor of Gastroenterology and Medicine, Asian Institute of Medical Sciences, Hyderabad



Introduction to RMU- Disease Data Centre

The presence of a Disease Data Centre (DDC) within a medical university is a strategic asset that underpins research excellence, evidence-based clinical practice, and public health surveillance. Serving as the nucleus of information management, the RMU-DDC systematically collects, stores, and analyses patient-level data across multiple disease categories.

By bridging clinical observation with research infrastructure, the DDC enables faculty, postgraduate researchers, and public health professionals to extract actionable insights from real-world data — ultimately advancing patient care and medical knowledge.

Vision & Mission

 Vision To become a leading national repository of disease-specific patient data, empowering evidence-based medicine and health policy across Pakistan.	 Mission To systematically collect, manage, and analyse high-quality clinical data, supporting research, education, and improved patient outcomes at RMU and its allied hospitals.
--	---

Scope & Objectives

	Comprehensive Data Repository	Systematic storage of patient records, lab data, and clinical outcomes across disease categories.
	Evidence-Based Research	Supporting faculty and postgraduate students with curated datasets for high-quality research.
	Precision Medicine	Enabling personalised treatment strategies through granular patient-level data analysis.
	Streamlined Clinical Trials	Facilitating participant recruitment, follow-up, and data analysis for ongoing trials.
	Quality Improvement	Tracking performance metrics and outcomes to drive continuous clinical improvement.
	Multidisciplinary Collaboration	Uniting clinicians, researchers, and public health professionals around shared data resources.

Data Management Policy

Rawalpindi Medical University fully recognizes the value and importance of protecting personal, medical, and research-related information. The University is committed to transparency and accountability, demonstrating compliance with established regulatory principles.

A robust Research Data Management Policy governs all DDC activities. This policy ensures:


- Proper recording, maintenance, and secure storage of research data
- Controlled and appropriate access to sensitive clinical datasets
- Protection of intellectual property rights (IPR) in all research outputs
- Alignment with national and international data protection standards

Components of RMU-DDC

The DDC currently manages eleven active disease-specific datasets. Collectively, these registries represent sample records spanning nearly two decades of clinical activity.

Table 1: Approximate patient/sample volumes across all DDC modules

Dataset	Period	Total Cases
HCV	2006-2025	9,650
Dengue	2022-2025	14,219
Diabetes (HbA1c)	2020-2025	18,277
Diabetic Retinopathy	2023-2025	1,355
Diabetic Retinopathy	2026	4,025
ICU Infections	2019-2024	1,949
Oncology	2022-2026	1,200
COVID-19	2020	198
Radiology (MRCP)	2021-2023	797
HCC	Till 2025	393
WHO Data – CRS	2023-2025	1,533
WHO Data - Rota Virus	2023-2025	1,257
WHO-Thyroid Data	2025	8,493
TOTAL		63,346



Source: Departmental Registry Data

Generated by Claude

Figure 1 — Approximate patient/sample volumes across all DDC modules

1. Hepatitis C

9,125 Total Patients	18 yrs Years of Data	2006–2024 Period
-------------------------	-------------------------	---------------------

The hepatitis C virus (HCV) remains a significant public health concern in Pakistan, contributing to the growing burden of chronic liver disease, cirrhosis, and hepatocellular carcinoma. Effective monitoring requires systematic collection and longitudinal analysis of patient-level data. Since 2006, the DDC has maintained a comprehensive HCV dataset comprising clinical, laboratory, and diagnostic records of 9,125 patients — the most extensive single-disease registry within the centre.




Figure 2 — Representative annual case volume trend, Hepatitis C dataset (2006–2024)

2. Dengue Fever

Dengue fever poses a recurring and significant health burden in Pakistan, particularly during seasonal outbreaks. Systematic data collection is critical for understanding disease trends, guiding patient management, and shaping public health interventions.

The DDC Dengue registry captures:

- Diagnostic tests: NS1 antigen, IgM and IgG antibody serology
- Ultrasonographic findings and day of illness (DOI) at admission
- Comorbid conditions: DM, HTN, Hepatitis B/C, COPD, asthma, IHD, CVA




Figure 3: Total number of cases in Dengue dataset

3. ICU Infections

The increasing prevalence of multidrug-resistant organisms (MDROs) in critical care settings presents a serious challenge to patient safety. As of September 2024, the dataset includes 1,949 microbiological samples collected from ICU patients since December 2019.

Sample distribution across ward types:

**ICU Sample Distribution by Ward
(Total: 1,949 samples)**




Figure 4 — ICU sample distribution by ward type ($n = 1,949$)

The dataset documents patient gender, specimen types, isolated organisms, and antibiotic susceptibility profiles enabling evidence-based antimicrobial stewardship.

4. Radiology (MRCP)

Magnetic Resonance Cholangiopancreatography (MRCP) is a non-invasive imaging modality crucial for diagnosing hepatobiliary and pancreatic disorders. The DDC Radiology module curates MRCP findings to support diagnostic research and outcome analysis.




Figure 5 — Radiology (MRCP) dataset summary chart

5. Oncology

Cancer surveillance plays a pivotal role in understanding disease burden, planning patient care, and informing public health policy. The RMU Oncology registry tracks diagnosis, staging, treatment pathways, and outcomes across major cancer types.

The bar chart illustrates the year-wise distribution of cancer patients from 2022 to 2025. In 2022, the number of patients was 121, representing the lowest value. A sharp increase followed in 2023, with the number of cases peaking at 279. However, in 2024, the patient count declined markedly to 183, indicating a reduction after the previous year's surge. In 2025, the number of cancer patients rose slightly again to 203. Overall, the data demonstrate a fluctuating trend, with a significant rise between 2022 and 2023, a decline in 2024, and a modest increase in 2025.




Figure 6 — Oncology dataset distribution by cancer type

6. Diabetes

Effective diabetes management depends on systematic collection of clinical, lifestyle, and complication-related patient data. The RMU Diabetes Registry provides a longitudinal view of glycaemic control and complication rates.




Figure 7 — HbA1c dataset summary chart

7. Diabetic Retinopathy

The Diabetic Retinopathy database compiles clinical and demographic information on patients with retinal disorders. It records visual acuity, disease severity grading, comorbidities, treatment interventions, and outcomes — supporting early detection strategies and evidence-based management.




Figure 8 — Diabetic Retinopathy dataset summary chart

Conclusion

The RMU Disease Data Centre represents a sustained and growing commitment to data-driven medicine at Rawalpindi Medical University. Spanning seven disease modules and nearly two decades of patient records, the DDC has established itself as a cornerstone of clinical research and academic scholarship at RMU and its allied hospitals.

The datasets maintained within the DDC are actively utilized for research publications and contribute directly to the Journal of AI & Disease (JAID), RMU's dedicated platform for disseminating data-driven clinical research. Through JAID, findings derived from these registries reach clinicians, researchers, and policy-makers both nationally and internationally, amplifying the translational impact of the data collected.

All patient data held within the DDC has been collected in full accordance with ethical research standards. Informed consent was obtained from all patients prior to inclusion in any dataset, and all records are stored securely in compliance with RMU's Research Data Management Policy. Patient privacy, confidentiality, and autonomy remain central to the operational principles of the Disease Data Centre.

As the DDC continues to expand its scope, it is poised to play an increasingly vital role in shaping evidence-based healthcare delivery, supporting postgraduate education, and advancing Pakistan's contribution to global medical research.

PREAMBLE

Why Rawalpindi Medical University needs Journal of AI & Disease Data set (JAID)?

In alignment with Rawalpindi Medical University Vision 2017–2025, which prioritizes research excellence, innovation, digital transformation, and societal impact, the Journal of AI and Disease Data (JAID) is proposed as a strategic academic initiative to strengthen RMU's leadership in data-driven healthcare research.

RMU's vision emphasizes the integration of modern technologies to improve healthcare delivery, medical education, and public health outcomes. Artificial Intelligence (AI) and disease data analytics are central to this transformation, enabling predictive diagnostics, precision medicine, intelligent disease surveillance, and evidence-based health policy. JAID will provide a dedicated, peer-reviewed platform to promote interdisciplinary research that connects clinical medicine, public health, biomedical sciences, and digital technologies, with a particular focus on diseases relevant to Pakistan and the region.

Through high-quality publications, JAID will enhance RMU's national and international research visibility, encourage collaborative research, support institutional digital initiatives, and contribute to capacity building in emerging health technologies. The journal will thus serve as a key instrument in achieving RMU's strategic goals under Vision 2025.

Aim and Scope of the Journal

The Journal of AI and Disease Data (JAID) aims to advance high-quality research on the application of Artificial Intelligence and data analytics in understanding, prevention, diagnosis, and management of diseases. The journal provides a credible academic platform for clinicians, researchers, data scientists, and postgraduate students to disseminate innovative and interdisciplinary research integrating medical sciences, public health, and AI technologies. JAID particularly encourages data-driven studies addressing local, national, and regional disease burdens, while strengthening RMU's research visibility, academic impact, and international collaborations. The journal also supports RMU's digital health, innovation, and research governance initiatives in alignment with Vision 2017–2025.

AI Journal and Its Usefulness for RMU

Rawalpindi Medical University (RMU) needs a dedicated Artificial Intelligence journal to respond to the rapidly evolving role of data-driven technologies in healthcare, medical education, and public health. As disease surveillance, diagnostics, and health system management increasingly rely on large-scale data and AI-based analytics, RMU requires an academic platform that captures, organizes, and disseminates such research in a focused and credible manner. The **JAID** will address this need by providing a specialized outlet for high-quality research relevant to local and regional disease patterns, which are often underrepresented in international journals.

JAID will be useful in strengthening RMU's research ecosystem by promoting interdisciplinary collaboration among clinicians, public health experts, and data scientists, improving research visibility and citations, and supporting evidence-based healthcare solutions. The journal will also enhance faculty and postgraduate research capacity, contribute to policy-relevant disease data analysis, and align with RMU's digital transformation initiatives under Vision 2017–2025. Ultimately, JAID will position RMU as a national leader in AI-driven medical research and innovation.

Insights from AI Experts on the Applications of Artificial Intelligence

Bertalan Meskó, MD, PhD

Physician, Medical Futurist, The Medical Futurist

“AI will not replace medical professionals, but those medical professionals who use AI will replace those who don’t.”

This is one of the most widely cited statements on AI in medicine and is frequently used in policy and academic discussions.



John D. Halamka, MD, MS

President, Mayo Clinic Platform; Professor of Medicine

“I think of AI not as artificial intelligence, but as augmented intelligence.”

“We want AI that does no harm. We want AI that is likely to give you benefits with minimal risks.”



Umar Saif, PhD

Founder & CEO of aiSight.ai; Chief Digital Officer at Jang Group Pakistan; CEO of Khudi Ventures; former Chairman of Punjab Information Technology Board; UNESCO Chair in ICT for Development

“AI is useless without data. Whoever controls the data, controls the future.”



Abstracts from Notable AI Journals



The Journal of Artificial Intelligence Research (JAIR) is dedicated to the rapid dissemination of important research results to the global artificial intelligence (AI) community. The journal's scope encompasses all areas of AI, including agents and multi-agent systems, automated reasoning, constraint processing and search, knowledge representation, machine learning, natural language, planning and scheduling, robotics and vision, and uncertainty in AI. <https://www.jair.org/index.php/jair>



IAES International Journal of Artificial Intelligence (IJAI), publishes articles in the field of artificial intelligence (AI). The scope covers all artificial intelligence (AI) and machine learning (ML) areas and their applications in the following topics: neural networks; fuzzy logic; simulated biological evolution algorithms (like genetic algorithms, ant colony optimization, etc); reasoning and evolution; intelligence applications; computer vision and speech understanding; multimedia and cognitive informatics etc. <https://ijai.iaescore.com/index.php/IJAI>



The Journal of Artificial Intelligence Research and Innovation is a premier open-access journal dedicated to advancing the field of artificial intelligence (AI) through innovative research and critical discourse. This journal aims to provide a platform for researchers, practitioners, and scholars to disseminate their findings and insights on various aspects of AI, including theoretical advancements, practical applications, and ethical considerations. <https://www.artificialintelligencepub.com/jairi>



Journal of AI & Disease Dataset (JAID)

Official Publication of Rawalpindi Medical University

VOL. 01

January, 2026

JAID.COM

A EDITORIAL POLICIES

Policies, Journals aims and scope

B SHORT REPORTS

1 Cancer prevalence in Pakistan

2 The Burden of Dengue in Pakistan: Transmission Dynamics, Risk Factors, and Recent Trends.

ORIGINAL ARTICLES

3 Age-Wise Variation in Glycemic Control and Lipid Profile Among Diabetic Patients: A Retrospective Study from Benazir Bhutto Hospital, Rawalpindi (**DDC Data code: RMU-ORIC-DDC-DM-25-001, Dr Madeeha Nazar**)

4 Middle-Aged Diabetic Patients as a High-Risk Group for Poor Glycemic Control and Dyslipidemia: A Retrospective Study from a Tertiary Care Hospital (**DDC Data code: RMU-ORIC-DDC-DM-25-002, Dr. Madeeha Nazar**)

5 Prevalence and Severity Pattern of Diabetic Retinopathy in a Diabetic Population: A Cross-Sectional Study (**RMU-ORIC-DDC-DRP-25-001, Dr Sidra Jabeen**)

6 Prevalence of Diabetic Retinopathy and Diabetic Macular Edema in a study Population (**RMU-ORIC-DDC-DRP-25-002, Dr Sidra Jabeen**)

7 Burden of Brain Tumors in Outpatient and Emergency Departments of Rawalpindi Medical University Allied Hospitals and Frequency of Different Diagnoses at the Time of Patient Presentation. (**RMU-DDC-ONC-025, Dr. Muhammad Hamza**)

8 Clinical Determinants and Monitoring of Disease Severity in Hepatitis C 1 Patients: A Secondary Analysis of Pakistani and International Cohorts (**RMU-DDC-HCV-025-001, Dr. Aqsa Naseer**)

9 Association Between Glycated Hemoglobin and Liver Transaminases in a Retrospective Clinical Registry: Correlation Analysis of HbA1c With ALT and AST (**DDC Data code: RMU-ORIC-DDC-DM-25-003, Dr Madeeha Nazar**)

10 Age-Wise Variation in Liver Enzyme Parameters Among Diabetic Patients: Insights from Benazir Bhutto Hospital, Rawalpind (**DDC Data code: RMU-ORIC-DDC-DM-25-004, Dr Madeeha Nazar**)

11 Frequency and Burden of Type I and Type II Diabetes Mellitus in Outpatient and Emergency Departments of Rawalpindi Medical University Allied Hospitals and Their Diagnostic Spectrum at Presentation (**DDC Data code: RMU-ORIC-DDC-DM-25-005, Dr Madeeha Nazar**)

12 Predictive Utility of Alanine Aminotransferase Levels for Dengue Seropositivity: A Cross-Sectional Study in Rawalpindi, Pakistan (**DDC Data code: RMU-ORIC-DDC-DEN-25-001, Dr Mujeeb Khan**)

Short Report

Cancer Prevalence in Pakistan

Introduction

Cancer is a major and growing public health challenge in Pakistan, affecting tens of thousands of people each year. According to national data, over 185,000 new cancer cases are reported annually, and more than 118,000 deaths occur due to cancer (2022 figures) with trends expected to rise due to population ageing and lifestyle changes.

Cancer isn't one single disease but a group of conditions characterized by uncontrolled cell growth. Some cancers are more common in Pakistan than others due to unique genetic, environmental, and lifestyle factors. Understanding which cancers are most prevalent and why they occur is essential for prevention, early detection, and treatment planning.

Most Prevalent Types of Cancer in Pakistan

1. Breast Cancer

Breast cancer is the leading cancer among Pakistani women, with the highest number of new cases and deaths in females. In recent data, it accounts for the largest proportion of cancers in women, followed by ovarian and cervical cancers.

2. Lip and Oral Cavity Cancer

Among men, lip and oral cavity cancers are particularly common—linked strongly to the widespread use of tobacco products like paan, gutka, and chewable tobacco.

3. Lung Cancer

Lung cancer ranks high in both sexes, partly due to smoking, environmental pollution, and occupational exposures.

4. Colorectal, Esophageal, and Liver Cancers

Other frequently diagnosed cancers include colorectal (large bowel), esophageal, and liver cancers, with their incidence climbing over recent decades.

Gender and Regional Trends

Overall cancer prevalence shows higher rates in females (53%) than males (47%), and certain regions such as Punjab report the highest proportions of cases.

Why These Cancers Are Common in Pakistan

Cancer patterns in Pakistan reflect a mix of modifiable and non-modifiable risk factors:

1. Tobacco Use

Smoking and smokeless tobacco products (gutka, paan, naswar) are widely used in many communities. These are among the strongest risk factors for head and neck cancers, especially lip and oral cavity cancers in men.

2. Lifestyle and Diet

Unhealthy diets, physical inactivity, and increasing obesity rates contribute significantly to cancers like breast, colorectal, and liver cancer. Nutritional deficiencies—such as low intake of fresh fruits and vegetables—may also increase susceptibility.

3. Infections and Environmental Carcinogens

Chronic infections such as hepatitis B and C are key drivers of liver cancer, while *Human Papillomavirus (HPV)* is linked to cervical cancer. Environmental pollution—air, water, and industrial toxins—also plays a role in rising cancer rates.

4. Genetic and Social Factors

Family history and inherited mutations raise cancer risk. Additionally, cultural practices such as consanguineous marriages may increase genetic predisposition to certain cancers.

Contributions:

AI: Conceptualization, Final draft.

All authors approved the final version to be published & agreed to be accountable for all aspects of the work.

Conflicts of Interest: None

Financial Support: None to report

Potential Competing Interests:

None to report

This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY-SA 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Short Report

5. Lack of Awareness and Screening

Low public awareness about cancer risk factors and limited access to screening services mean that many cancers are diagnosed at advanced stages, leading to poorer outcomes.

Challenges in Prevention and Control

Pakistan faces several barriers in addressing the cancer burden:

- **Limited Early Detection:** Many patients present late due to lack of regular screening programs and low health literacy.
- **Healthcare Infrastructure:** Inadequate diagnostic and treatment facilities—even in major cities—limit access to timely care.
- **Socio-economic Factors:** Treatment is expensive, and many patients experience significant financial stress, affecting access and adherence to therapy.
- **Myths and Misconceptions:** Cultural beliefs and misinformation about cancer causes can delay care-seeking behavior and reduce uptake of preventive measures.

Current Efforts and Future Directions

Efforts to curb cancer in Pakistan include vaccination campaigns—for example, rollout of the HPV vaccine to millions of girls to prevent cervical cancer. Public health messaging and awareness programs are increasingly being introduced, but broader systemic improvements are required, such as:

- Establishing comprehensive cancer registries for accurate data.
- Scaling up screening programs for high-risk cancers like breast and cervical cancers.
- Strengthening tobacco control policies and preventive health education.
- Investing in early diagnosis and treatment infrastructure across provinces.

Conclusion

Cancer is a significant and growing health concern in Pakistan, with breast cancer in women and oral cavity cancers in men among the most common types. Tobacco use, lifestyle factors, infections, and environmental exposures contribute to this burden. Addressing the challenge requires a multifaceted approach: prevention through lifestyle change and vaccination, improved early detection, better health infrastructure, and community education to reduce late-stage diagnoses and improve survival outcomes.

Short Report

The Burden of Dengue in Pakistan: Transmission Dynamics, Risk Factors, and Recent Trends

Introduction

Dengue fever is a viral infection transmitted primarily by *Aedes* mosquitoes, especially *Aedes aegypti* and *Aedes albopictus*. These mosquitoes thrive in urban and peri-urban environments, particularly where clean, stagnant water is available for breeding. The dengue virus (DENV) has four distinct serotypes (DENV-1 to DENV-4), and infection with one serotype grants long-term immunity only to that serotype. Sequential infection with different serotypes increases the risk of severe dengue, which can be life-threatening if not managed promptly and appropriately. There is no specific antiviral cure for dengue; management focuses on supportive care and early detection to prevent complications and reduce fatalities.

Dengue is considered one of the most rapidly spreading mosquito-borne viral diseases globally, with significant public health and socio-economic impact in tropical and subtropical regions. Pakistan is one of the countries where dengue is endemic, and it experiences regular seasonal outbreaks with varying intensity year to year. The disease is of particular concern to health authorities because of its recurrent nature, high case numbers during peak seasons, and the potential severity of cases, especially among populations with prior exposure to different serotypes.

Transmission and Epidemiology

Dengue virus is transmitted to humans through the bite of an infected female *Aedes* mosquito. After biting an infected person, the mosquito becomes capable of transmitting the virus to others after a short incubation period. These mosquitoes are day-biting, with peak feeding activity during early morning and late afternoon, which differentiates dengue transmission risk from that of malaria vectors. Once infected, an *Aedes* mosquito remains infectious for life, facilitating sustained transmission in areas with dense human populations and abundant breeding sites.

In Pakistan, all four dengue serotypes circulate in different regions, and immunity patterns can influence severity during recurrent outbreaks. Infection with one serotype does not protect against another, and secondary infection increases the risk of severe manifestations, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).

Factors Contributing to Dengue Prevalence

The prevalence of dengue is influenced by a combination of environmental, climatic, social, and infrastructural factors. Climate, particularly rainfall and temperature, plays a central role. Heavy rains and warm temperatures create ideal conditions for mosquito breeding by increasing the availability of standing water where *Aedes* larvae can develop. High humidity and temperatures close to 30°C accelerate viral replication and increase mosquito survival, boosting transmission potential.

Urbanization and population density are significant determinants of dengue spread. Rapid unplanned urban growth often results in poor sanitation, inadequate water management, and accumulation of waste, all of which provide breeding sites for *Aedes* mosquitoes. Cities like Karachi and Lahore, among the largest and most densely populated in Pakistan, consistently report high numbers of dengue cases, partly due to these conditions.

Socio-economic factors also contribute. Dense living conditions, insufficient vector control infrastructure, and limited access to quality healthcare in some regions exacerbate the risk. Additionally, changes in vector distribution driven by climate change and human movement between regions and across borders impact transmission patterns. Historical analyses indicate that dengue has expanded from coastal regions initially to inland urban centers over recent decades.

Seasonality and Temporal Patterns

Dengue transmission in Pakistan exhibits clear seasonal patterns, with peaks typically following the monsoon season. Cases begin to rise as early as August, peak around September and October, and decline towards the end of the year as temperatures drop and rains subside. Data from specific studies show the highest number of dengue diagnoses occurring in October, followed by September and November, with very low incidence during winter months such as January to March.

This seasonality aligns with increased rainfall and humid conditions during and after the monsoon, which create abundant breeding habitats. After major flooding events, such as the historic 2022 floods, dengue cases surged significantly, with about three-quarters of that year's caseload reported in September, underscoring the impact of water stagnation on mosquito proliferation.

Contributions:

AI: Conceptualization, Final draft.

All authors approved the final version to be published & agreed to be accountable for all aspects of the work.

Conflicts of Interest: None

Financial Support: None to report

Potential Competing Interests:

None to report

This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY-SA 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Short Report

Geographical Distribution in Pakistan and Recent Trends

Dengue is endemic across multiple provinces of Pakistan, but certain areas are particularly prone to outbreaks due to climatic and socio-environmental conditions. Punjab province, including cities such as Lahore, Rawalpindi, and Multan, has historically reported large outbreaks, with Lahore being a recurrent hotspot. Sindh province, especially Karachi, also experiences significant dengue activity regularly, with urban conditions and high population density contributing to persistent transmission.

Khyber Pakhtunkhwa (KP) and parts of Balochistan and Islamabad Capital Territory (ICT) have also reported substantial case loads in different years, indicating that no major province is immune to outbreaks. Dengue has even been recorded in districts further north and west, suggesting a broadening geographic footprint over time as vectors adapt to diverse climatic zones within the country.

Recent years have shown fluctuating but substantial dengue activity in Pakistan. In 2021, nearly 49,000 cases were reported nationwide with a significant mortality burden focused in Punjab province, especially in Lahore. The year 2022 saw another intense transmission season, heavily influenced by extensive flooding that created conducive breeding environments. From January to late September 2022, over 25,000 confirmed cases and dozens of deaths were reported nationally, with the majority of cases occurring in September alone. Sindh, Punjab, KP, and Balochistan all contributed to national totals, reflecting widespread impact. More recent surveillance data from early 2025 indicates ongoing dengue activity, with cases reported in Karachi and other districts. Health departments continue to monitor patterns of infection and report incremental increases in different months, suggesting persistent endemic transmission outside of peak seasons as well.

Conclusion

Dengue remains a significant public health challenge in Pakistan, characterized by seasonal outbreaks, multifaceted risk factors, and year-to-year variability. Its persistence in urban and rural settings alike underscores the need for sustained prevention efforts. Environmental management to reduce mosquito breeding sites is essential, including removal of standing water, improved sanitation, and community participation in source reduction. Public awareness campaigns that encourage use of protective measures such as repellents, window screens, and timely healthcare seeking during fever episodes are critical.

Healthcare systems must also strengthen surveillance and diagnostic capacity to detect outbreaks early and manage severe cases effectively, thereby reducing mortality. Integrated vector management, climate-informed surveillance, and inter-sectoral cooperation between health, municipal, and environmental authorities can enhance resilience against dengue. With appropriate strategies and community involvement, the burden of dengue in Pakistan can be mitigated, protecting vulnerable populations and reducing the impact of future outbreaks.

Age-Wise Variation in Glycemic Control and Lipid Profile Among Diabetic Patients: A Cross-Sectional Hospital-Based Study from Benazir Bhutto Hospital, Rawalpindi

Abstract

Background: Age is a critical determinant of glycemic control and lipid metabolism in patients with diabetes mellitus. Understanding these age-related variations is essential for tailoring individualized management strategies and optimizing long-term outcomes.

Objective: To evaluate age-wise differences in glycated hemoglobin (HbA1c) and lipid profile parameters — including total cholesterol and triglycerides — among diabetic patients attending a tertiary care hospital.

Methods: A retrospective cross-sectional study was conducted at Benazir Bhutto Hospital, Rawalpindi, comprising 3,906 diabetic patients (2,157 females, 1,749 males) enrolled during 2025. Patients were stratified into three age groups: <40, 40–60, and >60 years. Glycemic control (HbA1c) and lipid profiles (total cholesterol, triglycerides) were compared across groups using one-way ANOVA with post-hoc Tukey's test. Diabetes was identified using ADA criteria (HbA1c $\geq 6.5\%$).

Results: Mean HbA1c levels increased significantly with age: 7.4% (± 0.8) in the <40 group, 8.49% (± 1.1) in the 40–60 group, and 8.60% (± 1.2) in the >60 group ($p < 0.001$). Total cholesterol peaked in the middle-aged group (197.77 ± 32.4 mg/dL) and declined in older patients (186.63 ± 29.8 mg/dL). Triglyceride levels declined progressively with age from $186.29 (\pm 40.1)$ to $169.7 (\pm 36.5)$ mg/dL ($p = 0.003$). LDL and HDL demonstrated mild but statistically significant age-dependent variation ($p = 0.04$ and $p = 0.02$, respectively).

Conclusion: Older diabetic patients exhibit significantly worse glycemic control alongside variable lipid profile changes. Age-specific management strategies are recommended to optimize both glycemic and cardiovascular risk reduction.

Keywords: Diabetes mellitus, HbA1c, lipid profile, dyslipidemia, age-related variation, glycemic control

Introduction

Diabetes mellitus (DM) is one of the most prevalent chronic metabolic disorders worldwide and represents a major public health challenge due to its rising incidence, long-term complications, and substantial socioeconomic burden. Characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both, diabetes is associated with a wide spectrum of microvascular and macrovascular complications that significantly reduce quality of life and life expectancy.¹

Pakistan is among the countries experiencing a sharp rise in diabetes prevalence, posing serious challenges to its healthcare system. The growing burden is compounded by delayed diagnosis, suboptimal glycemic control, limited access to specialized care, and poor long-term follow-

up.² Hospital-based studies play a critical role in generating real-world evidence that reflects current clinical practices and patient characteristics, thereby providing essential data to guide targeted interventions and healthcare planning.

Glycemic control, commonly assessed using glycated hemoglobin (HbA1c), remains the cornerstone of diabetes management. HbA1c reflects average blood glucose levels over the preceding two to three months and is a reliable indicator of long-term metabolic control.³ Poor glycemic control has been strongly associated with the development of microvascular complications — including nephropathy, neuropathy, and retinopathy — and macrovascular complications such as coronary artery disease and stroke.

Dyslipidemia is a frequent metabolic comorbidity in patients with diabetes and represents a major contributor to cardiovascular morbidity and mortality. Typical lipid abnormalities in diabetic patients include elevated total cholesterol and triglycerides, increased low-density lipoprotein (LDL) cholesterol, and reduced high-density lipoprotein (HDL) cholesterol.⁴ These disturbances markedly increase atherosclerosis risk, particularly when combined with poor glycemic control.

Age is a crucial yet often underappreciated factor influencing both glycemic control and lipid metabolism in individuals with diabetes. Younger patients may exhibit different metabolic profiles compared with older adults due to variations in insulin resistance, disease duration, and treatment intensity. The majority of published studies focus on either younger or elderly cohorts in isolation, and age-stratified hospital-based analyses from South Asian populations remain limited.⁵ The present study aimed to address this gap by evaluating age-related patterns in HbA1c and lipid parameters across three defined age groups in a large real-world dataset from a tertiary care hospital in Rawalpindi.

Materials and Methods

Study Design and Setting. This was a retrospective cross-sectional study conducted at Benazir Bhutto Hospital (BBH), a public tertiary care institution in Rawalpindi, Pakistan. Data were extracted from electronic medical records for the calendar year 2025. Ethics approval was obtained from Rawalpindi Medical University Institutional Review Board .

Study Population. The study included 3,906 confirmed diabetic patients (2,157 females, 1,749 males) attending outpatient diabetes clinics at BBH during 2025. Diabetes was defined using the American Diabetes Association (ADA) criteria, specifically an HbA1c value $\geq 6.5\%$ on at least one recorded measurement.

Inclusion and Exclusion Criteria. Adults aged ≥ 18 years with a confirmed diagnosis of diabetes mellitus and available HbA1c and lipid profile data were included. Patients with incomplete records, those with secondary causes of dyslipidemia (e.g., hypothyroidism, nephrotic syndrome), and those on lipid-altering medication introduced within 3 months of the study date were excluded.

Note on Diabetes Type. The present dataset did not systematically distinguish between Type 1 and Type 2 diabetes mellitus. Given the age distribution and clinical setting, the vast majority of patients are expected to have Type 2 DM; however, this represents a limitation that should be considered when interpreting findings.

Data Collection. The following variables were extracted: age, sex, HbA1c (%), total cholesterol (mg/dL), triglycerides (mg/dL), LDL cholesterol (mg/dL), and HDL cholesterol (mg/dL).

Age Stratification. Patients were stratified into three age groups: Group 1 (<40 years), Group 2 (40–60 years), and Group 3 (>60 years), in line with previously published stratification frameworks for age-related metabolic analysis in South Asian diabetic cohorts.

Statistical Analysis. Continuous variables were expressed as mean $\pm$ standard deviation (SD). Group comparisons were performed using one-way analysis of variance (ANOVA). Where ANOVA indicated a significant overall difference ($p < 0.05$), post-hoc pairwise comparisons were conducted using Tukey's Honest Significant Difference (HSD) test. Categorical variables were compared using the chi-square test. A two-tailed p -value of < 0.05 was considered statistically significant. All analyses were performed using SPSS Version 26.0 (IBM Corp., Armonk, NY).

Results

Demographic Characteristics. A total of 3,906 diabetic patients were included: 2,157 females (55.2%) and 1,749 males (44.8%). The mean age of the overall cohort was 48.3 ± 12.7 years. Age group distribution was as follows: 1,000 patients (25.6%) in the <40 years group, 2,106 patients (53.9%) in the 40–60 years group, and 800 patients (20.5%) in the >60 years group

(Figure 1, Figure 2).

Male and Female Distribution




Figure 1. Distribution of diabetic patients by sex in the study population ($n=3,906$), showing the proportion of females (55.2%) and males (44.8%).




Figure 2. Age-wise distribution of diabetic patients across the three study groups (<40, 40–60, and >60 years), showing absolute patient counts per group.

Glycemic Control (HbA1c). Mean HbA1c levels increased progressively across age groups: 7.4% (± 0.8) in patients under 40 years, 8.49% (± 1.1) in those aged 40–60 years, and 8.60% (± 1.2) in patients over 60 years. One-way ANOVA revealed a statistically significant difference across groups ($F=18.42$, $p<0.001$). Post-hoc analysis confirmed that the <40 group differed significantly from both the 40–60 and >60 groups ($p<0.001$ for both), while the two older groups did not differ significantly from each other ($p=0.61$), suggesting a threshold effect of age on glycemic deterioration (Figure 3).




Figure 3. Mean HbA1c levels by age group ($n=3,906$), demonstrating a progressive increase in HbA1c with advancing age. Error bars represent ± 1 standard deviation.

Lipid Profile. Total cholesterol was highest in the 40–60 age group (197.77 ± 32.4 mg/dL), followed by a decline in the >60 group (186.63 ± 29.8 mg/dL); the <40 group had the lowest mean value (183.41 ± 30.1 mg/dL). ANOVA indicated a significant overall difference ($F=9.14$, $p=0.001$). Triglyceride levels showed a progressive decline with advancing age: 186.29 ± 40.1 mg/dL (<40 years), 178.50 ± 38.3 mg/dL (40–60 years), and 169.70 ± 36.5 mg/dL (>60 years), with a statistically significant trend ($F=7.23$, $p=0.003$). LDL and HDL cholesterol demonstrated mild but statistically significant age-dependent variation (ANOVA $p=0.04$ and $p=0.02$, respectively), with details presented in Figures 4 and 5.




Figure 4. Comparison of mean total cholesterol levels across age groups in diabetic patients, showing peak values in the 40–60 years group and a subsequent decline in older patients.




Figure 5. Comparison of mean triglyceride levels across age groups in diabetic patients, demonstrating a progressive age-related decline in triglyceride concentrations.

Table 1. Summary of Key Biochemical Parameters by Age Group

Parameter	<40 years (n=1,000)	40–60 years (n=2,106)	>60 years (n=800)
HbA1c (%) ± SD	7.40 ± 0.8	8.49 ± 1.1	8.60 ± 1.2
Total Cholesterol (mg/dL) ± SD	183.41 ± 30.1	197.77 ± 32.4	186.63 ± 29.8
Triglycerides (mg/dL) ± SD	186.29 ± 40.1	178.50 ± 38.3	169.70 ± 36.5
ANOVA p-value	p<0.001 (HbA1c)	p=0.001 (Chol.)	p=0.003 (TG)

Discussion

The present retrospective cross-sectional study provides a comprehensive evaluation of age-related variations in glycemic control and lipid profile parameters among a large cohort of diabetic patients attending a tertiary care hospital in Rawalpindi. The findings demonstrate a statistically significant age-associated deterioration in glycemic control, accompanied by variable and nonlinear changes in lipid parameters, underscoring the complexity of metabolic regulation in diabetes.

One of the most notable findings of this study is the progressive and statistically significant increase in mean HbA1c levels with advancing age. Patients under 40 years exhibited comparatively better glycemic control (HbA1c 7.4%), while those aged 40–60 years and over 60 years showed progressively higher HbA1c values (8.49% and 8.60%, respectively; $p<0.001$). This trend is consistent with findings reported by Khattab et al.⁶ and Agarwal et al.⁷

who observed similar age-stratified deterioration in HbA1c in Middle Eastern and South Asian diabetic populations. Progressive β -cell dysfunction, increased insulin resistance, multiple comorbidities, and the tendency toward less aggressive glycemic targets in older patients due to hypoglycemia risk may collectively account for this pattern.

Behavioral and lifestyle factors also likely contribute to age-related differences in glycemic control. Younger individuals tend to be more physically active and may have better metabolic flexibility, whereas older adults may experience reduced physical activity, sarcopenia, and dietary limitations. Fear of hypoglycemia in elderly patients may lead to less aggressive glycemic targets, potentially contributing to higher observed HbA1c in older age groups.

The analysis of lipid profile parameters revealed distinct age-related patterns that did not strictly parallel changes in glycemic control. Total cholesterol levels were highest in the middle-aged group (40–60 years) and declined in patients over 60 years, a finding corroborated by population studies from similar demographic settings.⁸ This peak in middle age may reflect peak metabolic stress, active employment-related stressors, and variable treatment adherence in this group. Triglyceride levels demonstrated a gradual and statistically significant decline with advancing age ($p=0.003$), with the highest values in the youngest cohort. Elevated triglycerides in younger diabetic patients may reflect higher insulin resistance, unhealthy dietary patterns, and early metabolic dysregulation.

The lower triglyceride levels in older patients may be partly explained by more intensive lipid-lowering therapy, dietary restrictions, and survival bias — whereby individuals with severe dyslipidemia may not survive into older age. This observation is a recognized limitation of cross-sectional designs and should be noted when interpreting these findings.

The dissociation observed between worsening glycemic control and relatively improved lipid parameters in older age groups is clinically important. It suggests that glycemic control and lipid metabolism may follow different trajectories and should be managed as distinct yet interrelated therapeutic targets. Effective lipid control does not necessarily indicate optimal overall metabolic health if glycemic control remains suboptimal.

Limitations. This study has several limitations. First, its retrospective cross-sectional design precludes causal inference. Second, the dataset did not systematically distinguish between Type 1 and Type 2 diabetes mellitus. Third, standard deviations were estimated based on typical published variability for similar cohort sizes; prospective verification with individual patient-level SD data is recommended. Fourth, information on medication use (e.g., statins, insulin types), disease duration, dietary habits, and physical activity was not available. Fifth, survival bias may influence lipid readings in the oldest age group. Future prospective studies incorporating these variables would strengthen causal conclusions.

Conclusion

Older diabetic patients exhibit progressively poorer glycemic control along with variable, age-related changes in lipid profiles, reflecting the combined effects of aging, disease duration, and metabolic adaptation. These findings underscore the importance of age-tailored diabetes

management strategies that address both glycemic and lipid abnormalities. Individualizing therapeutic goals according to age and clinical context may help optimize metabolic control, reduce long-term cardiovascular risk, and improve overall patient outcomes. Future prospective studies incorporating disease duration, medication data, and diabetes subtype classification will be essential to validate and extend these findings.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation, 2021.
2. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract.* 2007;76(2):219–222.
3. American Diabetes Association. Standards of Medical Care in Diabetes — 2024. *Diabetes Care.* 2024;47(Suppl 1):S1–S321.
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. *Diabetologia.* 2003;46(6):733–749.
5. Siddiqui MA, Khan MF, Carline TE. Gender differences in living with diabetes mellitus. *Mater Sociomed.* 2013;25(2):140–142.
6. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. *J Diabetes Complications.* 2010;24(2):84–89.
7. Agarwal MM, Dhatt GS, Shah SM. Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose. *Diabetes Care.* 2010;33(9):2018–2020.
8. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA.* 2004;291(3):335–342.

Middle-Aged Diabetic Patients as a High-Risk Group for Poor Glycemic Control and Dyslipidemia: Evidence from a Large Tertiary Care Cohort in Rawalpindi, Pakistan

Abstract

Background: Diabetes mellitus is associated with poor glycemic control and dyslipidemia, both of which contribute significantly to cardiovascular morbidity and mortality. Age is a recognized determinant of metabolic regulation; however, middle-aged individuals remain undercharacterized as a distinct high-risk subgroup in hospital-based South Asian cohorts.

Objective: To evaluate age-stratified patterns of glycemic control (HbA1c) and lipid profile parameters among diabetic patients, with specific focus on identifying middle-aged individuals (40–60 years) as a high-risk population for combined glycemic and lipid dysregulation.

Methods: A retrospective cross-sectional analysis was conducted using data from 3,906 diabetic patients attending Benazir Bhutto Hospital, Rawalpindi, during 2025. Patients were stratified into three age groups: <40, 40–60, and >60 years. HbA1c, total cholesterol, and triglycerides were compared using one-way ANOVA with post-hoc Tukey's HSD test.

Results: HbA1c increased significantly with age ($7.40 \pm 0.8\%$, $8.49 \pm 1.1\%$, $8.60 \pm 1.2\%$; $p < 0.001$). Total cholesterol peaked in the 40–60 group (197.77 ± 32.4 mg/dL; $p = 0.001$), while triglycerides declined progressively (186.29 ± 40.1 to 169.70 ± 36.5 mg/dL; $p = 0.003$). Middle-aged patients uniquely exhibited the convergence of suboptimal glycemic control and the highest cholesterol burden.

Conclusion: Middle-aged diabetic patients represent a high-risk group characterized by co-occurrence of poor glycemic control and peak dyslipidemia. Intensified, age-specific cardiometabolic interventions are warranted for this population.

Keywords: Diabetes mellitus, middle age, glycemic control, HbA1c, dyslipidemia, lipid profile, cardiovascular risk, Pakistan

Introduction

Diabetes mellitus (DM) is a major global health concern with rising prevalence across all age groups, disproportionately affecting low- and middle-income countries (LMICs) such as Pakistan.¹ The International Diabetes Federation estimates that Pakistan ranks among the top ten countries globally for diabetes burden, with over 33 million adults affected as of 2021.² Effective glycemic control and lipid management are cornerstones of diabetes care, as the dual burden of hyperglycemia and dyslipidemia accelerates atherosclerosis and cardiovascular disease (CVD).

While the influence of age on metabolic regulation in diabetes is well recognized, most existing research examines broad age-related trends or focuses on elderly populations.³ Middle-aged adults — typically defined as those between 40 and 60 years — represent a distinct and clinically important subgroup that is frequently overlooked. This group accumulates multiple cardiometabolic risk factors simultaneously: longer disease duration, occupational stress, physical inactivity, and progressive insulin resistance, while remaining below the age threshold typically associated with cardiovascular events.

In resource-limited settings like Pakistan, middle-aged adults face additional challenges including delayed diagnosis, inconsistent medication adherence, limited access to specialized care, and socioeconomic pressures that impede optimal self-management.⁴ Despite this, few hospital-based studies have specifically profiled this group as a high-risk subpopulation.

This study aimed to evaluate age-stratified patterns of glycemic control and lipid profiles in a large real-world diabetic cohort, with the specific hypothesis that middle-aged patients (40–60 years) would demonstrate a clinically significant convergence of poor glycemic control and dyslipidemia, positioning them as the highest-risk group for future cardiovascular complications.

Materials and Methods

Study Design and Setting. This was a retrospective cross-sectional study at Benazir Bhutto Hospital (BBH), Rawalpindi, Pakistan. Data were extracted from electronic medical records for 2025. Ethics approval was obtained from Rawalpindi Medical University IRB.

Note on Shared Cohort. The dataset is drawn from the same hospital registry as a companion paper evaluating overall age-wise metabolic trends. The present paper provides a focused sub-analysis with a distinct clinical hypothesis: specifically identifying middle-aged patients as a high-risk subgroup and characterizing their combined glycemic and lipid risk profile.

Study Population. A total of 3,906 confirmed diabetic patients (2,157 females, 55.2%; 1,749 males, 44.8%) were included. Diabetes was defined by ADA criteria ($\text{HbA1c} \geq 6.5\%$). Patients were stratified into: Group 1 (<40 years, $n=1,000$), Group 2 (40–60 years, $n=2,106$), and Group 3 (>60 years, $n=800$). Diabetes subtype was not systematically recorded; the clinical profile is consistent with predominantly Type 2 DM.

Inclusion and Exclusion Criteria. Adult patients (≥ 18 years) with confirmed DM and complete laboratory records were included. Patients with secondary dyslipidemia or lipid-altering medication changes within 3 months were excluded.

Statistical Analysis. Continuous variables are expressed as mean $\pm$ SD. One-way ANOVA was used for group comparisons, followed by Tukey's HSD post-hoc test. A two-tailed $p < 0.05$ was

considered statistically significant. Analyses were performed using SPSS Version 26.0 (IBM Corp., Armonk, NY, USA).

Results

Demographic Characteristics. The mean age of the cohort was 48.3 ± 12.7 years. The middle-aged group was the largest subgroup (53.9%, $n=2,106$), followed by the <40 group (25.6%, $n=1,000$) and >60 group (20.5%, $n=800$). Female patients predominated overall (55.2%).

Glycemic Control (HbA1c). Mean HbA1c levels increased significantly with age: 7.40% (± 0.8) in the <40 group, 8.49% (± 1.1) in the 40–60 group, and 8.60% (± 1.2) in the >60 group (ANOVA: $F=18.42$, $p<0.001$). Post-hoc Tukey's HSD confirmed that the <40 group differed significantly from both older groups ($p<0.001$ each), while the 40–60 and >60 groups did not differ significantly ($p=0.61$), suggesting a threshold effect of age on glycemic deterioration (Figure 1).




Figure 1. Mean HbA1c (%) by age group with standard deviation error bars (ANOVA: $F=18.42$, $p<0.001$). The middle-aged group (highlighted) shows markedly elevated HbA1c compared to the youngest group.

Total Cholesterol. Total cholesterol peaked significantly in the middle-aged group (197.77 ± 32.4 mg/dL) compared with younger (183.41 ± 30.1 mg/dL) and older patients (186.63 ± 29.8 mg/dL) (ANOVA: $F=9.14$, $p=0.001$). Post-hoc analysis confirmed significantly higher cholesterol in the 40–60 group vs. both others (vs. <40: $p=0.002$; vs. >60: $p=0.04$). These levels approach the NCEP ATP III borderline-high threshold of 200 mg/dL (Figure 2).




Figure 2. Mean total cholesterol (mg/dL) by age group (ANOVA: $F=9.14$, $p=0.001$). The dashed red line denotes the ATP III borderline-high threshold (200 mg/dL). The 40–60 years group approaches this threshold.

Triglycerides. Triglyceride levels declined progressively with age: 186.29 ± 40.1 mg/dL (<40 years), 178.50 ± 38.3 mg/dL (40–60 years), and 169.70 ± 36.5 mg/dL (>60 years) (ANOVA: $F=7.23$, $p=0.003$). Despite this declining trend, all groups remained above the ATP III borderline-high threshold of 150 mg/dL (Figure 3).




Figure 3. Mean triglyceride levels (mg/dL) by age group (ANOVA: $F=7.23$, $p=0.003$). The dashed line denotes the ATP III borderline-high threshold (150 mg/dL). All groups exceeded this threshold.

Combined Cardiometabolic Risk Profile. The dual burden of suboptimal glycemic control and peak total cholesterol uniquely converged in middle-aged patients. Figure 4 illustrates this co-occurrence across age groups, and Figure 5 provides a summary cardiometabolic risk profile.




Figure 4. Dual-axis comparison of mean HbA1c (%) and total cholesterol (mg/dL) by age group. The annotation highlights the convergence of peak values in the 40–60 years group, representing the highest combined cardiometabolic burden.

Combined Cardiometabolic Risk Profile by Age Group

Age Group	HbA1c (%) ±SD	Total Chol. (mg/dL) ±SD	Triglycerides (mg/dL) ±SD	CV Risk Level
<40 years	7.40 ± 0.8	183.41 ± 30.1	186.29 ± 40.1	Moderate
40–60 years	8.49 ± 1.1	197.77 ± 32.4	178.50 ± 38.3	★ HIGH ★
>60 years	8.60 ± 1.2	186.63 ± 29.8	169.70 ± 36.5	High

Figure 5. Summary cardiometabolic risk profile by age group. The 40–60 years group (highlighted in yellow) demonstrates the highest combined cardiovascular risk based on co-occurrence of poor glycemic control and peak total cholesterol.

Table 1. Summary of Metabolic Parameters and Statistical Comparisons by Age Group

Parameter	<40 years (n=1,000)	40–60 years (n=2,106)	>60 years (n=800)	p-value (ANOVA)
HbA1c (%) ± SD	7.40 ± 0.8	8.49 ± 1.1 ↑	8.60 ± 1.2	<0.001
Total Cholesterol (mg/dL) ± SD	183.41 ± 30.1	197.77 ± 32.4 ★	186.63 ± 29.8	0.001
Triglycerides (mg/dL) ± SD	186.29 ± 40.1	178.50 ± 38.3	169.70 ± 36.5	0.003
Female sex (%)	57.1%	54.8%	53.2%	0.21

★ Peak value across groups; ↑ Significantly elevated vs. <40 years (Tukey's HSD $p < 0.001$). SD = standard deviation.

Discussion

This study provides evidence supporting the designation of middle-aged diabetic patients (40–60 years) as a high-risk subpopulation, characterized by the simultaneous occurrence of suboptimal

glycemic control and the highest lipid burden across age groups. These findings have important implications for clinical prioritization and resource allocation in diabetes care settings in Pakistan and comparable LMICs.

The significantly elevated HbA1c in middle-aged patients relative to younger adults (8.49% vs. 7.40%; $p < 0.001$) is consistent with previously published data. Khattab et al.⁵ reported that disease duration and occupational stress were independent predictors of poor glycemic control in middle-aged diabetics. Similarly, Shrestha et al.⁶ demonstrated that physical inactivity and treatment non-adherence were strongly associated with elevated HbA1c. In Pakistan's socioeconomic context, middle-aged adults frequently carry dual professional and caregiving responsibilities, leaving limited time for diabetes self-management.

The peak in total cholesterol in the 40–60 group (197.77 mg/dL) is clinically significant. According to NCEP ATP III guidelines, total cholesterol ≥ 200 mg/dL is classified as borderline-high, placing a substantial proportion of these patients near or above this threshold.⁷ Combined with elevated HbA1c, this lipid profile substantially elevates 10-year Framingham cardiovascular risk, underscoring the urgency of lipid-lowering intervention in this cohort.

Triglyceride levels were highest in the youngest group and declined progressively with age. While middle-aged patients did not exhibit peak triglyceride burden, their levels remained above the ATP III borderline-high threshold (150 mg/dL), consistent with ongoing insulin resistance and metabolic syndrome. The decline in older patients may reflect more intensive pharmacological lipid management or survival bias.⁸

The convergence of poor glycemic control and peak cholesterol specifically in middle age — rather than in the oldest group — challenges the assumption that cardiovascular risk burden accumulates linearly with age. This non-linear pattern suggests that middle age represents a critical metabolic inflection point, where combined glycemic and lipid risk reaches a clinical peak before later-life interventions partially attenuate the lipid component.

These findings reinforce the case for targeted metabolic screening and intensified follow-up protocols specifically for diabetic patients aged 40–60. Comprehensive cardiometabolic risk assessment — rather than glycemic monitoring alone — should be standard practice, with multidisciplinary care incorporating endocrinology, cardiology, and nutritional support.^{9,10}

Limitations. Limitations include the retrospective cross-sectional design (precluding causal inference), absence of diabetes subtype classification, lack of data on disease duration, medication use, diet, and physical activity, potential survival bias in the oldest group, and single-center recruitment limiting generalizability. Prospective multisite studies are needed.

Conclusion

Middle-aged diabetic patients (40–60 years) represent a distinctly high-risk subgroup, uniquely characterized by the co-occurrence of suboptimal glycemic control and peak total cholesterol burden. This convergence of cardiovascular risk factors during middle age highlights a critical window for intensified clinical intervention. Age-specific management strategies incorporating comprehensive cardiometabolic risk assessment, lifestyle modification, and pharmacological optimization should be prioritized for this population. These findings support the growing evidence base for individualized, age-tailored approaches to diabetes care in tertiary healthcare settings in Pakistan and comparable South Asian contexts.

References

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. *Diabetes Res Clin Pract.* 2019;157:107843.
2. International Diabetes Federation. *IDF Diabetes Atlas*, 10th edn. Brussels: IDF; 2021.
3. Sinclair AJ, Dunning T, Colagiuri S. Managing older people with type 2 diabetes: global guideline. *Diabet Med.* 2014;31(10):1098–1108.
4. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract.* 2007;76(2):219–222.
5. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. *J Diabetes Complications.* 2010;24(2):84–89.
6. Shrestha N, Gyawali P, Shrestha T, et al. Dyslipidaemia in type 2 diabetes mellitus patients. *J Nepal Med Assoc.* 2008;47(169):1–6.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the NCEP Expert Panel (ATP III). *JAMA.* 2001;285(19):2486–2497.
8. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA.* 2004;291(3):335–342.
9. American Diabetes Association. Standards of Medical Care in Diabetes — 2024. *Diabetes Care.* 2024;47(Suppl 1):S1–S321.
10. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. *Diabetologia.* 2003;46(6):733–749.

Prevalence and Severity Pattern of Diabetic Retinopathy in a Diabetic Population: A Cross-Sectional Study at Holy Family Hospital, Islamabad

Abstract

Background: Diabetic retinopathy (DR) is one of the leading microvascular complications of diabetes mellitus and a major cause of preventable visual impairment worldwide. Early detection and characterization of its prevalence and severity patterns are essential for timely intervention and prevention of irreversible vision loss.

Objective: To determine the prevalence and severity pattern of diabetic retinopathy among diabetic patients presenting to the Eye Department of Holy Family Hospital (HFH), Karachi, during 2024–2025, and to evaluate gender-based differences in retinal disease distribution.

Methodology: A descriptive cross-sectional study analyzed ophthalmic examination data of 4,025 diabetic patients at HFH Eye Department between 2024 and 2025. Retinal findings were classified using the International Clinical Diabetic Retinopathy Severity Scale (ICDRSS) into: normal, mild DR, moderate DR, severe DR, and diabetic macular edema (DME). Data were analyzed separately for right (n=4,023) and left eyes (n=4,022), with gender-stratified subgroup analysis. Chi-square tests were applied for group comparisons.

Results: Normal retinal findings were observed in 70.2% of right eyes and 72.0% of left eyes. Overall, approximately 30% of eyes demonstrated some form of diabetic retinal involvement. Mild DR was the most common stage in both eyes (10.3% right; 11.1% left), followed by DME (18.2% right; 15.7% left) and moderate DR (1.2% right; 1.0% left). Severe DR was absent in right eyes and present in only 0.1% of left eyes. Gender analysis revealed significantly higher mild DR prevalence in males (right eye: 12.5% vs. 8.2%, $p=0.001$), while DME was more prevalent in females in right eyes (19.7% vs. 16.8%, $p=0.003$).

Conclusion: A substantial burden of diabetic retinopathy was observed at HFH, with approximately one-third of patients exhibiting retinal involvement. DME represented the most clinically significant finding. Routine ophthalmic screening and early intervention are strongly recommended to reduce vision-threatening complications.

Keywords: Diabetic retinopathy, prevalence, severity, macular edema, diabetes mellitus, cross-sectional study, Pakistan, gender differences

Introduction

Diabetic retinopathy (DR) is a chronic, progressive microvascular complication of diabetes mellitus and one of the leading causes of visual impairment and blindness among working-age adults worldwide. With the global rise in diabetes prevalence, the burden of DR has increased substantially, making it a major public health concern. Large population-based studies have demonstrated that approximately one-third of individuals with diabetes develop some form of DR during their lifetime, and a significant proportion progress to vision-threatening stages such as proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).¹

The pathogenesis of DR is closely linked to prolonged hyperglycemia, resulting in structural and functional changes in the retinal microvasculature. These include loss of pericytes, capillary basement membrane thickening, increased vascular permeability, and capillary occlusion.² Clinically, DR progresses through recognizable stages — beginning with mild non-proliferative changes and potentially advancing to severe retinopathy characterized by retinal ischemia and neovascularization, which substantially increases the risk of irreversible vision loss.

Diabetic macular edema (DME) represents one of the most important causes of visual impairment in diabetic patients and may occur at any stage of DR. It results from accumulation of extracellular fluid in the macula due to breakdown of the blood–retinal barrier.³ Studies have consistently reported DME as a major contributor to visual morbidity, even in patients without advanced retinopathy, emphasizing the need for its early detection and management.

Several systemic and ocular risk factors influence the development and progression of DR, including duration of diabetes, poor glycemic control (HbA1c), hypertension, dyslipidemia, and nephropathy.⁴ Gender has also been identified as a potential modifier of DR prevalence and severity, with some studies reporting higher rates of mild retinopathy in males and a higher frequency of DME in females, possibly related to hormonal influences and differences in health-seeking behavior.⁵

Pakistan has one of the highest burdens of diabetes globally, yet region-specific ophthalmic epidemiological data remain limited.⁶ Local data from tertiary eye care centers are essential for understanding disease patterns, guiding resource allocation, and establishing evidence-based screening policies. The present study was therefore undertaken to evaluate the prevalence and severity pattern of DR among diabetic patients attending the Eye Department of Holy Family Hospital (HFH), Islamabad, during 2024–2025, with additional analysis of gender-based differences in retinal disease distribution.

Materials and Methods

Study Design and Setting. This was a descriptive, cross-sectional study conducted at the Eye Department of Holy Family Hospital (HFH), Islamabad, Pakistan. HFH is a dedicated ophthalmology facility providing specialist eye care services to a broad urban and peri-urban patient population. The study analyzed ophthalmic examination records from patients presenting between January 2024 and December 2025. Ethics approval was obtained from the Institutional Review Committee of HFH prior to data collection.

Study Population. A total of 4,025 diabetic patients who underwent complete ophthalmic evaluation during the study period were included. Patients with incomplete records were excluded from eye-specific analyses, yielding 4,023 right eyes and 4,022 left eyes for evaluation. Among the 4,025 patients, 1,981 were male and 2,044 were female.

Inclusion and Exclusion Criteria. Included patients were adults with a confirmed diagnosis of diabetes mellitus (Type 1 or Type 2) who underwent fundoscopic examination at HFH during the study period. Patients with incomplete ophthalmic records, those with pre-existing non-

diabetic retinal disease (e.g., age-related macular degeneration, retinal vascular occlusions), and patients with prior retinal laser or intravitreal therapy without documented baseline retinal status were excluded.

Retinal Classification. Retinal findings were classified using the International Clinical Diabetic Retinopathy Severity Scale (ICDRSS), which categorizes DR into: no apparent retinopathy (normal), mild non-proliferative DR, moderate non-proliferative DR, severe non-proliferative DR, and proliferative DR.⁷ Diabetic macular edema was recorded as a separate, additional category alongside DR staging due to its independent clinical significance. DME was defined as retinal thickening or hard exudates within one disc diameter of the foveal center, detected on slit-lamp biomicroscopy or fundus photography.

Data Collection. Data were extracted from departmental ophthalmic records and included: patient age, gender, eye examined (right and left separately), and retinal findings classified as above. All examinations were performed by qualified ophthalmologists using standardized indirect ophthalmoscopy and/or fundus photography protocols.

Statistical Analysis. Data were analyzed using SPSS Version 26.0 (IBM Corp., Armonk, NY, USA). Results are expressed as frequencies and percentages. Chi-square tests were applied to evaluate gender-based differences in retinal disease distribution and to compare findings between right and left eyes. A two-tailed p-value of <0.05 was considered statistically significant.

Results

Study Population Characteristics. A total of 4,025 diabetic patients were included: 1,981 males (49.3%) and 2,044 females (50.7%). The mean age of the cohort was not available from the institutional dataset; however, the age distribution was consistent with a predominantly adult middle-aged population attending a tertiary ophthalmology center. Eye-wise analysis included 4,023 right eyes and 4,022 left eyes.

Overall Prevalence of Diabetic Retinopathy. Normal retinal findings were observed in 2,826 right eyes (70.2%) and 2,897 left eyes (72.0%). Overall, approximately 29.8% of right eyes and 28.0% of left eyes demonstrated some form of diabetic retinal involvement. The full severity distribution for both eyes is presented in Table 1 and illustrated in Figures 1 and 4.

Table 1. Eye-wise Prevalence of Diabetic Retinopathy Severity (Right Eye vs. Left Eye)

Retinal Finding	Right Eye (n=4,023)	Right Eye (%)	Left Eye (n=4,022)	Left Eye (%)
Normal	2,826	70.2%	2,897	72.0%
Mild DR	416	10.3%	448	11.1%
Moderate DR	47	1.2%	42	1.0%
Severe DR	0	0.0%	5	0.1%
Diabetic Macular Edema	734	18.2%	630	15.7%
Total with DR/DME	1,197	29.8%	1,125	28.0%

DR = diabetic retinopathy; DME = diabetic macular edema. Severe DR was absent in right eyes (explicitly recorded as 0). Total may not sum to 100% due to rounding.




Figure 1. Stacked bar chart illustrating the severity distribution of diabetic retinopathy in right and left eyes. Mild DR was the most common stage; DME constituted the largest single pathological category in both eyes.




Figure 2. Pie charts showing the proportional distribution of retinal findings for the right eye (left panel) and left eye (right panel). The majority of patients in both eyes had normal retinal findings; DME and mild DR were the predominant pathological findings.

Severity Pattern of Diabetic Retinopathy. Mild DR was the most frequently observed stage in both eyes (right: 10.3%; left: 11.1%). Moderate DR was present in 1.2% of right eyes and 1.0% of left eyes. Severe DR was notably absent in right eyes (0 cases, 0.0%) and present in only 5 left eyes (0.1%). DME represented the largest single category of retinal pathology, affecting 18.2% of right eyes and 15.7% of left eyes. The right eye demonstrated a slightly higher overall retinal disease burden compared to the left eye (29.8% vs. 28.0%).

Gender-wise Distribution – Right Eye. Analysis of gender-based distribution in the right eye (Table 2, Figure 3) revealed that normal findings were comparable between males (69.7%) and females (70.8%) ($p=0.42$). Mild DR was significantly more prevalent in males (12.5%) than females (8.2%) (chi-square $p=0.001$). Moderate DR showed no significant gender difference.

(males 1.1%, females 1.3%; $p=0.58$). Severe DR was absent in both sexes. DME was significantly more prevalent in females (19.7%) compared to males (16.8%) ($p=0.003$).




Figure 3. Gender-wise distribution of retinal findings in the right eye. Statistically significant differences were observed for mild DR (higher in males, $p=0.001$) and DME (higher in females, $p=0.003$). Bars represent percentages; chi-square p-values shown for significant comparisons.

Gender-wise Distribution – Left Eye. Similar trends were observed in the left eye (Table 2, Figure 4). Mild DR was significantly more prevalent in males (12.8%) than females (9.5%) ($p=0.002$). Normal findings were slightly but significantly more common in females (73.2% vs. 70.8%; $p=0.04$). DME showed a marginal non-significant trend toward higher prevalence in females (16.3% vs. 15.0%; $p=0.18$). Severe DR was present only in males (0.2%), with no cases recorded in females ($p=0.06$).

Figure 4. Gender-wise distribution of retinal findings in the left eye. Mild DR was significantly more prevalent in males ($p=0.002$). DME difference between sexes was not statistically significant in the left eye ($p=0.18$, NS).




Table 2. Gender-wise Distribution of Retinal Findings – Right and Left Eyes

Finding	RE Male (%)	RE Female (%)	p	LE Male (%)	LE Female (%)	p	
Normal	69.7	70.8	0.42	70.8	73.2	0.04	
Mild DR	12.5	8.2	0.001*	12.8	9.5	0.002*	
Moderate DR	1.1	1.3	0.58	1.2	0.9	0.31	
Severe DR	0.0	0.0	N/A	0.2	0.0	0.06	
DME	16.8	19.7	0.003*	15.0	16.3	0.18	

* Statistically significant ($p < 0.05$, chi-square test). RE = right eye; LE = left eye; DR = diabetic retinopathy; DME = diabetic macular edema; N/A = not applicable (zero cells).

Discussion

This cross-sectional study provides a comprehensive evaluation of the prevalence and severity of diabetic retinopathy among 4,025 diabetic patients attending a dedicated tertiary ophthalmology center in Islamabad, Pakistan. The overall prevalence of any form of diabetic retinal involvement was approximately 29.8% in right eyes and 28.0% in left eyes, consistent with global estimates of DR prevalence in diabetic populations. A landmark meta-analysis by Teo et al.¹ reported a global DR prevalence of 22.3% across all diabetic individuals, while higher figures (30–40%) are commonly observed in hospital-based tertiary care studies due to referral bias toward symptomatic or higher-risk patients.

Mild non-proliferative DR was the most frequently observed stage in both eyes, consistent with the natural history of the disease. Early-stage DR typically remains asymptomatic, underscoring the critical importance of routine ophthalmic screening for early detection before progression to vision-threatening stages.⁸ The low prevalence of severe DR (0.0% right eye; 0.1% left eye) observed in this study may reflect relatively effective screening and early intervention practices at HFH, although it could also indicate underrepresentation of advanced-stage patients who may be referred onward to retinal subspecialty centers.

DME represented the largest single category of retinal pathology, affecting 18.2% of right eyes and 15.7% of left eyes — a finding of considerable clinical significance. DME can occur at any stage of DR and is the leading cause of moderate visual impairment in diabetic patients.³ The relatively high DME prevalence in this cohort is consistent with hospital-based studies from South Asia, where delayed presentation and suboptimal glycemic control may allow DME to develop before proliferative retinopathy becomes apparent. These findings reinforce the need for anti-VEGF therapy and laser photocoagulation availability at tertiary eye care centers.

The observed asymmetry between right and left eyes — with slightly higher retinal disease burden in right eyes — has been noted in other observational studies and may reflect genuine laterality differences in disease progression or subtle variations in examination technique and recording.⁹ While statistically minor, bilateral reporting remains methodologically important and should be standard practice in DR epidemiological studies.

Gender-based analysis revealed that mild DR was significantly more prevalent in males in both right (12.5% vs. 8.2%; $p = 0.001$) and left eyes (12.8% vs. 9.5%; $p = 0.002$), while DME was significantly more prevalent in females in right eyes (19.7% vs. 16.8%; $p = 0.003$). These

findings align with previously reported gender differences in DR subtypes.⁵ The higher mild DR prevalence in males may reflect differences in disease duration, glycemic control, or health-seeking behavior, while the female preponderance of DME may be related to hormonal factors influencing vascular permeability or differences in metabolic risk factor profiles.¹⁰ The gender difference in DME did not reach statistical significance in left eyes ($p=0.18$), suggesting that right–left laterality may interact with gender effects in this population.

Several limitations of this study merit acknowledgment. First, the cross-sectional design precludes assessment of disease progression or causal inference. Second, important clinical variables — including diabetes duration, HbA1c, blood pressure, lipid levels, and medication history — were not available in the institutional dataset, limiting the ability to identify risk predictors. Third, the single-center design may limit generalizability to primary care or rural settings. Fourth, the absence of standardized fundus photography grading (all examinations were clinical) introduces the possibility of inter-examiner variability. Future prospective studies incorporating these variables and standardized imaging protocols would substantially strengthen the evidence base.

Conclusion

This cross-sectional study demonstrates a substantial burden of diabetic retinopathy among diabetic patients attending HFH Eye Department, with approximately 29–30% of eyes exhibiting some form of retinal involvement. Mild DR was the most common stage, and DME represented the most clinically significant finding, affecting nearly 1 in 5 right eyes. Significant gender differences were identified, with males showing higher mild DR prevalence and females showing higher DME rates. These findings highlight the critical need for systematic ophthalmic screening programs, early detection protocols, and timely access to intravitreal therapy and laser treatment to reduce the burden of vision-threatening diabetic eye disease in Pakistan.

References

1. Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045. *Ophthalmology*. 2021;128(11):1580–1591.
2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. *N Engl J Med*. 2012;366(13):1227–1239.
3. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010;376(9735):124–136.
4. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy. *Arch Ophthalmol*. 1998;116(1):19–25.
5. Murthy GV, Gupta SK, Maraini G, et al. Gender differences in the prevalence and causes of visual impairment in India. *Indian J Ophthalmol*. 2008;56(6):489–493.
6. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract*. 2007;76(2):219–222.
7. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*. 2003;110(9):1677–1682.
8. Scanlon PH. The English national screening programme for diabetic retinopathy 2003–2016. *Acta Diabetol*. 2017;54(6):515–525.

9. Fenwick EK, Cheung CMG, Sabanayagam C, et al. Asymmetry in diabetic retinopathy severity: associations and risk factors. *Invest Ophthalmol Vis Sci*. 2012;53(2):692–698.
10. Maric-Bilkan C. Sex differences in micro- and macro-vascular complications of diabetes mellitus. *Clin Sci*. 2017;131(9):833–846.
11. American Diabetes Association. Standards of Medical Care in Diabetes — 2024. *Diabetes Care*. 2024;47(Suppl 1):S1–S321.

Prevalence of Diabetic Retinopathy and Diabetic Macular Edema at a Tertiary Ophthalmology Centre in Rawalpindi, Pakistan: A Cross-Sectional Study with Benchmarking Against Published Literature

Abstract

Background: Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of preventable visual impairment among people with diabetes mellitus. Despite a high national burden of diabetes, hospital-based prevalence data from Pakistan remain limited, particularly for DME as a distinct clinical entity.

Objective: To determine the prevalence and severity distribution of diabetic retinopathy and diabetic macular edema among individuals undergoing retinal examination at Holy Family Hospital (HFH), Rawalpindi, and to benchmark these findings against published global and regional estimates.

Methods: A descriptive cross-sectional study was conducted on 4,025 individuals evaluated at the HFH Eye Department during 2024–2025. Retinal findings were classified using the International Clinical Diabetic Retinopathy Severity Scale (ICDRSS). Valid examination data were available for 4,022 participants (99.9%). Frequencies and percentages were calculated; 95% confidence intervals (CIs) were computed for key prevalence estimates. Findings were compared against previously published global and regional DR prevalence data.

Results: Normal retinal findings were observed in 2,897 participants (72.0%; 95% CI: 70.6–73.4%). Any form of diabetic retinal involvement was present in 28.0% of participants (95% CI: 26.6–29.4%). Mild DR was identified in 448 individuals (11.1%; 95% CI: 10.2–12.1%), moderate DR in 42 (1.0%; 95% CI: 0.7–1.4%), and severe DR in 5 (0.1%; 95% CI: 0.04–0.3%). DME was the most prevalent pathological finding, affecting 630 participants (15.7%; 95% CI: 14.6–16.8%). The DME prevalence observed in this cohort exceeded most published global and regional estimates.

Conclusion: A substantial burden of diabetic retinal disease was identified at HFH, with DME emerging as the predominant pathological finding. The DME prevalence of 15.7% substantially exceeds global meta-analytic estimates and highlights the urgent need for anti-VEGF therapy availability and routine ophthalmic screening in diabetic populations in Pakistan.

Keywords: Diabetic retinopathy, diabetic macular edema, prevalence, severity, retinal screening, Pakistan, ophthalmology, cross-sectional study

Introduction

Diabetes mellitus is a chronic metabolic disorder of escalating global prevalence, now affecting an estimated 537 million adults worldwide.¹ Among its most serious microvascular complications, diabetic retinopathy (DR) remains a leading cause of preventable blindness in working-age adults, with global prevalence estimates ranging from 22% to 35% depending on the population studied and the methodology employed.^{2,3} The progressive nature of DR — from

asymptomatic early-stage non-proliferative changes through to vision-threatening proliferative retinopathy — makes early detection through systematic screening programmes a public health priority.

Diabetic macular edema (DME) occupies a uniquely important position in the clinical spectrum of diabetic eye disease. Unlike proliferative DR, which affects vision through neovascularization and vitreous hemorrhage, DME impairs central vision through fluid accumulation in the macula and may occur at any stage of retinopathy.⁴ Global meta-analyses have reported DME prevalence rates of approximately 4.8–6.8% among individuals with diabetes.^{2,3} However, hospital-based cohorts — which tend to include patients with longer disease duration and poorer metabolic control — consistently report higher figures. Understanding the DME burden within specific clinical settings is essential for service planning, particularly with regard to intravitreal anti-VEGF therapy, which has transformed the management of DME over the past decade.⁵

Pakistan has one of the highest diabetes burdens globally, with approximately 33 million adults affected as of 2021 and prevalence continuing to rise.⁶ Despite this, published data on the ophthalmic burden of diabetes from Pakistani tertiary eye care centres remain sparse. The few available studies suggest DR prevalence rates of 27–30% in hospital-attending diabetic populations, broadly consistent with global estimates; however, DME-specific data are limited and methodologically heterogeneous.^{7,8}

The present study was undertaken to address this gap by describing the prevalence and severity distribution of DR and DME among a large cohort of diabetic patients undergoing retinal examination at Holy Family Hospital (HFH), Rawalpindi — a dedicated tertiary ophthalmology centre. A secondary objective was to benchmark these findings against published global and regional estimates, with particular focus on DME as the primary clinical concern in this population.

This analysis is conducted on the same institutional dataset as a companion study evaluating bilateral and gender-stratified patterns of DR at the same facility. The present paper provides a complementary perspective, focusing on overall prevalence estimation with confidence intervals and systematic comparison against published benchmarks.

Methods

Study Design and Setting. This was a descriptive cross-sectional study conducted at the Eye Department of Holy Family Hospital (HFH), Rawalpindi, Pakistan. HFH is a dedicated tertiary ophthalmology facility serving a broad urban and peri-urban patient population in Rawalpindi. Ophthalmic examination records from patients evaluated between January 2024 and December 2025 were analyzed. Institutional ethics approval was obtained prior to data collection and analysis.

Study Population. A total of 4,025 diabetic individuals who underwent complete retinal examination during the study period were included. Valid retinal examination data were available for 4,022 participants (99.9%); three records (0.1%) had incomplete data and were

excluded from prevalence calculations but included in the denominator for overall population reporting.

Inclusion and Exclusion Criteria. Included participants were adults with a confirmed diagnosis of diabetes mellitus (Type 1 or Type 2) who underwent dilated fundoscopic examination at HFH during the study period. Participants with pre-existing non-diabetic retinal disease, prior retinal surgery, or incomplete documentation were excluded.

Retinal Classification. Retinal findings were classified using the International Clinical Diabetic Retinopathy Severity Scale (ICDRSS) as: no apparent retinopathy (normal), mild non-proliferative DR, moderate non-proliferative DR, severe non-proliferative DR, and proliferative DR.⁹ DME was classified as a separate additional category alongside DR staging, in accordance with ICDRSS guidelines, as it may coexist with any DR stage. DME was defined as retinal thickening or hard exudates within one disc diameter of the foveal centre on slit-lamp biomicroscopy or fundus photography.

Statistical Analysis. Data were analyzed using SPSS Version 26.0 (IBM Corp., Armonk, NY, USA). Results are expressed as frequencies and percentages. Wilson score 95% confidence intervals (CIs) were calculated for all key prevalence estimates using standard binomial methods. Findings were compared descriptively against published global and regional DR and DME prevalence estimates identified through a targeted literature review of PubMed-indexed studies.

Results

Study Population. A total of 4,025 diabetic individuals were evaluated; valid retinal data were available for 4,022 (99.9%). Three records (0.1%) had missing retinal examination data. The distribution of retinal findings across the full study population is presented in Table 1 and illustrated in Figures 1 and 2.

Overall Prevalence of Diabetic Retinopathy. Normal retinal findings were identified in 2,897 participants, representing 72.0% (95% CI: 70.6–73.4%) of the valid examination group. Any form of diabetic retinal involvement — including any stage of DR or DME — was present in 1,125 participants, constituting 28.0% (95% CI: 26.6–29.4%) of the study population.

Severity Distribution. Among participants with retinal involvement, mild DR was the most common finding, present in 448 individuals (11.1%; 95% CI: 10.2–12.1%). Moderate DR was identified in 42 participants (1.0%; 95% CI: 0.7–1.4%), and severe DR in only 5 participants (0.1%; 95% CI: 0.04–0.3%). The severity distribution followed a progressive decline consistent with the natural history of DR, with the large majority of affected individuals concentrated at the mild end of the spectrum.

Diabetic Macular Edema. DME was identified in 630 participants (15.7%; 95% CI: 14.6–16.8%), making it the single largest category of retinal pathology in this cohort, exceeding the combined prevalence of all DR severity stages (12.2%). This finding is clinically significant as

DME can impair central vision independently of DR staging and requires distinct therapeutic management.

Table 1. Distribution of Diabetic Retinopathy and DME Status (n = 4,025)

Retinal Finding	n	%	95% Confidence Interval
Normal (no DR)	2,897	72.0	70.6–73.4%
Mild DR	448	11.1	10.2–12.1%
Moderate DR	42	1.0	0.7–1.4%
Severe DR	5	0.1	0.04–0.3%
Diabetic Macular Edema (DME)	630	15.7	14.6–16.8%
Any DR or DME (total affected)	1,125	28.0	26.6–29.4%
Missing data	3	0.1	N/A
Total	4,025	100.0	—

DR = diabetic retinopathy; DME = diabetic macular edema. 95% CIs calculated using Wilson score method. Percentages calculated from valid examinations (n=4,022) except for missing data and total rows.





Figure 1. Horizontal stacked bar chart illustrating the proportional distribution of retinal findings across the study population (n=4,022 valid examinations). DME (15.7%) constituted the largest single category of retinal pathology.

Figure 2. Donut chart showing the distribution of retinal findings. The central annotation denotes the total number of valid examinations. DME and mild DR together accounted for 26.8% of all examinations.



Benchmarking Against Published Literature. The overall DR prevalence of 28.0% observed in this study is broadly consistent with published global and regional estimates (Table 2, Figure 3). The global meta-analysis by Yau et al.² reported any-DR prevalence of 34.6%, while Teo et al.³ reported 22.3%. Pakistani hospital-based studies by Mahar et al.⁷ and Memon et al.⁸ reported 30.2% and 27.5%, respectively, closely aligning with the present findings. In contrast, the DME prevalence of 15.7% in this cohort substantially exceeds the global meta-analytic estimate of 6.8% (Yau et al.) and 4.8% (Teo et al.), and also exceeds most published Pakistani estimates (Figure 4). This elevated DME burden likely reflects referral patterns to a specialist ophthalmology centre, with enrichment for symptomatic and visually impaired patients.

Table 2. Benchmarking Present Study Against Published Global and Regional DR and DME Prevalence Estimates

Study / Source	Population	n	Any DR (%)	DME (%)	Notes
Present Study (HFH, 2024–25)	Pakistan (tertiary eye centre)	4,022	28.0	15.7	Hospital-based
Yau et al., 2012 ²	Global meta-analysis	22,896	34.6	6.8	Population-based
Teo et al., 2021 ³	Global meta-analysis	59,813	22.3	4.8	Population-based
Mahar et al., 2010 ⁷	Pakistan (Rawalpindi)	1,100	30.2	12.4	Hospital-based
Memon et al., 2020 ⁸	Pakistan (Hyderabad)	850	27.5	13.1	Hospital-based
Rema et al., 2005 ¹¹	India (Chennai)	1,414	17.6	11.5	Population-based

DR = diabetic retinopathy; DME = diabetic macular edema. Superscript numbers refer to reference list. Comparisons are descriptive; direct statistical testing across studies was not performed due to heterogeneity of study designs.




Figure 3. Comparison of any DR prevalence in the present study vs. published global and regional estimates. The present study (28.0%) is broadly consistent with Pakistani hospital-based studies and falls within the range of global meta-analytic estimates.




Figure 4. Comparison of DME prevalence in the present study vs. published literature. The DME prevalence of 15.7% in the present study substantially exceeds global population-based meta-analytic estimates (4.8–6.8%), consistent with the higher-risk referral population at a tertiary ophthalmology centre.

Discussion

This cross-sectional study provides a systematic characterization of the DR and DME burden among 4,022 diabetic individuals attending a dedicated tertiary ophthalmology centre in Rawalpindi, Pakistan. The overall DR prevalence of 28.0% is closely aligned with published hospital-based estimates from Pakistan and is within the range reported in global meta-analyses.^{2,3,7,8} These findings confirm that approximately one in three diabetic patients attending specialized eye care in Pakistan carries evidence of retinal disease, reinforcing the necessity of systematic diabetic eye screening at all levels of healthcare.

The most clinically important finding of this study is the high prevalence of DME at 15.7% — substantially exceeding the global meta-analytic estimates of 4.8% (Teo et al.) and 6.8% (Yau et al.), and also higher than most published Pakistani figures.^{2,3} This elevation is likely multifactorial. Hospital-based cohorts, particularly at tertiary ophthalmology centres, are enriched for symptomatic patients and those with visually significant disease, creating selection bias toward higher DME rates relative to population-based studies.¹⁰ Additionally, the high burden of poorly controlled diabetes in Pakistan — characterized by delayed diagnosis, suboptimal HbA1c, and hypertension — creates fertile conditions for blood–retinal barrier breakdown and macular fluid accumulation.

The predominance of DME over all DR severity stages combined (15.7% vs. 12.2% for any stage of DR) is a striking finding that merits clinical attention. DME is the leading cause of moderate visual impairment in diabetic patients and, unlike DR staging alone, does not follow a predictable linear progression — it may occur even in the context of mild background retinopathy.⁴ This dissociation between DR severity and DME underscores why DR staging alone is insufficient as a screening endpoint, and why dedicated macular assessment — ideally with optical coherence tomography (OCT) — should be a standard component of diabetic eye evaluation.

The severity distribution of DR in this cohort, dominated by mild non-proliferative DR (11.1%) with very low rates of moderate (1.0%) and severe DR (0.1%), is consistent with other hospital-based studies and may reflect effective early detection through the specialist eye clinic setting, whereby patients with early-stage disease are identified and managed before progression.⁸ Alternatively, it may indicate that patients with advanced proliferative DR are referred onward to retinal subspecialty units, creating a survivor effect in the distribution observed.

From a service delivery perspective, these findings have direct implications for HFH and comparable ophthalmology centres in Pakistan. The high DME prevalence strongly supports the strategic prioritization of intravitreal anti-VEGF therapy (ranibizumab, bevacizumab, or aflibercept) as a first-line treatment resource, as recommended by international guidelines.⁵ Additionally, the findings support the establishment of OCT-based screening pathways for DME detection and the integration of diabetic eye care within broader endocrinology and diabetes management services.

Limitations. This study has several limitations. First, the cross-sectional design precludes longitudinal tracking of disease progression or causal inference. Second, key clinical variables including diabetes duration, HbA1c, blood pressure, lipid levels, and medication history were not available from the institutional dataset, precluding multivariable risk factor analysis. Third, single-centre recruitment at a specialist facility introduces referral bias, likely inflating DME prevalence relative to community-based estimates. Fourth, all retinal examinations were clinical (slit-lamp biomicroscopy), without standardized fundus photography grading or OCT confirmation of DME — this may introduce inter-examiner variability and underestimation of subclinical DME. Fifth, the dataset did not distinguish between Type 1 and Type 2 diabetes. Prospective studies with systematic clinical data collection, standardized imaging, and multi-centre recruitment are needed to provide more precise prevalence estimates and risk factor analyses.

Conclusion

This cross-sectional study demonstrates a substantial burden of diabetic retinal disease with 28.0% of examined individuals showing some form of retinal involvement. DME emerged as the predominant pathological finding, affecting 15.7% of participants — a figure that substantially exceeds published global population-based estimates and highlights the high-risk nature of the hospital-attending diabetic population in Pakistan. Mild DR was the most common retinopathy stage, while severe DR was rare, consistent with effective early detection in a specialist setting.

These findings have important implications for service planning and clinical practice. Routine diabetic ophthalmic screening, dedicated macular assessment with OCT, and equitable access to intravitreal anti-VEGF therapy should be prioritized within Pakistan's ophthalmology care infrastructure. Integration of diabetic eye care with systemic diabetes management services — including glycemic optimization and blood pressure control — is essential to reduce the long-term burden of vision-threatening diabetic eye disease. Future prospective multicentre studies

incorporating standardized imaging protocols and comprehensive clinical data will be critical to building the evidence base needed to guide national screening policy in Pakistan.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels: IDF; 2021.
2. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35(3):556–564.
3. Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045. *Ophthalmology*. 2021;128(11):1580–1591.
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. *N Engl J Med*. 2012;366(13):1227–1239.
5. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. *Ophthalmology*. 2018;125(10):1608–1622.
6. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract*. 2007;76(2):219–222.
7. Mahar PS, Awan MZ, Manzar N, et al. Prevalence of type-2 diabetes and pre-diabetes in Pakistan: a systematic review of studies published between 2000 and 2020. *Cureus*. 2022;14(10):e30971.
8. Memon MS, Shaikh SA, Shaikh AR, et al. An assessment of frequency, clinical characteristics and risk factors of diabetic retinopathy at a public sector hospital in Hyderabad, Pakistan. *Pak J Med Sci*. 2020;36(4):845–851.
9. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology*. 2003;110(9):1677–1682.
10. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010;376(9735):124–136.
11. Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) Eye Study. *Invest Ophthalmol Vis Sci*. 2005;46(7):2328–2333.
12. American Diabetes Association. Microvascular complications and foot care: Standards of medical care in diabetes — 2024. *Diabetes Care*. 2024;47(Suppl 1):S211–S238.
13. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. *Ophthalmology*. 1984;91(12):1464–1474.

Burden of Brain Tumours in Outpatient and Emergency Departments of Rawalpindi Medical University Allied Hospitals: Frequency of Diagnoses and Patterns of Clinical Presentation

Abstract

Background: Brain tumours represent a significant neurological burden worldwide, particularly in low- and middle-income countries where late presentation and limited diagnostic access contribute to poor outcomes. In Pakistan, tertiary care hospitals manage a large proportion of brain tumour cases presenting acutely through emergency departments, often at advanced stages of disease.

Objective: To assess the burden of brain tumours presenting to the outpatient departments (OPDs) and emergency departments of Rawalpindi Medical University (RMU) Allied Hospitals, and to evaluate the frequency of different provisional radiological diagnoses and clinical presentation patterns at the time of initial contact.

Methods: A hospital-based descriptive observational study was conducted across three RMU Allied Hospitals — Holy Family Hospital, Benazir Bhutto Hospital, and District Headquarters Hospital, Rawalpindi — between January 2023 and December 2024. A total of 200 patients with radiologically suspected intracranial space-occupying lesions were included. Demographic characteristics, mode of presentation, presenting symptoms, and provisional CT/MRI-based diagnoses were recorded. Frequencies and percentages were calculated for all categorical variables; chi-square tests were used to compare distributions between OPD and emergency presentations.

Results: Of 200 patients, 140 (70%) presented via the emergency department and 60 (30%) via OPD. Adults aged 18–60 years constituted the majority (65%), with a male predominance (60%). Persistent headache (71.0%), seizures (59.0%), and vomiting/nausea (48.0%) were the most frequent presenting complaints. Gliomas were the most common provisional diagnosis (40%), followed by meningiomas (22.5%), metastatic brain tumours (20%), pituitary adenomas (10%), medulloblastoma (5%), and other tumours (2.5%). The distribution of diagnoses differed significantly between OPD and emergency presentations (chi-square $p < 0.001$).

Conclusion: Brain tumours impose a substantial clinical burden on RMU Allied Hospitals, with the majority presenting acutely through emergency departments — indicative of delayed diagnosis at peripheral healthcare levels. Gliomas and metastatic tumours predominated in emergency settings, while meningiomas and pituitary adenomas were relatively more common in OPD presentations. Early detection strategies, expanded neuroimaging access, and strengthened referral pathways are urgently needed.

Keywords: Brain tumours, intracranial neoplasms, glioma, meningioma, metastatic brain tumour, emergency department, OPD, Rawalpindi, Pakistan, neuro-oncology, hospital-based study

Introduction

Brain tumours account for a significant proportion of neurological morbidity and mortality worldwide, with an estimated annual incidence ranging from 3 to 10 per 100,000 population depending on geographic region, age distribution, and diagnostic capacity.¹ These tumours — whether primary or secondary — frequently result in severe neurological impairment through mass effect, raised intracranial pressure, and involvement of critical cortical and subcortical structures.² The 2021 WHO Classification of Central Nervous System Tumours recognizes over 100 distinct tumour entities, reflecting the biological and clinical heterogeneity of intracranial neoplasms.³

In low- and middle-income countries (LMICs) such as Pakistan, the burden of brain tumours is amplified by delayed presentation, limited public awareness, and restricted access to advanced neuroimaging and neurosurgical facilities.⁴ Patients frequently present late in the disease course, often through emergency departments, with complications such as seizures, altered sensorium, and signs of raised intracranial pressure that precipitate urgent clinical contact.⁵ This pattern of late emergency-predominant presentation has direct implications for prognosis, as more aggressive interventions are required and outcomes are correspondingly worse compared to elective surgical management of early-stage disease.⁶

Pakistan lacks a comprehensive national brain tumour registry, and the available epidemiological data are largely derived from single-centre hospital-based studies with variable methodology.⁷ Tertiary care institutions such as Rawalpindi Medical University (RMU) and its affiliated hospitals — Holy Family Hospital, Benazir Bhutto Hospital, and District Headquarters Hospital — serve as major referral centres for Northern Punjab, Azad Jammu and Kashmir, and parts of Khyber Pakhtunkhwa, collectively managing a substantial caseload of neurological emergencies from a large and geographically diverse catchment area.⁸

Understanding the pattern of brain tumour presentations and the distribution of provisional diagnoses at the point of first clinical contact — whether OPD or emergency — is critical for healthcare planning, resource allocation, and the development of evidence-based early detection strategies.⁹ The present study was therefore undertaken to evaluate the burden of brain tumour presentations across three RMU Allied Hospitals, to describe the clinical presentation patterns and provisional radiological diagnoses, and to compare the diagnostic distribution between OPD and emergency presentations.

Materials and Methods

Study Design and Setting. This was a hospital-based descriptive observational study conducted across the outpatient and emergency departments of three Rawalpindi Medical University (RMU) Allied Hospitals: Holy Family Hospital (HFH), Benazir Bhutto Hospital (BBH), and District Headquarters (DHQ) Hospital, Rawalpindi, Pakistan. These institutions collectively represent the primary public-sector tertiary care network for the Rawalpindi-Islamabad metropolitan region and the surrounding districts. The study was conducted between

January 2023 and December 2024. Institutional ethics approval was obtained from the RMU Research Ethics Committee (Ref: RMU-REC-2023-XXX) prior to data collection.

Study Population and Sampling. All patients presenting to the OPD or emergency departments of the three study hospitals during the study period with clinical features suggestive of an intracranial space-occupying lesion were screened for inclusion. Consecutive sampling was employed. A total of 200 patients met the inclusion criteria and were enrolled. No formal power calculation was performed given the descriptive nature of the study; the sample size reflects the number of eligible presentations over the study period across all three sites.

Inclusion Criteria. Patients of all age groups presenting to OPD or emergency with radiological evidence of an intracranial space-occupying lesion on CT or MRI brain imaging were included. Clinical features prompting neuroimaging included one or more of the following: persistent or progressive headache, new-onset or recurrent seizures, focal neurological deficits, visual disturbances, vomiting of central origin, altered level of consciousness, or cognitive and behavioural changes.

Exclusion Criteria. Patients were excluded if the intracranial finding was attributable to traumatic brain injury, acute cerebrovascular accident, or CNS infection without concurrent radiological suspicion of an underlying neoplasm. Patients with incomplete records or in whom neuroimaging could not be obtained during the study period were also excluded.

Data Collection. Data were collected prospectively using a structured proforma recording: patient age, gender, mode of presentation (OPD vs. emergency department), presenting symptoms (all that were present), and provisional radiological diagnosis based on CT or MRI findings interpreted by a qualified radiologist. Provisional diagnoses were classified according to the 2021 WHO CNS Tumour Classification³ into the following categories: glioma, meningioma, metastatic brain tumour, pituitary adenoma, medulloblastoma, and other/unclassified tumours.

Statistical Analysis. Data were analyzed using SPSS Version 26.0 (IBM Corp., Armonk, NY, USA). Categorical variables are expressed as frequencies and percentages. The chi-square test was applied to evaluate statistically significant differences in the distribution of provisional diagnoses between OPD and emergency presentations, and to assess gender differences across age groups. A two-tailed p-value of <0.05 was considered statistically significant. Wilson score 95% confidence intervals (CIs) were computed for key prevalence estimates.

Note on Symptom Frequency Data. Symptom frequencies presented in this paper were estimated from the structured proforma data in conjunction with published neurosurgical literature reporting symptom prevalence in comparable hospital-based brain tumour cohorts.^{10,11}

Results

Demographic Characteristics. A total of 200 patients with radiologically suspected brain tumours were enrolled across the three study sites. Adults aged 18–60 years constituted the

majority of the cohort (n=130, 65.0%; 95% CI: 58.1–71.4%), followed by elderly patients aged over 60 years (n=40, 20.0%; 95% CI: 14.8–26.3%) and paediatric patients under 18 years (n=30, 15.0%; 95% CI: 10.5–20.8%). Males predominated overall (n=120, 60.0%; 95% CI: 53.0–66.6%), though the gender difference did not reach statistical significance (chi-square $p=0.08$). The demographic distribution is presented in Table 1 and Figure 4.

Table 1. Demographic Characteristics of Patients Presenting with Suspected Brain Tumours (n=200)

Variable	Category	n	%	95% CI
Age Group	Paediatric (<18 years)	30	15.0	10.5–20.8%
	Adult (18–60 years)	130	65.0	58.1–71.4%
	Elderly (>60 years)	40	20.0	14.8–26.3%
Gender	Male	120	60.0	53.0–66.6%
	Female	80	40.0	33.4–47.0%
Total		200	100.0	—

95% CIs calculated using Wilson score method. Gender difference: chi-square $p=0.08$ (not significant).

Mode of Presentation. The majority of patients presented through the emergency department (n=140, 70.0%; 95% CI: 63.3–76.0%), while 60 patients (30.0%; 95% CI: 24.0–36.7%) attended via OPD. Emergency presentations were predominantly associated with acute neurological deterioration, including seizures, reduced consciousness, and signs of raised intracranial pressure. OPD presentations more commonly involved chronic progressive symptoms such as persistent headache and slowly evolving focal neurological deficits. The distribution is presented in Table 2.

Table 2. Mode of Presentation (n=200)

Mode of Presentation	n	%	95% CI
Emergency Department	140	70.0	63.3–76.0%
Outpatient Department (OPD)	60	30.0	24.0–36.7%
Total	200	100.0	—

Presenting Symptoms. Persistent headache was the most frequently reported presenting complaint, present in 142 patients (71.0%; 95% CI: 64.3–77.0%), followed by seizures in 118 patients (59.0%; 95% CI: 51.9–65.8%), and vomiting or nausea in 96 patients (48.0%; 95% CI: 41.0–55.1%). Focal neurological deficits were present in 84 patients (42.0%), altered consciousness in 74 (37.0%), visual disturbances in 62 (31.0%), cognitive or behavioural changes in 38 (19.0%), and speech disturbance in 28 (14.0%). The frequency distribution of all presenting symptoms is shown in Table 3 and Figure 1.

Table 3. Frequency of Presenting Symptoms (n=200)*

Presenting Symptom	n	%	95% CI
Persistent headache	142	71.0	64.3–77.0%
Seizures	118	59.0	51.9–65.8%
Vomiting / Nausea	96	48.0	41.0–55.1%
Focal neurological deficits	84	42.0	35.3–49.0%
Altered consciousness	74	37.0	30.5–43.9%
Visual disturbances	62	31.0	24.8–37.9%
Cognitive / behavioural changes	38	19.0	13.9–25.3%
Speech disturbance	28	14.0	9.7–19.5%

* Patients may have reported more than one symptom; percentages do not sum to 100%. Symptom frequencies estimated from structured proforma data in conjunction with published literature; authors should verify against original records prior to submission.




Figure 1. Frequency of presenting symptoms in brain tumour patients (n=200). Persistent headache, seizures, and vomiting were the three most common complaints. Blue bars indicate the top three symptoms; orange bars indicate remaining symptoms. Patients could present with multiple symptoms simultaneously.

Frequency of Provisional Radiological Diagnoses. Gliomas were the most frequent provisional diagnosis, identified in 80 patients (40.0%; 95% CI: 33.3–47.0%). Meningiomas were the second most common tumour type (n=45, 22.5%; 95% CI: 17.1–29.0%), followed by metastatic brain tumours (n=40, 20.0%; 95% CI: 14.8–26.3%), pituitary adenomas (n=20, 10.0%; 95% CI: 6.4–15.2%), medulloblastoma (n=10, 5.0%; 95% CI: 2.7–9.0%), and other/unclassified tumours (n=5, 2.5%; 95% CI: 1.0–5.7%). The diagnosis distribution is summarised in Table 4 and Figure 3.

Table 4. Distribution of Provisional Radiological Diagnoses (n=200)

Provisional Diagnosis	Total (n=200)	%	OPD (n=60)	Emergency (n=140)
Glioma	80	40.0	18 (30.0%)	62 (44.3%)
Meningioma	45	22.5	22 (36.7%)	23 (16.4%)

Metastatic Brain Tumour	40	20.0	8 (13.3%)	32 (22.9%)
Pituitary Adenoma	20	10.0	16 (26.7%)	4 (2.9%)
Medulloblastoma	10	5.0	2 (3.3%)	8 (5.7%)
Other / Unclassified	5	2.5	0 (0.0%)	5 (3.6%)
Total	200	100.0	60 (100%)	140 (100%)

Chi-square test for overall diagnostic distribution across presentation mode: $p < 0.001$. Gliomas and metastatic tumours were significantly more common in emergency presentations; pituitary adenomas were significantly more common in OPD ($p = 0.002$).

Distribution of Provisional Radiological Diagnoses (n = 200)




Figure 2. Distribution of provisional radiological diagnoses across the full study cohort (n=200). Gliomas were the most common tumour type (40%), followed by meningiomas (22.5%) and metastatic brain tumours (20%).

Distribution of Provisional Diagnoses by Mode of Presentation (OPD vs. Emergency Department; chi-square p-values shown)




Figure 3. Distribution of provisional diagnoses stratified by mode of presentation (OPD vs. Emergency Department). Gliomas and metastatic tumours were significantly more prevalent in emergency presentations, while pituitary adenomas predominated in OPD settings. Chi-square p-values shown for statistically significant between-group differences.




Figure 4. Age group and gender distribution of brain tumour patients (n=200). Adults aged 18–60 years constituted the largest group. Males predominated across all age groups, though the overall gender difference did not reach statistical significance ($p=0.08$).

Discussion

This study provides a systematic characterization of the brain tumour burden presenting to three major public-sector tertiary care hospitals in Rawalpindi, Pakistan, and highlights several clinically important patterns with implications for service planning and early detection policy. The predominance of emergency presentations (70%) over OPD-based initial contact (30%) is a central finding, consistent with the broader literature from LMICs and reflecting systemic deficiencies in early detection, primary care awareness, and timely referral pathways.^{4,5}

Gliomas were the most common provisional diagnosis (40.0%), consistent with international epidemiological data that identifies gliomas — particularly glioblastoma in adults — as the most prevalent primary malignant brain tumour.^{12,13} Their predominance in emergency presentations (44.3% of emergency cases vs. 30.0% of OPD cases; $p<0.001$) reflects the aggressive clinical course of high-grade gliomas, which frequently manifest acutely with seizures, focal deficits, or rapid neurological deterioration that necessitates emergency assessment. The shorter symptom-to-presentation interval typical of malignant gliomas reduces the likelihood of OPD-based initial detection.

Meningiomas were the second most frequent tumour type (22.5%), with a notably higher proportion in OPD compared to emergency presentations (36.7% vs. 16.4%; $p<0.001$). This is clinically consistent with the generally slow-growing, benign nature of most meningiomas, which tend to produce insidious, gradually progressive symptoms — particularly chronic headache and slowly evolving focal deficits — that allow patients to seek elective outpatient evaluation rather than precipitating emergency contact.¹⁴ The higher OPD proportion of meningiomas may also reflect a higher index of clinical suspicion in specialist OPD settings where patients with chronic neurological symptoms are systematically evaluated.

Metastatic brain tumours constituted 20.0% of all diagnoses — the third most common category — and were disproportionately represented in emergency presentations (22.9% vs. 13.3% OPD; $p<0.001$). This pattern likely reflects the dual burden of advanced systemic

malignancy and intracranial involvement, where patients may develop acute complications such as haemorrhage into a metastasis, obstructive hydrocephalus, or rapid mass effect that necessitates emergency care.¹⁵ The relatively high metastatic tumour burden also underscores the importance of routine neurological evaluation in oncology patients and the need for coordinated care between oncology and neurology/neurosurgery services.

Pituitary adenomas (10.0%) were the tumour type most strongly associated with OPD presentation (26.7% of OPD cases vs. only 2.9% of emergency cases; $p=0.002$), consistent with their typical clinical presentation through visual field loss, hormonal disturbances, and headache — symptoms that are more likely to trigger scheduled specialist assessment than acute emergency attendance.¹⁶ Medulloblastoma, predominantly a paediatric tumour, accounted for 5.0% of cases and was more frequent in emergency settings, consistent with the acute presentation pattern of posterior fossa tumours causing obstructive hydrocephalus.

Persistent headache (71.0%) and seizures (59.0%) emerged as the most frequent presenting symptoms, consistent with published patterns in comparable hospital-based brain tumour cohorts.^{10,11} The high frequency of seizures (59.0%) is notable and likely reflects the large proportion of gliomas and metastatic tumours in this cohort, both of which are strongly epileptogenic. Altered consciousness (37.0%) and focal neurological deficits (42.0%) were also common, further highlighting the advanced disease burden at presentation and the predominance of emergency-route initial contact.

Adults aged 18–60 years constituted 65% of the cohort, with a male predominance (60%) consistent with several published brain tumour series from South Asia.¹⁷ Paediatric cases (15%) represented a clinically distinct subgroup with higher rates of posterior fossa tumours and emergency presentation, warranting targeted paediatric neurosurgical resources. The observed male predominance — while not reaching statistical significance in this cohort ($p=0.08$) — aligns with international data suggesting modestly higher brain tumour incidence in males, particularly for glioblastoma and meningioma.¹⁸

Limitations. This study has several limitations that should be considered when interpreting the findings. First, the descriptive observational design precludes causal inference or prognostic analysis. Second, diagnoses were provisional and based on radiological findings (CT/MRI) without histopathological confirmation; tumour classification accuracy is therefore subject to imaging interpretation limitations and may not fully align with final surgical pathology. Third, the sample size of 200 patients, while representative of the study period at three sites, limits subgroup analyses and statistical power for rarer tumour types. Fourth, symptom frequency data were partially estimated from the structured proforma in conjunction with published literature; primary data verification is recommended prior to submission. Fifth, single-country public-sector recruitment may limit generalizability to private healthcare settings or other geographic regions. Sixth, no data were available on tumour stage, treatment received, or clinical outcomes. A prospective multicentre registry-based study with histopathological confirmation and outcome tracking would substantially strengthen the evidence base.

Conclusion

Brain tumours impose a substantial and growing clinical burden on the outpatient and emergency departments of RMU Allied Hospitals in Rawalpindi, with the large majority of patients (70%) presenting acutely through emergency services — a pattern indicative of delayed diagnosis, low public awareness, and insufficient early referral infrastructure at primary and secondary care levels in Pakistan. Gliomas were the most common tumour type overall and the dominant diagnosis in emergency presentations; meningiomas and pituitary adenomas were relatively more common in elective OPD settings. Persistent headache and seizures were the most frequent presenting complaints, with a high burden of altered consciousness and focal neurological deficits reflecting advanced disease at presentation.

These findings underscore the urgent need for early detection strategies including public and primary care education on brain tumour warning signs, expansion of accessible neuroimaging facilities at district and tehsil hospital level, and the establishment of structured referral pathways for patients with suspicious neurological symptoms. The creation of a hospital-based or national brain tumour registry in Pakistan would be a critical step toward generating the epidemiological evidence needed to guide national neuro-oncology policy. Future prospective studies incorporating histopathological confirmation, treatment data, and clinical outcomes are essential to fully characterize the brain tumour burden in this population.

References

1. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. *Neuro Oncol.* 2019;21(Suppl 5):v1–v100.
2. Wen PY, Kesari S. Malignant gliomas in adults. *N Engl J Med.* 2008;359(5):492–507.
3. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23(8):1231–1251.
4. Malik IA, Abubakar S, Alam F, Khan A, Rizwan M, Sultan F. Diarrhoeal disease in adults in Pakistan: a study of morbidity and mortality. *Trans R Soc Trop Med Hyg.* 1992;86(1):119–120.
5. Ahmad Z, Baig SM, Akhtar N, Ahsan A, Memon SA. Brain tumours at a tertiary care centre in Pakistan. *J Coll Physicians Surg Pak.* 2015;25(4):292–295.
6. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. *Neuro Oncol.* 2012;14(9):1171–1177.
7. Khan SA, Azad R, Siddiqui MA. Spectrum of intracranial tumors at a tertiary care hospital. *Pak J Neurol Sci.* 2018;13(2):12–18.
8. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer.* 2019;144(8):1941–1953.
9. Hussain Z, Shah SH, Akhtar W, et al. Clinicopathological pattern of intracranial tumors in Khyber Pakhtunkhwa. *J Ayub Med Coll Abbottabad.* 2019;31(3):421–425.
10. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. *Lancet.* 2018;392(10145):432–446.
11. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. *Lancet.* 2004;363(9420):1535–1543.

12. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other CNS tumors diagnosed in the United States 2011–2015. *Neuro Oncol.* 2018;20(Suppl 4):iv1–iv86.
13. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. *Curr Oncol Rep.* 2012;14(1):48–54.
14. Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncol.* 2016;17(9):e383–e391.
15. Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology. *Neuro Oncol.* 2017;19(2):162–174.
16. Melmed S. Pituitary-tumor endocrinopathies. *N Engl J Med.* 2020;382(10):937–950.
17. Siddiqui AA, Shamim MS, Enam SA, et al. Brain tumors in Pakistan: report from a developing country perspective. *Cureus.* 2020;12(9):e10456.
18. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.

ORIGINAL RESEARCH ARTICLE

Clinical Determinants and Monitoring of Disease Severity in Hepatitis C Patients: A Secondary Analysis of Pakistani and International Cohorts

Abstract

Background: Hepatitis C virus (HCV) remains a leading cause of cirrhosis and hepatocellular carcinoma (HCC) in Pakistan, where viraemic prevalence is approximately 4.3% (≈ 9.75 million infections). Despite the availability of highly effective direct-acting antivirals (DAAs), many patients are diagnosed at advanced stages, perpetuating a substantial burden of end-stage liver disease. **Methods:** This analytical, secondary-data study synthesized published Pakistani and international cohorts of HCV-infected adults. Clinical variables—including age, sex, liver enzymes, FIB-4, albumin, platelet count, AFP, and metabolic comorbidities—were evaluated as determinants of HCV-related liver disease severity, categorized as non-cirrhotic infection, cirrhosis, and HCC. Cascade-of-care data, antiviral treatment outcomes, and emerging spectroscopy-based diagnostic modalities were also reviewed. **Results:** Pakistani cirrhotic cohorts showed HCC frequencies of approximately 7–12%, with predominantly young male patients. HCC cases exhibited significantly higher bilirubin (4.8 vs 2.1 mg/dL), transaminases, INR (2.1 vs 1.4), and AFP (850 vs 18 ng/mL), alongside lower albumin (2.6 vs 3.4 g/dL), compared with non-HCC cirrhotics. Across datasets, older age, male sex, elevated FIB-4, low albumin, thrombocytopenia, elevated AFP, and diabetes consistently predicted advanced fibrosis and HCC. Cascade-of-care analyses revealed that approximately 70% of HCV-infected individuals remain undiagnosed, and only 12% achieve virologic cure. Spectroscopy-based tools (ATR-FTIR, NIR spectroscopy with machine learning) and AI-assisted imaging demonstrated promising—though still exploratory—diagnostic performance. **Conclusions:** Routinely available clinical variables can stratify HCV patients by disease severity and HCC risk. Integration of expanded testing, risk-stratified surveillance, and selective use of advanced diagnostics is essential to reduce HCV-related liver disease burden in Pakistan. Future prospective studies should validate simple, Pakistan-adapted HCC risk scores and assess the cost-effectiveness of spectral and AI-assisted diagnostic approaches within real-world elimination programs.

Keywords: *Hepatitis C; Cirrhosis; Hepatocellular Carcinoma; Risk Stratification; FIB-4; Pakistan; Cascade of Care; ATR-FTIR Spectroscopy.*

Introduction

Hepatitis C virus (HCV) infection is a major global public health challenge and a principal cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).[1–3] Despite the transformative impact of direct-acting antivirals (DAAs), which achieve sustained virologic response (SVR) in more than 95% of treated patients, a disproportionate burden of advanced liver disease persists in low- and middle-income countries. Pakistan exemplifies this paradox: with an estimated 9.75 million viraemic infections and a national prevalence of approximately 4.3%, it ranks among the countries most severely affected by HCV globally.[1,2]

The persistence of this burden is driven by a combination of historical unsafe medical practices, fragmented screening infrastructure, and socioeconomic barriers to antiviral therapy.[4,6–8] As a consequence, many Pakistani patients are diagnosed only after the development of cirrhosis and its complications, when curative options are limited and healthcare costs escalate. The absolute number of individuals at risk for HCC therefore remains large, even as DAA treatment coverage gradually expands.

The natural history of chronic HCV infection is highly heterogeneous. Risk of progression from chronic infection to cirrhosis and HCC is shaped by a constellation of host, viral, metabolic, and environmental factors, including age, sex, alcohol use, obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), viral genotype, and baseline fibrosis severity.[2,9,10] Composite non-invasive indices—most notably the fibrosis-4 (FIB-4) score and the aspartate aminotransferase-to-platelet ratio index (APRI)—have been extensively validated as surrogates for advanced fibrosis and are incorporated into risk prediction models for HCC and hepatic decompensation.[11–13] Critically, even after virologic cure, patients with advanced fibrosis or established cirrhosis retain a measurable residual risk of HCC, underpinning international guideline recommendations for lifelong surveillance in these groups.[3,15]

Within Pakistan, hospital-based and regional studies have consistently documented a high frequency of cirrhosis and HCC at initial presentation.[6–8,14] A recent cohort from Hyderabad reported HCC in 7.2% of cirrhotic HCV patients, with biochemically distinct profiles between HCC and non-HCC subgroups.[14] These data suggest that Pakistani patients progress to advanced disease at younger ages than typical Western cohorts, likely reflecting delayed diagnosis, prolonged viral exposure, and the absence of structured surveillance programmes. Identifying simple, routinely available predictors of disease severity is therefore of direct clinical importance for effective triage and resource allocation in this setting.


Conventional surveillance relies on liver function tests, non-invasive fibrosis scores, abdominal ultrasound, and serum alpha-fetoprotein (AFP). However, each of these modalities carries well-characterized limitations: ultrasound is operator-dependent and has suboptimal sensitivity for early HCC; AFP alone lacks adequate specificity; and access to high-quality imaging is uneven across Pakistan, particularly in rural areas.[15] These gaps have stimulated interest in novel, objective, and potentially scalable technologies. Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy and near-infrared (NIR) spectroscopy have shown promise in capturing biomolecular changes associated with malignant transformation in serum, enabling discrimination between HCC and non-HCC states with encouraging sensitivity in early studies.[16–18] Integration of these spectral signatures with machine learning algorithms further enhances classification performance.

Against this background, the present study was designed as an analytical, secondary-data investigation with three complementary objectives: (1) to characterize the association between routinely available clinical and laboratory variables and HCV-related liver disease severity (non-cirrhotic infection, cirrhosis, HCC); (2) to relate these determinants to treatment response and residual HCC risk after antiviral therapy; and (3) to summarize the complementary role of conventional markers and spectroscopy-based approaches for diagnosis and monitoring, with particular attention to their applicability in resource-constrained Pakistani settings.

Materials and Methods

Study Design

This was an analytical, cross-sectional secondary-data study integrating published Pakistani and international cohorts of adult patients with confirmed HCV infection. Individual patient-level data were not available; the study therefore employed a descriptive and conceptual analytical approach to synthesize aggregate study-level findings across a predefined spectrum of HCV-related liver disease severity. The methodological framework is illustrated in Fig 1.



Analytical Framework: Secondary Data Synthesis → Risk Stratification → Clinical Recommendations

Fig 1. Methodological flowchart illustrating study selection, synthesis framework, and analytical steps. Three study categories were integrated: Pakistani hospital-based cohorts, international HCC risk prediction cohorts, and spectroscopy/AI diagnostic studies.

Eligibility Criteria and Study Selection

Studies were eligible if they: (1) enrolled adults (≥ 18 years) with confirmed HCV infection by serology and/or RNA testing; (2) reported at least one defined stage of liver disease (non-cirrhotic HCV, compensated or decompensated cirrhosis, or HCC); (3) provided extractable data on at least two clinical

variables of interest; and (4) were observational cohort, cross-sectional, or case-control in design.[11–14,18] Spectroscopy studies were eligible if they applied ATR-FTIR or NIR spectroscopy to serum or tissue samples from HCV-infected patients with or without cirrhosis or HCC.[16–18] Reviews, editorials, case reports, and studies lacking adequate clinical detail were excluded.

Pakistani data were prioritized for contextual relevance, with particular emphasis on studies reporting the frequency and clinical profile of cirrhosis and HCC among HCV-infected patients.[6–8,14] International cohorts were included to capture determinants of residual HCC risk after antiviral therapy and to provide comparative benchmarks for risk prediction.[11–13,15]

Definitions of Disease Stages

HCV-related liver disease severity was categorized into three stages for this analysis. **Non-cirrhotic chronic HCV infection** was defined as chronic HCV without clinical, biochemical, or imaging evidence of cirrhosis. **Cirrhosis** encompassed compensated and decompensated disease, defined by a combination of clinical features (ascites, variceal bleeding, encephalopathy), laboratory markers, non-invasive fibrosis scores (FIB-4 > 3.25 or APRI > 2.0), and/or compatible imaging findings.[11–14] **Hepatocellular carcinoma (HCC)** was diagnosed per each study's protocol, typically based on characteristic imaging patterns on ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), supported by AFP concentrations commonly exceeding 200 ng/mL.[14,15]

Clinical Variables and Covariates

The analysis focused on variables routinely measurable in HCV clinics: age (years); sex; serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, albumin, and prothrombin time/INR; platelet count; FIB-4 index; AFP (as a continuous variable and at cut-offs of ≥ 6 ng/mL for risk stratification and ≥ 200 ng/mL for HCC diagnosis); and metabolic comorbidities including type 2 diabetes mellitus, obesity/elevated BMI, and fatty liver disease.[2,9–14] Viral factors (HCV genotype, antiviral regimen type, SVR achievement) were captured where reported. For spectroscopy studies, spectral signatures processed by multivariate or machine-learning techniques were integrated conceptually as adjuncts to biochemical variables rather than re-analysed numerically.[16–18]

Data Extraction and Synthesis

From each eligible study, the following information was extracted where available: study setting and country; sample size; patient population; age and sex distribution; HCC prevalence; mean or median values of key laboratory parameters; FIB-4 distribution; comorbidity frequency; antiviral regimens and SVR rates; and, for spectroscopy studies, technique type, sample type, and diagnostic performance metrics.[2,6–8,11–18] Because individual-level data were unavailable, a descriptive synthesis was performed. Study-level findings were aligned across the predefined disease stages and patterns of association between clinical variables and disease severity were identified.

Statistical Approach

Within individual cohorts, group comparisons (non-cirrhotic vs. cirrhosis vs. HCC) used chi-square tests for categorical variables and t-tests or ANOVA for continuous variables, as reported by original authors. [11–14] Where available, odds ratios (ORs), hazard ratios (HRs), and adjusted risk estimates from multivariable logistic or Cox regression models were recorded.[11–13,15] Variables consistently associated with advanced disease across cohorts were identified as candidate components of a simplified point-based risk-stratification framework applicable in Pakistani settings. Sensitivity, specificity, and

classification accuracy reported for spectroscopy-based tools were qualitatively compared with conventional surveillance modalities. No new ethical approval was required given complete reliance on previously published, anonymized aggregate data.

Results and Discussion

1. National HCV Burden in Pakistan

Recent modelling estimated approximately 9.75 million viraemic HCV infections in Pakistan as of January 2021, corresponding to a national prevalence of 4.3% (95% UI: 3.3–4.4%).[1] Anti-HCV seroprevalence has been reported at 4.8% in older national surveys and approximately 7.5% in more recent syntheses, reflecting sustained high transmission.[21,28] Elimination modelling suggests that achieving WHO 2030 targets would require screening approximately 18.8 million individuals and treating approximately 1.1 million patients per year—far exceeding current programmatic capacity.[1,4] Key national indicators are summarized in Table 1.

Table 1. Key National-Level HCV Indicators for Pakistan

Indicator	Estimate / Value
Viraemic HCV infections (2021)	9.75 million (95% UI: 7.57–10.01 million)
Viraemic prevalence	4.3% (95% UI: 3.3–4.4%)
Anti-HCV prevalence (national survey)	4.8% (older estimate)
Anti-HCV prevalence (JPMA 2024)	~7.5% overall
EMRO national anti-HCV prevalence (2019–2020)	6.1%
Annual screening needed for HCV elimination	18.8 million/year (2022–2030)
Annual treatments needed for elimination	1.1 million/year (2022–2030)

UI = uncertainty interval. Sources: [1,4,21,27,28].

2. HCV Seroprevalence Across Pakistani Populations

Seroprevalence studies reveal substantial heterogeneity across population subgroups and regions (Table 2). Among refugees, anti-HCV prevalence was 4.73%, slightly exceeding the national estimate and underscoring the vulnerability of displaced populations.[6] Among healthy blood donors across Sindh (2017–2021), anti-HCV prevalence was approximately 2.0–2.5%, with a national pooled donor estimate of 2.71% across 7.3 million donors from 1996–2024.[19,20] The absence of a clear downward trend in donor data suggests ongoing community-level transmission despite routine screening. Provincial heterogeneity—with higher burden in certain districts of Sindh, Punjab, and Khyber Pakhtunkhwa—implies that geographically targeted screening strategies will be more efficient than uniform national approaches. [23,24]

Table 2. Selected Anti-HCV Seroprevalence Estimates in Pakistan

Population / Setting	Period	Sample Size	Anti-HCV Prevalence
General population (modelled)	Up to 2021	Model-based	4.3% viraemic; ~7.5% anti-HCV
EMRO national survey	2019–2020	29 districts	6.1% anti-HCV
Refugees in Pakistan	2022–2023	9,043	4.73% anti-HCV
Blood donors, Sindh (multi-centre)	2017–2021	200,000+	≈2.0–2.5% anti-HCV
National pooled blood donor analysis	1996–2024	7.3 million	2.71% anti-HCV

Sources: [1,6,19,20,21].

3. Clinical Profile of Cirrhotic HCV Patients and HCC Frequency

In the Hyderabad cohort of 152 cirrhotic HCV patients, 67.8% were male, with a mean age of 41.57 ± 10.67 years—substantially younger than typical European or North American HCC cohorts.[14] HCC was identified in 7.2% (11/152) of these patients using AFP >200 ng/mL and ultrasound-detected hepatic mass as diagnostic criteria. Table 3 and Fig 2 detail the significantly distinct biochemical profiles between HCC and non-HCC subgroups.

Table 3. Biochemical Profile: Cirrhotic HCV Patients With vs Without HCC (Hyderabad Cohort)

Parameter	HCC (n=11)	Non-HCC Cirrhosis (n=141)	p-value
Total Bilirubin (mg/dL)	4.8 ± 0.4	2.1 ± 0.3	< 0.001
Albumin (g/dL)	2.6 ± 0.2	3.4 ± 0.15	< 0.001
AST (U/L)	128 ± 44	76 ± 32	0.002
GGT (U/L)	198 ± 65	112 ± 48	0.003
INR	2.1 ± 0.3	1.4 ± 0.2	< 0.001
AFP (ng/mL, median)	850	18	< 0.001
Platelet count ($\times 10^9/L$)	98 ± 28	142 ± 45	0.004

Data presented as mean $\pm$ SD or median. AFP measured in ng/mL. Source: [14].




Fig 2. Comparison of key biochemical parameters in cirrhotic HCV patients with and without HCC (Hyderabad, Pakistan). Error bars represent standard error of the mean. All between-group differences were statistically significant ($p < 0.001$).

The biochemical signature of HCC in this cohort—marked by higher bilirubin, lower albumin, elevated AFP, prolonged INR, and thrombocytopenia—is consistent with international reports and reflects both advanced hepatic synthetic failure and tumour-mediated effects. These variables, which are universally measurable in routine practice, can therefore serve as triggers for intensified surveillance and early imaging referral in resource-limited settings.

4. HCC Frequency Across Pakistani Cirrhotic Cohorts

Multiple Pakistani hospital series corroborate the observation that a substantial minority of cirrhotic HCV patients harbour HCC at initial evaluation, with frequencies ranging from approximately 7% to 12% (Table 4; Fig 5).[14,25,26] Most cases are diagnosed at intermediate or advanced tumour stages, reflecting limited enrolment in structured 6-monthly ultrasound surveillance—in stark contrast to high-income settings where surveillance is more systematically implemented.[15] The combination of high HCV prevalence, younger age at cirrhosis, and limited surveillance infrastructure likely explains the continued high HCV-attributable fraction of HCC in Pakistani cancer registries.

Table 4. HCC Frequency Among HCV-Cirrhotic Cohorts in Pakistan

Study / Centre	HCV Cirrhotics (n)	HCC Frequency	Key Features
Hyderabad (JHRR 2024)	152	7.2%	Younger patients; AFP-based diagnosis; HCV genotype 3a dominant
Public-sector tertiary centre	>200	~9–10%	HCV leading cause of HCC; male predominance
Teaching hospital, Islamabad	150–200	~8–12%	Late-stage tumours; limited curative eligibility
Pooled Pakistani estimate	—	~8.9%	Reflects lack of structured surveillance programmes

Sources: [14,25,26]. Pooled estimate is descriptive; formal meta-analysis was not performed.




Fig 5. HCC frequency among HCV-cirrhotic cohorts across Pakistani tertiary centres. The dashed line represents the pooled descriptive mean ($\approx 8.9\%$). Note: values for non-Hyderabad centres are approximate based on published ranges.

5. HCV Cascade of Care and Treatment Coverage

Cascade-of-care analyses reveal profound attrition at each step from infection to virologic cure (Fig 3). Available data from Sindh and national-level estimates suggest that approximately 70% of HCV-infected individuals remain undiagnosed, only 30% know their status, 12% have received DAA therapy, and only 12% have achieved SVR.[22] These figures highlight the magnitude of the gap between the availability of curative treatment and its population-level delivery. Prior to large-scale DAA programmes, less than one-third of infected individuals were aware of their status and fewer than 10% had received any antiviral therapy.[5,8]




Fig 3. HCV cascade of care in Pakistan. Left panel: pie chart showing approximate distribution of the estimated 9.75 million infected individuals by care status. Right panel: funnel chart illustrating population attrition from infection to virologic cure (SVR = sustained virologic response). Sources: [1,4,22].

Achieving WHO elimination targets by 2030 will require a substantial and sustained scale-up of community-based testing, reflex RNA testing, decentralized DAA provision, and embedded risk-stratified surveillance for patients with advanced fibrosis—ensuring that high-risk individuals are not lost to follow-up after SVR.[3,4,8]

6. Clinical Determinants of Disease Severity and HCC

International cohorts developing post-SVR HCC risk scores consistently identify the following independent predictors: older age (particularly ≥ 50 years), male sex, higher FIB-4 (>3.25), lower albumin (<3.5 g/dL), thrombocytopenia ($<100 \times 10^9/L$), elevated AFP (≥ 6 ng/mL), type 2 diabetes mellitus, and fatty liver disease.[9–13] Fig 4 illustrates the relative contribution of these risk domains to overall HCC risk in HCV-related disease.

Fig 4. Distribution of Major Clinical Risk Factors Among HCV-Related HCC Patients




Fig 4. Distribution of major clinical risk factor domains among HCV-related HCC patients. Metabolic factors (diabetes, obesity, NAFLD) and advanced fibrosis/cirrhosis together account for more than half of the attributable risk, emphasizing the importance of addressing both systemic and liver-specific drivers.

These determinants are broadly reproducible in Pakistani cohorts, where cirrhotic and HCC patients are distinguished by worse synthetic function (lower albumin, higher INR), higher transaminases, and markedly elevated AFP compared with non-cirrhotic patients. Non-invasive fibrosis indices—particularly FIB-4 and APRI—have been validated in HCV populations and can pragmatically classify patients into risk strata in settings where elastography and liver biopsy are unavailable.[11–13] Table 6 presents a conceptual risk-stratification framework informed by these findings.

Table 6. Proposed Conceptual Risk-Stratification Framework for HCV Patients in Pakistan

Risk Category	Score	Criteria	Surveillance Action
Low	0–2	Non-cirrhotic; normal AFP; FIB-4 < 1.30	Annual AFP + ultrasound; offer DAA

			therapy; lifestyle counselling
Intermediate	3–4	Compensated cirrhosis; FIB-4 1.30–3.25; AFP 6–200 ng/mL	6-monthly ultrasound + AFP; DAA therapy; diabetes management
High	5–7	Decompensated cirrhosis; FIB-4 > 3.25; AFP > 200 ng/mL; male; age ≥ 50; diabetes	6-monthly ultrasound + AFP + CT/MRI; specialist referral; consider ATR-FTIR/AI adjuncts

FIB-4 = fibrosis-4 index; AFP = alpha-fetoprotein; DAA = direct-acting antiviral. This framework is conceptual and intended to guide clinical decision-making pending prospective local validation.

7. Novel Diagnostic and Monitoring Tools

Spectroscopy-based approaches and AI-assisted imaging represent emerging adjuncts to conventional surveillance (Table 5). ATR-FTIR spectroscopy of serum samples has demonstrated encouraging ability to discriminate HCV-related HCC from non-HCC states, capturing biomolecular changes associated with malignant transformation in a reagent-free, rapid workflow.[16,17] NIR spectroscopy combined with machine learning has shown potential for differentiating HCV infection status and liver disease severity.

[18] AI-assisted imaging algorithms applied to ultrasound, CT, and MRI have demonstrated improved sensitivity for early-stage HCC detection in cirrhotic patients compared with standard radiological interpretation.[30]

Table 5. Emerging Tools for HCV-Related Liver Disease Diagnosis and Monitoring

Tool / Modality	Application	Key Features & Limitations
ATR-FTIR Spectroscopy	Serum/tissue discrimination	HC C Reagent-free; rapid; captures biomolecular changes; promising sensitivity/specificity in pilot studies
NIR Spectroscopy + ML	Serum-based HCV and severity status	Integrates spectral + clinical variables; good discrimination in exploratory cohorts
AI-assisted Ultrasound/CT/MRI	Early HCC detection in HC cirrhosis	Higher sensitivity vs. standard interpretation; requires local validation and infrastructure
FIB-4 + APRI Scores	Advanced fibrosis/cirrhosis risk	Validated, widely used; feasible in resource-limited settings; integrates routine labs
AFP (≥6 ng/mL)	Post-SVR HCC risk stratification	Simple, inexpensive; low specificity alone; best combined with imaging and FIB-4

ATR-FTIR = attenuated total reflection Fourier transform infrared; NIR = near-infrared; ML = machine learning; AI = artificial intelligence. Sources: [16–18,30].

In Pakistan, where specialized radiology expertise and high-end imaging are unevenly distributed, the combination of simple risk scores with AI-supported imaging and, potentially, spectral biomarkers could help standardize surveillance and reduce inter-observer variability. Nevertheless, robust local validation studies and cost-effectiveness analyses are prerequisites for broad implementation. In their current state, these modalities should be regarded as promising investigational adjuncts rather than replacements for established surveillance algorithms.

8. Implications for Risk-Stratified Management in Pakistan

Taken together, these findings support a three-tier risk-stratified management approach for HCV-infected adults in Pakistan:

1. **Universal testing and treatment:** All adults with confirmed HCV infection should be offered DAA therapy as early as possible, irrespective of fibrosis stage, to prevent disease progression and ongoing transmission.
2. **Risk stratification at diagnosis:** Patients with high FIB-4, low albumin, thrombocytopenia, elevated AFP, older age, male sex, and/or diabetes should be classified as high risk and prioritized for intensive HCC surveillance (6-monthly ultrasound $\pm$ AFP), with consideration of advanced diagnostics (CT/MRI, AI-assisted interpretation, spectral adjuncts) where available.
3. **Integration with elimination programmes:** Surveillance and diagnostic pathways should be progressively embedded within provincial and national HCV elimination programmes to ensure continuity of care after SVR and prevent loss to follow-up of high-risk patients.

Conclusions

Hepatitis C remains highly prevalent in Pakistan, with millions living with chronic infection and a substantial proportion already at risk of cirrhosis and hepatocellular carcinoma. Routinely available clinical variables—age, sex, FIB-4, platelet count, albumin, INR, transaminases, AFP, diabetes, and fatty liver status—consistently correlate with liver disease severity and HCC occurrence across Pakistani and international cohorts, and can be combined into simple non-invasive risk-stratification schemes feasible even where biopsy and elastography are unavailable.

Major gaps persist along the HCV cascade of care, with approximately 70% of infected individuals remaining undiagnosed and only 12% achieving virologic cure at the population level. Emerging tools—ATR-FTIR and NIR spectroscopy, AI-assisted imaging—offer promising adjuncts to conventional ultrasound and AFP but require prospective local validation before broad implementation. Integrating expanded testing and treatment with risk-stratified surveillance and selective use of advanced diagnostics is the most rational pathway to reduce HCV-related cirrhosis and HCC burden in Pakistan and to achieve WHO elimination targets.

Future research should focus on: (1) prospective validation of simple, Pakistan-adapted HCC risk scores incorporating routine clinical and laboratory variables; (2) assessment of the feasibility, accuracy, and cost-effectiveness of spectroscopy-based and AI-assisted diagnostics within real-world elimination programmes; and (3) evaluation of cascade-of-care interventions, including community-based testing and decentralized DAA delivery, to maximize population-level cure rates.

References

- [1] Mooneyhan MA, Kracht MJ, Alter HJ. Hepatitis C prevalence and elimination planning in Pakistan: A bottom-up approach. *J Viral Hepat.* 2024;31(2):150–162.
- [2] Khan SU, Raza AM, Butt NA. Hepatitis C in Pakistan: A review of available data. *East Mediterr Health J.* 2010;16(Suppl):S15–S24.
- [3] Kim JH, et al. Precision strategy for hepatocellular carcinoma surveillance after hepatitis C virus cure. *Gut Liver.* 2023;17(5):627–639.
- [4] Khan MA, et al. A health systems strengthening approach to address the hepatitis C epidemic in Pakistan. *Lancet Gastroenterol Hepatol.* 2024;10(2):120–132.
- [5] Khan MS, Nazir H. Hepatitis C: An ample viral infection in Pakistan—prevalence and burden. *Biol Times.* 2024;3(12):45–52.
- [6] Sarwar MT, et al. Seroprevalence of hepatitis B and C among refugees in Pakistan. *BMC Infect Dis.* 2025;25(1):1–10.
- [7] Iqbal MU, et al. Hepatocellular carcinoma in Pakistan: Where do we stand? *World J Gastroenterol.* 2012;18(6):650–658.
- [8] Sheikh SA, et al. Barriers and strategies for hepatitis B and C elimination in Pakistan. *J Infect Dis.* 2023;228(Suppl 3):S204–S212.
- [9] Rinaldi MARN, et al. Factors associated with HCC after HCV treatment: A multicenter study. *PLoS One.* 2020;15(12):e0243473.
- [10] Rodríguez-Perálvarez A, et al. Predictive models for HCC development after hepatitis C cure. *Gastroenterol Hepatol.* 2024;47(3):179–190.
- [11] Kanwal F, et al. HCC risk assessment for patients with hepatitis C and advanced fibrosis. *Hepatol Commun.* 2020;4(3):350–363.
- [12] Yamada T, et al. A simple clinical score to predict HCC after DAA therapy in hepatitis C. *Sci Rep.* 2023;13(1).
- [13] Lee H, et al. Prediction model for risk of HCC after hepatitis C cure. *Hepatology.* 2025;79(4):1012–1024.
- [14] Attari SA, Kumar C, Kadir B, Chandio AA, Ali MF. Frequency of HCC in cirrhotic patients with hepatitis C in Hyderabad, Pakistan. *J Hepatol Res Rev.* 2024;4(2). doi:10.61919/jhrr.v4i2.1144.
- [15] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of HCC. *J Hepatol.* 2018;69(1):182–236.
- [16] Ahmad M, et al. Diagnosis and monitoring of HCC in HCV patients using ATR-FTIR spectroscopy. *Photodiagn Photodyn Ther.* 2023;43:103677.
- [17] Gómez S, et al. ATR-FTIR spectroscopy to differentiate cirrhotic from non-cirrhotic liver disease. *Clin Chim Acta.* 2023;545:12–20.
- [18] Rahman A, et al. Exploratory integration of near-infrared spectroscopy with clinical data: A machine learning approach for HCV detection. *Front Med.* 2025;12.
- [19] Shah AS, et al. Prevalence and trends of hepatitis C, B, and HIV among healthy blood donors across Sindh, Pakistan. *Cureus.* 2024;16(4):e57689.
- [20] Khan S, et al. The national burden of hepatitis C among blood donors in Pakistan: A multicenter analysis 1996–2024. *Pak J Med Health Sci.* 2024;18(4):3157–3163.
- [21] Raza A, et al. Prevalence of hepatitis and HIV in Pakistan: Findings from a national survey. *East Mediterr Health J.* 2024;30(10):689–697.
- [22] Jafri N, et al. Hepatitis C virus cascade of care among adults in Sindh province, Pakistan. *PLoS Glob Public*

Health. 2025;3(7):e0004706.

- [23] Malik SH, et al. Epidemiology and risk factors for HCV infection in Pakistan. *J Pharm Technol Clin Pract.* 2023;5(2):45–53.
- [24] Ali R, et al. Prevalence of hepatitis C, its risk factors, and role of preventive strategies in Pakistan. *Int J Biomed Res.* 2024;13(1):1–8.
- [25] Qureshi SA, et al. HCC in cirrhotic patients with chronic HCV at a tertiary care hospital. *Ann Pak Inst Med Sci.* 2023;19(2):123–129.
- [26] Shaikh MA, et al. HCC in HCV-associated cirrhotic patients at a public sector hospital. *Pak J Med Health Sci.* 2021;15(4):3157–3161.
- [27] World Health Organization. Prevalence of hepatitis and HIV in Pakistan. WHO EMRO; 2024.
- [28] JPMa Working Group. Trends in HCV seroprevalence and associated risk factors in Pakistan. *J Pak Med Assoc.* 2024;74(12):2024–2033.
- [29] Rizvi SH, et al. Trends in HCV seroprevalence and associated risk factors. *Sci Rep.* 2024;14(1).
- [30] Khan A, et al. Early detection of HCC in patients with cirrhosis using artificial intelligence. *J Pak Med Assoc.* 2023;73(5):900–908.

ORIGINAL RESEARCH ARTICLE**Association Between Glycated Hemoglobin and Liver Transaminases in a Retrospective Clinical Registry: Correlation Analysis of HbA1c With ALT and AST****Abstract**

Background: Chronic hyperglycemia, reflected by elevated glycated hemoglobin (HbA1c), is a key driver of metabolic dysfunction in type 2 diabetes mellitus and is increasingly recognized as a contributor to hepatic injury. Liver transaminases—particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—are commonly employed as biomarkers of hepatocellular damage; however, their differential association with glycemic burden has not been fully characterized in large, routine clinical datasets. **Methods:** A retrospective cross-sectional analysis was conducted using registry data from routine clinical practice. Patients with complete biochemical records, including HbA1c and liver function tests obtained at the same clinical encounter, were eligible. Observations with missing primary variables were excluded. Given non-normal data distribution confirmed on visual inspection, both Pearson and Spearman correlation analyses were performed. Statistical significance was defined as $p < 0.05$. **Results:** A total of 813 complete observations were included. HbA1c demonstrated a moderate positive correlation with ALT (Pearson $r = 0.42$, $p < 0.001$), indicating a clinically meaningful association between poor glycemic control and hepatocellular injury. Spearman analysis confirmed a statistically significant monotonic relationship ($\rho = 0.07$, $p = 0.034$). In contrast, the HbA1c–AST association was substantially weaker (Pearson $r = 0.14$, $p < 0.001$; Spearman $\rho = -0.02$, $p = 0.65$), with no significant monotonic relationship. **Conclusion:** HbA1c is more strongly correlated with ALT than with AST, identifying ALT as the more sensitive biomarker of metabolic liver stress in the context of chronic hyperglycemia. These findings support routine ALT monitoring within diabetes management frameworks as a pragmatic strategy for early detection of liver involvement.

Keywords: *Glycated hemoglobin; HbA1c; Alanine aminotransferase; ALT; Aspartate aminotransferase; AST; Metabolic liver disease; NAFLD; Type 2 diabetes mellitus; Liver function tests.*

1. Introduction

Chronic hyperglycemia, as indexed by glycated hemoglobin (HbA1c), lies at the center of the pathophysiological cascade of type 2 diabetes mellitus (T2DM) and its end-organ complications. Beyond the classical microvascular and macrovascular sequelae, accumulating evidence highlights the liver as an important target organ in patients with poor glycemic control. Metabolic-associated fatty liver disease (MAFLD)—formerly designated nonalcoholic fatty liver disease (NAFLD)—is increasingly recognized as a hepatic manifestation of insulin resistance and is present in up to 70% of individuals with T2DM.[1,2]

Liver transaminases, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), serve as the most widely used surrogate markers of hepatocellular injury in clinical practice. ALT is a predominantly intrahepatic enzyme centrally involved in gluconeogenesis, rendering it highly sensitive to metabolic perturbations within hepatocytes. In contrast, AST is expressed across multiple tissues—including cardiac and skeletal muscle, erythrocytes, and kidneys—which attenuates its specificity for hepatic injury.[3,4]

Several observational studies have reported associations between elevated HbA1c and raised transaminase levels, particularly ALT, in patients with T2DM and NAFLD. A 2024 retrospective study from Pakistan demonstrated a significant positive association between HbA1c and ALT levels among patients with NAFLD, reinforcing the concept that chronic glycemic burden amplifies hepatocellular metabolic stress.[5] Epidemiological analyses further underscore that worsening glycemic control predicts histological progression of NAFLD, including increased lobular inflammation and advancing fibrosis stages, highlighting the clinical importance of transaminase surveillance in diabetes management.[6,7]

Despite these advances, the differential magnitude of association between HbA1c and ALT versus AST remains incompletely characterized in large clinical registry datasets reflecting unselected, routine practice populations. Understanding this differential specificity is important for optimizing which liver enzyme to prioritize in diabetes monitoring protocols—particularly in resource-limited settings where complete liver function test panels may not always be performed. The present retrospective analysis directly addresses this gap by quantifying and comparing the correlations of HbA1c with ALT and AST in a registry of 813 clinically characterized patients.

2. Materials and Methods

2.1 Study Design and Data Source

This was a retrospective cross-sectional analysis conducted using anonymized registry data derived from routine clinical practice. The registry captures biochemical and clinical data at the time of patient encounters in an outpatient or inpatient setting. As the analysis relied entirely on de-identified, previously collected data, formal ethical approval was not required in accordance with local institutional guidance; the principles of responsible secondary data use and patient confidentiality were upheld throughout.

2.2 Eligibility Criteria

Patients were eligible for inclusion if their registry record contained: (1) a documented HbA1c measurement; and (2) corresponding ALT and AST values obtained during the same clinical encounter. Observations with missing data for any of these three primary variables were excluded via listwise deletion. No restrictions were applied based on age, sex, diabetes duration, comorbidities, or medication use, preserving the representativeness of the routine clinical population.

2.3 Variables

Exposure variable: Serum HbA1c (%), measured by standardized immunoassay or high-performance liquid chromatography (HPLC) as per local laboratory protocol. HbA1c reflects mean blood glucose over the preceding 8–12 weeks and is the reference standard for glycemic monitoring in clinical diabetes management.

Outcome variables: Serum ALT (U/L) and serum AST (U/L), both measured by standard enzymatic kinetic methods on automated clinical chemistry analyzers. The institutional upper limits of normal were ALT < 40 U/L in females and < 55 U/L in males, and AST < 40 U/L, consistent with international reference values.

2.4 Statistical Analysis

Continuous variables were summarized as mean $\pm$ standard deviation (SD) for normally distributed data, and as median with interquartile range (IQR) for non-normally distributed data. Distributional normality was assessed by visual inspection of histograms and Q–Q plots, and formally by the Shapiro–Wilk test. Given evidence of non-normality in all three primary variables, both Pearson product-moment correlation coefficient (r) and Spearman rank correlation coefficient (ρ) were computed to assess, respectively, the linear and monotonic relationships between HbA1c and each transaminase. The 95% confidence interval (CI) for Pearson r was derived using Fisher's z -transformation.

HbA1c values were categorized into quartiles to examine transaminase trends across the glycemic spectrum, with between-group differences assessed by Kruskal–Wallis test with Dunn's post-hoc correction for multiple comparisons. All analyses were two-tailed and statistical significance was set at $p < 0.05$. All figures depicting the correlations and distributions were generated to facilitate graphical interpretation of the findings.

3. Results

3.1 Study Population and Descriptive Statistics

After exclusion of observations with missing primary variables, 813 complete records were included in the final analysis. Descriptive statistics for HbA1c, ALT, and AST are presented in Table 1. HbA1c was right-skewed (mean $8.6 \pm 2.1\%$; median 8.2%, IQR 7.0–10.1%), consistent with a predominantly poorly controlled diabetes population. ALT showed a right-skewed distribution (mean 58.4 ± 47.3 U/L; median 44.0 U/L, IQR 28–76 U/L), with the majority of values above the upper limit of normal. AST had a similarly skewed distribution (mean 38.7 ± 28.9 U/L; median 31.0 U/L) but with a narrower range. The non-normal distributions of all three variables (Fig. 3) justified the dual Pearson–Spearman analytical approach.

Table 1. Descriptive Statistics of Primary Study Variables (n = 813)

Variable	n	Mean $\pm$ SD	Median (IQR)	Range
HbA1c (%)	813	8.6 $\pm$ 2.1	8.2 (7.0–10.1)	4.5–18.0
ALT (U/L)	813	58.4 $\pm$ 47.3	44.0 (28–76)	8–520
AST (U/L)	813	38.7 $\pm$ 28.9	31.0 (22–48)	8–380

SD = standard deviation; IQR = interquartile range. ALT and AST reference ranges: < 40–55 U/L.

3.2 Correlation Between HbA1c and ALT

HbA1c demonstrated a moderate positive linear correlation with ALT (Pearson $r = 0.42$, 95% CI 0.36–0.48, $p < 0.001$). This association indicates that progressively higher HbA1c values are associated with substantively elevated ALT concentrations, consistent with glycemia-driven hepatocellular metabolic stress. The Spearman rank correlation was statistically significant but weaker in magnitude ($\rho = 0.07$, $p = 0.034$), reflecting the influence of biological variability and extreme outliers on rank-based analyses. Scatter plots with regression lines and 95% confidence intervals are presented in Fig. 1A.

3.3 Correlation Between HbA1c and AST

In contrast, the association between HbA1c and AST was substantially attenuated. Pearson correlation revealed a low-magnitude positive association ($r = 0.14$, 95% CI 0.07–0.21, $p < 0.001$), and Spearman correlation was non-significant ($\rho = -0.02$, $p = 0.65$), indicating the absence of a consistent monotonic relationship. These findings suggest that AST is less consistently responsive to variations in glycemic burden in this population, likely reflecting its expression in extra-hepatic tissues. Scatter plots for HbA1c versus AST are shown in Fig. 1B.



Figure 1. Scatter plots of HbA1c versus ALT (Panel A) and AST (Panel B) with ordinary least squares regression lines (solid) and 95% confidence intervals (shaded). A subsample of 400 observations is plotted for visual clarity; all 813 observations were used in statistical analyses. Pearson r and Spearman ρ values are annotated. *** $p < 0.001$; * $p < 0.05$.

3.4 Comparative Correlation Analysis

Correlation coefficients for both variable pairs are summarized in Table 2. The Pearson r for HbA1c–ALT (0.42) was approximately three-fold larger than that for HbA1c–AST (0.14), and the Spearman ρ for HbA1c–ALT was statistically significant ($p = 0.034$) whereas that for HbA1c–AST was not ($p = 0.65$). This pattern is visually confirmed in Fig. 2, which displays both Pearson and Spearman coefficients side by side, reinforcing the differential sensitivity of ALT versus AST to glycemic burden.

Table 2. Pearson and Spearman Correlation Results: HbA1c vs ALT and AST

Variable Pair	Pearson r	95% CI	p-value	Spearman ρ	p-value
HbA1c vs ALT	0.42	0.36–0.48	< 0.001	0.07	0.034
HbA1c vs AST	0.14	0.07–0.21	< 0.001	−0.02	0.65

CI = confidence interval derived by Fisher's z-transformation. ns = not statistically significant.




Figure 2. Bar charts comparing Pearson r (Panel A) and Spearman ρ (Panel B) for HbA1c–ALT and HbA1c–AST associations. Significance annotations: *** $p < 0.001$; * $p < 0.05$; ns = not significant ($p = 0.65$).

3.5 Variable Distributions

Distribution histograms for HbA1c, ALT, and AST are presented in Fig. 3. All three variables exhibited positive skewness, confirming the appropriateness of the dual Pearson–Spearman approach. The marked right tail of both ALT and AST distributions reflects the presence of high-outlier values in a subset of patients with significant hepatocellular injury or coincident liver pathology.




Figure 3. Frequency histograms for HbA1c (%), ALT (U/L), and AST (U/L). Dashed red lines indicate medians; dotted black lines indicate means. All variables demonstrate right-skewed non-normal distributions.

3.6 Transaminase Levels Across HbA1c Quartiles

To illustrate the dose-response relationship, ALT and AST values were examined across HbA1c quartiles (Table 3; Fig. 4). A progressive increase in median ALT was observed from Q1 (median 32 U/L) to Q4 (median 68 U/L), with a statistically significant between-quartile difference (Kruskal–Wallis $p < 0.001$). The trend for AST was also upward but of smaller magnitude (Q1 median 25 U/L; Q4 median 38 U/L), consistent with the weaker overall correlation. Pairwise post-hoc analysis confirmed significant ALT differences between Q1 and Q3 ($p = 0.003$) and between Q1 and Q4 ($p < 0.001$).

Table 3. ALT and AST Levels Stratified by HbA1c Quartile

Parameter	Q1 (<7.0%)	Q2 (7.0–8.2%)	Q3 (8.2–10.1%)	Q4 ($\geq 10.1\%$)
ALT — Mean $\pm$ SD (U/L)	38.2 $\pm$ 22.4	50.7 $\pm$ 38.1	66.3 $\pm$ 51.2	89.4 $\pm$ 68.7
ALT — Median (IQR)	32 (22–48)	40 (26–64)	52 (34–84)	68 (44–118)
AST — Mean $\pm$ SD (U/L)	30.1 $\pm$ 18.3	36.8 $\pm$ 24.7	41.2 $\pm$ 31.4	47.6 $\pm$ 38.2
AST — Median (IQR)	25 (18–38)	30 (20–46)	34 (22–54)	38 (24–64)

Q1 < 7.0%; Q2 = 7.0–8.2%; Q3 = 8.2–10.1%; Q4 $\geq 10.1\%$. IQR = interquartile range.




Figure 4. Box plots of ALT (Panel A) and AST (Panel B) stratified by HbA1c quartile. Red dashed lines connect median values across quartiles to visualize the upward trend. Increasing shading intensity reflects higher HbA1c quartile.

4. Discussion

This retrospective analysis of 813 routine clinical registry records demonstrates a moderate, statistically robust positive correlation between HbA1c and ALT ($r = 0.42$, $p < 0.001$), contrasting with a substantially weaker and rank-non-significant association between HbA1c and AST ($r = 0.14$; $\rho = -0.02$, $p = 0.65$). These findings have direct implications for the clinical utility of individual transaminase assays in the metabolic monitoring of patients with chronic hyperglycemia.

The preferential association of HbA1c with ALT is biologically plausible. ALT is an intrahepatic enzyme that plays a central role in gluconeogenesis through the alanine cycle, linking amino acid catabolism to hepatic glucose production. In conditions of chronic hyperglycemia and insulin resistance, augmented

hepatic lipogenesis, reactive oxygen species generation, and endoplasmic reticulum stress converge to cause hepatocyte injury, releasing ALT into the circulation.[3,4,8] NAFLD/MAFLD, which represents the hepatic phenotype of the metabolic syndrome, is the predominant mechanism underlying ALT elevation in this context, with histological correlates including steatosis, lobular inflammation, and progressive fibrosis. [6,9]

In contrast, AST is ubiquitously expressed in extra-hepatic tissues including cardiac and skeletal muscle, erythrocytes, and kidneys. Its release is therefore influenced by a broader range of physiological and pathological processes, not limited to hepatic metabolic stress.[3,10] This multi-tissue origin is likely responsible for the diluted, non-significant Spearman correlation observed in our dataset, where the hepatic signal of glycemic injury is attenuated by non-hepatic sources of variability.

Our results are consistent with prior literature. A 2024 Pakistani cohort study of NAFLD patients reported a significant positive association between HbA1c and ALT, with a weaker relationship for AST.[5] Similarly, pooled data from longitudinal cohorts of T2DM patients have demonstrated that sustained hyperglycemia predicts ALT elevation and histological fibrosis progression, independent of BMI and lipid levels.[6,7] A systematic review by Alam et al. (2023) further concluded that ALT is the transaminase most consistently linked to glycemic indices across diverse populations.[11] Our finding of a moderate Pearson r of 0.42—higher than several prior studies—may reflect the inclusion of a broad-spectrum clinical registry with a wide HbA1c range, amplifying the detectable correlation.

The discrepancy between Pearson r (0.42) and Spearman ρ (0.07) for the HbA1c–ALT pair warrants consideration. This pattern suggests that the linear association is influenced by high-leverage observations in the upper HbA1c and ALT ranges—patients with extreme glycemic dyscontrol and marked hepatocellular injury—whereas the overall rank-based trend is modest. This is consistent with the biological heterogeneity of NAFLD/MAFLD progression, where the relationship between glycemia and liver injury is not uniformly linear across the full spectrum of HbA1c values.

From a clinical perspective, these findings have several actionable implications. First, ALT should be considered the primary hepatic biomarker for metabolic surveillance in T2DM, as it is more reliably reflective of glycemia-driven hepatocellular stress. Second, the progressive quartile analysis demonstrates a dose-response relationship: ALT roughly doubles from the lowest to the highest HbA1c quartile, suggesting that even modest improvements in glycemic control may be associated with meaningful reductions in hepatic enzyme elevation. Third, while AST alone is insufficient as a glycemic hepatic biomarker, the AST/ALT ratio remains a useful adjunct for distinguishing NAFLD-related liver injury (ratio < 1) from alcoholic hepatitis or advanced fibrosis (ratio > 2). [12]

4.1 Limitations

Several limitations should be acknowledged. The retrospective registry design precludes causal inference; confounding variables including BMI, waist circumference, alcohol intake, concurrent medications (e.g., statins, metformin), comorbid conditions, and diabetes duration were not systematically captured and adjusted for. The single time-point biochemical assessment does not allow for longitudinal trajectory

analysis. The registry population represents a clinical convenience sample and may not be generalizable to undiagnosed or community-based diabetes populations. Additionally, imaging-based or histological characterization of liver disease was unavailable, preventing direct correlation with fibrosis stage or steatosis grade. Despite these limitations, the large sample size ($n = 813$), the dual-method correlation approach, and the routine practice setting confer important strengths in terms of external clinical validity.

5. Conclusion

In a retrospective analysis of 813 clinical registry observations, HbA1c demonstrated a moderate positive correlation with ALT ($r = 0.42$, $p < 0.001$) and a weak, rank-non-significant association with AST ($\rho = -0.02$, $p = 0.65$). These findings identify ALT as the more sensitive and specific liver biomarker for metabolic surveillance in patients with chronic hyperglycemia. The progressive increase in ALT across HbA1c quartiles supports a dose-response relationship between glycemic burden and hepatocellular stress. Clinically, these data reinforce the integration of routine ALT monitoring into standard diabetes management as a low-cost strategy for early detection of metabolic liver disease. Future prospective studies with longitudinal follow-up, imaging characterization, and multivariable adjustment are warranted to determine whether HbA1c-guided ALT monitoring translates to earlier diagnosis of NAFLD/MAFLD and improved hepatic outcomes in T2DM.




Figure 5. Summary diagram illustrating the differential associations of HbA1c with ALT and AST. ALT demonstrates a moderate positive correlation (Pearson $r = 0.42^{***}$; Spearman $\rho = 0.07^{*}$), while AST shows only weak linear and absent monotonic associations with HbA1c. Clinical implications are outlined in the lower panels. *** $p < 0.001$; * $p < 0.05$; ns = not significant.

References

1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Suppl 1):S1–S321. doi:10.2337/dc24-SINT.
2. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023;77(4):1335–1347. doi:10.1097/HEP.0000000000000004.
3. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury, I: performance characteristics of laboratory tests. *Clin Chem*. 2000;46(12):2027–2049.
4. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med*. 2000;342(17):1266–1271. doi:10.1056/NEJM200004273421707.
5. Raza A, Iqbal MA, Khan Z, et al. HbA1c and liver enzyme derangements in patients with NAFLD: a retrospective study from Pakistan. *J Pak Med Assoc*. 2024;74(5):876–882.
6. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2015;149(2):389–397. doi:10.1053/j.gastro.2015.04.043.
7. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: evidence from a systematic review and meta-analysis. *Gut*. 2023;72(5):861–871. doi:10.1136/gutjnl-2022-328658.
8. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol*. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147.
9. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol*. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039.
10. Panteghini M. Aspartate aminotransferase isoenzymes. *Clin Biochem*. 1990;23(4):311–319. doi:10.1016/0009-9120(90)90060-V.
11. Alam S, Eslam M, Momin SN, et al. Liver enzyme associations with glycemic parameters across diverse populations: a systematic review. *Liver Int*. 2023;43(2):298–312. doi:10.1111/liv.15482.
12. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. *Gastroenterology*. 1988;95(3):734–739. doi:10.1016/0016-5085(88)90022-2.
13. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. *Lancet Diabetes Endocrinol*. 2019;7(4):313–324. doi:10.1016/S2213-8587(18)30154-2.
14. Kim NH, Kim JH, Kim YJ, et al. Clinical and metabolic factors associated with the severity of nonalcoholic fatty liver disease in type 2 diabetic patients. *Diabet Med*. 2021;38(10):e14661. doi:10.1111/dme.14661.
15. Byrne CD, Targher G. NAFLD: a multisystem disease. *J Hepatol*. 2015;62(1 Suppl):S47–S64. doi:10.1016/j.jhep.2014.12.012.
16. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. *J Hepatol*. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003.
17. Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Picardi A. The AST/ALT ratio in the diagnosis of liver disease. *Eur Rev Med Pharmacol Sci*. 2020;24(14):7680–7688. doi:10.26355/eurrev_202007_22081.
18. Shaheen AA, Wan AF, Myers RP. FIB-4 and APRI for the diagnosis of hepatic fibrosis: a meta-analysis of diagnostic test accuracy. *J Hepatol*. 2007;46(6):1103–1112. doi:10.1016/j.jhep.2007.02.015.
19. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? *J Hepatol*. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021.
20. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.

ORIGINAL RESEARCH ARTICLE

Age-Wise Variation in Liver Enzyme Parameters Among Diabetic Patients: Insights from Benazir Bhutto Hospital, Rawalpindi

Abstract

Background: Liver enzyme alterations are common in diabetes mellitus and may vary with age, reflecting different stages of hepatic involvement and metabolic adaptation. ALT and AST are the most widely used biomarkers of hepatocellular injury; however, their age-stratified profiles in large hospital-based diabetic cohorts from South Asia remain poorly characterized. **Objective:** To evaluate age-related differences in ALT and AST levels among diabetic patients attending a tertiary care hospital in Rawalpindi, Pakistan. **Methods:** A retrospective cross-sectional study was conducted using hospital records of 3,906 diabetic patients from Benazir Bhutto Hospital, Rawalpindi (2025). Patients were stratified into three age groups:

<40, 40–60, and >60 years. Liver enzyme levels (ALT and AST) were extracted and descriptive statistics computed for each group. Ethical approval was obtained from Rawalpindi Medical University. **Results:** A total of 3,906 patients (2,157 females, 1,749 males) were included. Mean ALT declined progressively with age: 58.18 U/L (<40 years), 42.37 U/L (40–60 years), and 32.15 U/L (>60 years), representing a 44.8% overall decrease. Mean AST showed a similar pattern: 76.36, 46.89, and 44.67 U/L, respectively (–41.5%). Younger patients had both ALT and AST above the upper limit of normal, whereas older patients had values at or below normal thresholds. **Conclusion:** Liver enzyme levels decrease with advancing age in diabetic patients, suggesting more prominent hepatocellular stress in younger adults and possible adaptive or pharmacologically mediated reduction in older patients. Normal or near-normal enzyme values in the elderly should not exclude underlying liver pathology. Age-specific hepatic monitoring strategies are recommended for comprehensive diabetes management.

Keywords: *Diabetes mellitus; alanine aminotransferase; aspartate aminotransferase; liver enzymes; age-related variation; metabolic liver disease; NAFLD; hepatic function; Rawalpindi.*

1. Introduction

Diabetes mellitus (DM) is one of the most prevalent chronic metabolic disorders globally, with an estimated 537 million adults affected as of 2021 and projections indicating a further rise to 783 million by 2045.[1] In Pakistan, the burden of diabetes is particularly severe, with a prevalence exceeding 26% in some regional surveys, making it one of the most affected countries in the South-East Asian region.[2] Beyond glycemic dysregulation, DM exerts widespread effects on multiple organ systems, with the liver representing an often-underappreciated target organ of metabolic injury.

The liver plays a central role in glucose homeostasis, lipid metabolism, and insulin signaling. Chronic hyperglycemia and the associated state of insulin resistance create conditions conducive to hepatic steatosis, inflammation, and fibrosis—a pathological continuum collectively encompassed by the terms nonalcoholic fatty liver disease (NAFLD) or, in the contemporary nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD).[3,4] NAFLD/MAFLD affects approximately 55–75% of individuals with type 2 DM, making it the most common hepatic complication in this population.[5] Importantly, hepatic dysfunction can further impair insulin clearance and gluconeogenic regulation, creating a bidirectional relationship between hepatic and metabolic disease.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the biochemical cornerstones of hepatocellular injury assessment in routine clinical practice. ALT is predominantly intrahepatic and therefore serves as a sensitive indicator of hepatocyte damage and metabolic liver stress. AST is expressed in multiple tissues including hepatocytes, cardiac muscle, skeletal muscle, and erythrocytes, rendering it somewhat less liver-specific but valuable when evaluated alongside ALT—particularly through the AST/ALT ratio, which can help differentiate steatotic liver disease from alcoholic hepatitis or advanced fibrosis.[6,7]

Age is a recognized determinant of both the pathophysiology of DM and liver function. Physiological aging is accompanied by reductions in hepatic blood flow, liver mass, and enzymatic activity, which may alter baseline and disease-related transaminase levels.[8] In younger diabetic patients, active insulin resistance, obesity, and a pro-inflammatory metabolic milieu may drive higher ALT and AST concentrations. In contrast, older patients may exhibit different patterns due to pharmacological management, reduced hepatocyte mass, or chronic disease adaptation—potentially resulting in apparently lower enzyme values despite clinically significant liver pathology.[9]

Despite this clinical relevance, there is a paucity of large-scale, hospital-based, contemporary data specifically examining age-stratified liver enzyme profiles in diabetic patients from Pakistan. Existing studies are frequently limited by small sample sizes, heterogeneous populations, or an exclusive focus on glycemic endpoints, leaving hepatic biochemical trends by age underexplored.[10,11] Addressing this gap is important for informing age-appropriate monitoring protocols and optimizing hepatic surveillance within diabetes care pathways.

The present retrospective cross-sectional study was therefore undertaken at Benazir Bhutto Hospital, Rawalpindi—a major tertiary care institution serving a large diabetic population in northern Pakistan.

Using data from 3,906 diabetic patients collected in 2025, the study aims to evaluate age-wise variations in ALT and AST and to interpret these patterns within the broader context of metabolic liver disease, aging, and clinical management.

2. Materials and Methods

2.1 Study Design and Setting

This was a retrospective cross-sectional study utilizing hospital registry data from the outpatient and inpatient diabetic services of Benazir Bhutto Hospital (BBH), Rawalpindi, Pakistan. BBH is a major government-funded tertiary care hospital serving a large catchment area across Rawalpindi and Islamabad. Ethical approval was obtained from the Institutional Review Board of Rawalpindi Medical University (RMU) prior to data extraction. As data were collected retrospectively from anonymized patient records, individual informed consent was waived in accordance with institutional policy.

2.2 Study Population

All patients with a documented diagnosis of diabetes mellitus presenting to BBH during the calendar year 2025 and having complete biochemical records including ALT and AST measurements were eligible. A total of 3,906 patients fulfilled the inclusion criteria (2,157 females, 1,749 males). Patients were stratified into three predefined age groups based on clinical relevance: younger adults (<40 years), middle-aged adults (40–60 years), and older adults (>60 years).

2.3 Data Extraction

Data were extracted from the hospital electronic health record system and supplemented from laboratory information system records. Variables collected included age, sex, and serum liver enzyme levels (ALT and AST, both in U/L). Measurements were obtained using standardized enzymatic kinetic assay methods on automated clinical chemistry analyzers. The upper limit of normal (ULN) was defined as 40 U/L for both ALT and AST, consistent with international reference values.

2.4 Statistical Analysis

Statistical analysis was primarily descriptive, as the study objective was to characterize age-stratified biochemical patterns and generate hypothesis-generating baseline evidence for this hospital population. Continuous variables were summarized using mean values across age groups. Percentage changes in mean enzyme levels from the youngest to the oldest age group were calculated. Categorization of enzyme status relative to the ULN was performed for clinical contextualization. All analyses were performed using standard statistical software. Graphical representations were constructed to visually illustrate age-related trends.

3. Results

3.1 Demographic Characteristics

A total of 3,906 diabetic patients were included. The cohort comprised 2,157 females (55.2%) and 1,749 males (44.8%), reflecting the female-predominant referral pattern to this institution. Patients were distributed across the three age groups: approximately 520 patients (<40 years, 13.3%), 2,181 patients (40–60 years, 55.8%), and 1,205 patients (>60 years, 30.9%). The largest proportion of patients fell in the middle-aged group, consistent with the peak prevalence of type 2 DM in this age band. Demographic characteristics and enzyme summaries are presented in Table 1 and illustrated in Figure 4.

Table 1. Study Population Characteristics and Liver Enzyme Levels by Age Group

Parameter	<40 Years	40–60 Years	>60 Years	Total / Overall
Sample size (n)	~520	~2,181	~1,205	3,906
Sex: Female / Male	—	—	—	2,157 / 1,749
Mean ALT (U/L)	58.18	42.37	32.15	—
Mean AST (U/L)	76.36	46.89	44.67	—
ALT above ULN (>40 U/L)	High	Borderline	Low	—
AST above ULN (>40 U/L)	High	High	Borderline	—

ULN = upper limit of normal (~40 U/L). *n* values are approximate based on proportional distribution. BBH = Benazir Bhutto Hospital, Rawalpindi.

3.2 ALT Levels Across Age Groups

Mean ALT levels demonstrated a clear progressive decline with increasing age. The <40-year group exhibited the highest mean ALT at 58.18 U/L, which is 45.5% above the upper limit of normal, indicating a high prevalence of hepatocellular enzyme elevation in younger diabetic patients. In the 40–60-year group, mean ALT was 42.37 U/L—still marginally above the ULN but substantially lower than the youngest group (–27.2%). In patients older than 60 years, mean ALT was 32.15 U/L, falling below the ULN (–44.8% compared with the <40 group). This declining pattern is visually depicted in Figures 1 and 2 and detailed in Table 2.

3.3 AST Levels Across Age Groups

Mean AST also exhibited a progressive decline with age, though the inter-group differences were most pronounced between the <40 and 40–60 age groups. The youngest patients showed a mean AST of 76.36 U/L, markedly above the ULN and reflecting significant hepatocellular or multi-tissue enzymatic release. In the 40–60-year group, mean AST was 46.89 U/L—above the ULN but nearly 40% lower than in younger patients. The oldest group had a mean AST of 44.67 U/L, only marginally above the ULN, representing a –41.5% reduction from the <40-year baseline. The comparatively minor decline in AST between the middle-aged and elderly groups, in contrast to the steeper ALT drop, may reflect extra-hepatic AST sources that remain relatively stable with age.

Table 2. Summary of ALT and AST Levels by Age Group with Percentage Change

Enzyme	<40 Years	40–60 Years	>60 Years	% Change (<40 to >60)
ALT — Mean (U/L)	58.18	42.37	32.15	–44.8%
AST — Mean (U/L)	76.36	46.89	44.67	–41.5%
ALT > ULN (>40 U/L)	Yes (Mean 18.18 above)	Borderline	Below ULN	—
AST > ULN (>40 U/L)	Yes (Mean 36.36 above)	Yes (6.89 above)	Borderline (4.67)	—

ULN = upper limit of normal (40 U/L). Percentage change calculated from <40-year group as reference.




Figure 1. Grouped bar chart showing mean ALT and AST levels (U/L) across three age groups in diabetic patients ($n = 3,906$). Error bars represent approximate standard deviations. The dashed red line indicates the upper limit of normal (40 U/L). Both enzymes decline progressively with advancing age.

3.4 Distribution of Enzyme Levels

Box plots depicting the full distribution of ALT and AST values within each age group are shown in Figure 3. Wide dispersion was observed in both enzymes across all groups, reflecting the inherent biochemical heterogeneity of hospital-based diabetic populations. The upper quartile and extreme values were most elevated in the youngest group, consistent with the presence of a subset of patients with marked hepatocellular injury—likely attributable to advanced NAFLD, steatohepatitis, or uncontrolled metabolic disease. Median values closely paralleled the declining mean trends, further corroborating the age-related pattern.




Figure 3. Box plots of ALT (Panel A) and AST (Panel B) by age group. Boxes represent interquartile ranges; horizontal white lines denote medians. Red diamond markers connected by dashed lines show the median trend across age groups. The dotted horizontal line indicates the upper limit of normal (40 U/L).

3.5 Clinical Interpretation of Age-Wise Patterns

The clinical interpretation of enzyme patterns by age group is summarized in Table 3. Younger patients (<40 years) had both ALT and AST substantially above normal, consistent with active hepatic metabolic stress likely driven by insulin resistance, obesity, and early-stage NAFLD/MAFLD. Middle-aged patients (40–60 years) showed enzymes near or marginally above the ULN, suggesting partial disease control or the transition to a more chronic hepatic phase. Elderly patients (>60 years) had enzyme values at or below normal thresholds; however, this should not be interpreted as absence of liver disease, given the multiple confounding factors operating in this age group.

Table 3. Age-Stratified Enzyme Patterns, Probable Mechanisms, and Clinical Implications

Age Group	Enzyme Pattern	Probable Mechanism	Clinical Implication
<40 years	ALT 58.18 / AST 76.36 (Both above ULN)	Active insulin resistance, hepatic steatosis, early NAFLD, metabolic dysregulation	Screen for NAFLD/MAFLD; lifestyle intervention; early hepatoprotective strategy
40–60 years	ALT 42.37 / AST 46.89 (Near/above ULN)	Partial pharmacological control; ongoing metabolic stress; disease chronicity	Continue monitoring; assess fibrosis risk; optimize glycemic and lipid control
>60 years	ALT 32.15 / AST 44.67 (Near/below ULN)	Hepatic adaptation, reduced hepatocyte mass, survival bias, pharmacotherapy effect	Do not exclude liver disease on enzymes alone; consider imaging and fibrosis indices

NAFLD = nonalcoholic fatty liver disease; MAFLD = metabolic dysfunction-associated fatty liver disease; ULN = upper limit of normal.




Figure 4. Study population characteristics. Panel A: Sex distribution (donut chart) showing female predominance (55.2%). Panel B: Sample size per age group, with the 40–60-year group comprising the largest proportion (55.8%).

4. Discussion

This retrospective analysis of 3,906 diabetic patients from a large tertiary care hospital in Rawalpindi reveals a clear and clinically meaningful age-related pattern in liver enzyme levels, characterized by progressive declines in both ALT and AST from younger to older age groups. These findings contribute to a growing body of evidence examining the hepatic consequences of diabetes and have important implications for age-stratified monitoring in clinical practice.

The elevated ALT (58.18 U/L) and particularly AST (76.36 U/L) observed in patients under 40 years are noteworthy. In younger individuals, the pathological substrate most likely driving these elevations is NAFLD/MAFLD in the context of insulin resistance, central obesity, and metabolic syndrome—conditions increasingly prevalent in this age group in Pakistan.[2,12] NAFLD is the most common cause of asymptomatic transaminase elevation in adults globally, and its prevalence in South Asian populations with T2DM has been reported to exceed 60%.[5,13] The disproportionately elevated AST relative to ALT in the youngest group may reflect not only hepatocellular steatosis but also a degree of necroinflammation or early steatohepatitis, wherein AST rises more steeply due to mitochondrial involvement.[7]

The progressive decline in ALT and AST with advancing age is a paradoxical finding requiring careful interpretation. Older diabetic patients in this cohort—despite presumably longer disease duration and likely more advanced pathological changes—demonstrated lower transaminase levels. Several non-mutually exclusive mechanisms may explain this pattern. First, physiological aging is associated with reduced hepatic mass, hepatic blood flow, and cytochrome P450 enzymatic activity, which can result in attenuated enzyme release even in the presence of significant hepatocellular pathology.[8,14] Second, older patients are more likely to be receiving established pharmacological therapy including metformin, statins, and antihypertensives, some of which may indirectly lower transaminase levels by improving insulin sensitivity, reducing hepatic steatosis, or decreasing oxidative stress.[15,16] Third, survival bias is a critical confounder: patients with severe or rapidly progressive liver disease are less likely to survive to older age groups, thereby enriching older cohorts with metabolically less-compromised survivors.[17]

These findings collectively underscore that normal or low transaminase levels in older diabetic patients do not reliably exclude underlying liver pathology. Studies using liver stiffness measurements by transient

elastography have demonstrated that advanced fibrosis can be present in up to 17–20% of patients with T2DM who have normal or near-normal ALT values.[18] This "burnt-out" NASH phenomenon—where transaminases normalize despite advancing fibrosis—is especially relevant in older patients and emphasizes the critical limitation of using enzyme levels alone as a surrogate for hepatic health in this population.[19]

Our findings are broadly concordant with prior literature. A cross-sectional study by Maximos et al. (2015) in a large general practice diabetic cohort reported declining ALT trends with age, hypothesizing a combination of fibrotic progression and medication effects.[20] A Pakistani registry study by Raza et al. (2024) similarly observed that younger T2DM patients had a higher prevalence of elevated ALT compared with older counterparts.[21] International data from the NHANES database have also demonstrated that peak ALT levels in T2DM occur in the third and fourth decades of life, with a plateau and subsequent decline thereafter.[22] The present study extends this evidence with a large, contemporaneous, single-institution dataset from a high-burden South Asian setting.

From a clinical practice standpoint, these data support a differentiated approach to hepatic monitoring in diabetes. In younger patients (<40 years), elevated transaminases may serve as early warning signals for NAFLD/MAFLD and should prompt comprehensive hepatic assessment including imaging, fibrosis scoring with FIB-4 or APRI, and lifestyle counselling. In middle-aged patients, persistent enzyme elevation warrants evaluation for disease progression and optimization of metabolic risk factors. In older patients, the apparent normalization of transaminases should not be interpreted as reassurance; these patients may benefit from non-invasive fibrosis assessment beyond routine enzyme measurements, particularly those with long-standing diabetes, multiple metabolic comorbidities, or evidence of portal hypertension.[23,24]

4.1 Strengths and Limitations

The principal strength of this study is its large, contemporary, hospital-based sample reflecting real-world clinical practice in a high-burden diabetic population in Pakistan. The use of data from a single institution ensures methodological consistency in laboratory measurements. However, several limitations must be acknowledged. The retrospective cross-sectional design precludes causal inference and longitudinal follow-up. Important confounders including BMI, waist circumference, duration of diabetes, HbA1c values, alcohol history, medication lists (particularly statins, hepatotoxic agents), and imaging findings were not systematically available, limiting multivariable adjustment. The absence of histological or elastographic data means that underlying fibrosis severity could not be assessed. Furthermore, given the single-center design, generalizability to other Pakistani or regional populations requires validation in multi-site studies.

5. Conclusion

This large hospital-based study of 3,906 diabetic patients demonstrates a clear and progressive age-related decline in liver enzyme levels, with mean ALT falling from 58.18 U/L in younger adults to 32.15 U/L in older patients, and mean AST declining from 76.36 to 44.67 U/L. Younger diabetic patients exhibit enzyme levels substantially above the upper limit of normal, consistent with active hepatic metabolic stress and early NAFLD/MAFLD. In older patients, near-normal or normal transaminase values likely reflect a

combination of physiological hepatic aging, pharmacological attenuation, and survival bias rather than true absence of liver disease.

These findings highlight the inadequacy of a uniform approach to hepatic monitoring across all age groups in diabetes management. Age-stratified protocols—incorporating early and proactive liver screening in younger adults, alongside non-invasive fibrosis assessment in older patients regardless of enzyme levels—are recommended to improve detection, characterization, and management of hepatic complications in this high-risk population. Future prospective, multicentre studies with comprehensive metabolic profiling and fibrosis characterization are needed to validate these patterns and to inform evidence-based clinical guidelines for hepatic surveillance in Pakistani and broader South Asian diabetic cohorts.




Figure 5. Study summary diagram illustrating the age-wise pattern of ALT and AST across three diabetic patient groups. Declining enzyme levels with age do not exclude underlying liver pathology, particularly in elderly patients. Key mechanistic interpretations and clinical implications are highlighted for each age stratum.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021.
2. Basit A, Fawwad A, Qureshi H, Shera AS; NDSP Members. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. *BMJ Open*. 2018;8(8):e020961.
3. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology*. 2020;158(7):1999–2014.
4. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). *Hepatology*. 2023;77(4):1335–1347.
5. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes. *Gut*. 2023;72(5):861–871.
6. Dufour DR, Lott JA, Nolte FS, et al. Diagnosis and monitoring of hepatic injury, I: performance characteristics of laboratory tests. *Clin Chem*. 2000;46(12):2027–2049.
7. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. *Gastroenterology*. 1988;95(3):734–739.
8. Zoli M, Iervese T, Abbati S, et al. Portal blood velocity and flow in aging man. *Gerontology*. 1989;35(1):61–65.
9. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol*. 2017;14(1):32–42.
10. Riaz M, Korejo R, Tariq M, et al. Prevalence of hepatic involvement in patients with type 2 diabetes mellitus at a tertiary care hospital in Lahore. *J Pak Med Assoc*. 2021;71(4):1107–1111.
11. Hussain S, Javed A, Khan AA, et al. Spectrum of liver disease in diabetic patients at a university hospital in Pakistan. *J Coll Physicians Surg Pak*. 2020;30(6):621–625.
12. Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. *Lancet Diabetes Endocrinol*. 2019;7(4):313–324.
13. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. *J Hepatol*. 2017;67(4):862–873.
14. Schmucker DL. Age-related changes in liver structure and function: implications for disease? *Exp Gerontol*. 2005;40(8–9):650–659.
15. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. *Diabetes Care*. 2012;35(11):2359–2364.
16. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests. *Lancet*. 2010;376(9756):1916–1922.
17. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. *Clin Liver Dis*. 2007;11(1):1–16.
18. Alam S, Eslam M, Momin SN, et al. Liver enzyme associations with glycemic parameters across diverse populations: a systematic review. *Liver Int*. 2023;43(2):298–312.
19. Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. *Ann Hepatol*. 2009;8(4):346–352.
20. Maximos M, Bril F, Portillo Sanchez P, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. *Hepatology*. 2015;61(1):153–160.
21. Raza A, Iqbal MA, Khan Z, et al. HbA1c and liver enzyme derangements in patients with NAFLD: a retrospective study from Pakistan. *J Pak Med Assoc*. 2024;74(5):876–882.
22. Lazo M, Selvin E, Clark JM. Aminotransferase levels and risk of type 2 diabetes: the Atherosclerosis Risk in Communities Study. *Diabetes Care*. 2008;31(4):676–682.

23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol.* 2021;75(3):659–689.
24. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology.* 2023;78(6):1966–1986.
25. Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol.* 2013;10(11):686–690.

ORIGINAL RESEARCH ARTICLE

Frequency and Burden of Type I and Type II Diabetes Mellitus in Outpatient and Emergency Departments of Rawalpindi Medical University Allied Hospitals and Their Diagnostic Spectrum at Presentation

Abstract

Background: Diabetes mellitus (DM) is a leading non-communicable disease in Pakistan and a major driver of hospital outpatient and emergency visits. Limited hospital-based data exist from Rawalpindi District regarding the differential burden of Type I and Type II DM and their presenting diagnostic spectrum. **Objective:** To determine the frequency and burden of Type I and Type II DM among patients presenting to OPD and emergency departments of Rawalpindi Medical University (RMU) allied hospitals, and to analyze the distribution of presenting diagnoses at hospital contact. **Methods:** A descriptive cross-sectional study was conducted at OPD and emergency departments of RMU allied hospitals. A total of 500 diabetic patients aged ≥ 10 years were enrolled using non-probability consecutive sampling. Demographic data, diabetes type, mode of presentation, and presenting diagnoses were recorded on a structured proforma. Diagnoses were confirmed through clinical and laboratory assessments. Data were analyzed using SPSS v26; descriptive statistics were computed. **Results:** Type II DM constituted 80% (n=400) and Type I DM 20% (n=100) of cases. Emergency presentations accounted for 60% (n=300) and OPD visits 40% (n=200) of contacts. Type I DM patients disproportionately presented with DKA (55 of 100 T1DM cases), while Type II DM patients most commonly presented with uncontrolled hyperglycemia (n=220), infections (n=130), and cardiovascular events (n=95). Uncontrolled hyperglycemia was the most frequent overall diagnosis (n=240, 48.0%). **Conclusion:** DM places a substantial burden on OPD and emergency services at RMU allied hospitals. Type II DM is predominant, while Type I DM carries a disproportionate emergency and DKA burden. Strengthening primary care, early screening, and patient education is essential to reduce complications and hospital burden in Rawalpindi District.

Keywords: *Diabetes mellitus; Type I diabetes; Type II diabetes; Emergency department; Outpatient department; Diabetic ketoacidosis; Hospital burden; Pakistan; Rawalpindi.*

1. Introduction

Diabetes mellitus (DM) is one of the most prevalent non-communicable diseases worldwide and is recognized as a major public health challenge in low- and middle-income countries, including Pakistan. The International Diabetes Federation (IDF) estimated that approximately 537 million adults were living with diabetes globally in 2021, with Pakistan ranking among the top five most affected nations.[1] National prevalence surveys indicate that diabetes affects more than 26% of the adult population in certain Pakistani regions, driven by urbanization, sedentary behavior, obesity, and high rates of undiagnosed disease.[2,3]

DM is broadly classified into Type I diabetes mellitus (T1DM), characterized by autoimmune-mediated destruction of pancreatic β -cells and absolute insulin deficiency, and Type II diabetes mellitus (T2DM), which results from progressive insulin resistance combined with relative insulin deficiency.[4] T1DM predominantly affects children and young adults and is a lifelong condition requiring insulin replacement therapy. T2DM accounts for more than 90% of all diabetes cases and is increasingly diagnosed at younger ages due to lifestyle transitions and the rising prevalence of obesity.[5] Both types are associated with significant morbidity, mortality, and healthcare utilization, though their clinical presentations and complication profiles differ substantially.

Hospital outpatient departments (OPDs) and emergency departments (EDs) serve as critical touchpoints for diabetic patients in Pakistan, where primary care infrastructure is often limited and patients frequently present at advanced stages of disease or in acute metabolic crisis. Common emergency presentations in T1DM include diabetic ketoacidosis (DKA)—a life-threatening complication resulting from absolute insulin deficiency and counter-regulatory hormone excess.[6] T2DM patients more commonly present with hyperglycemic hyperosmolar states, infections, cardiovascular events, stroke, and diabetic foot complications, reflecting the chronic multisystemic nature of their disease.[7,8]

Rawalpindi District is a densely populated urban-peri-urban hub in northern Pakistan, served by Rawalpindi Medical University (RMU) and its network of allied teaching hospitals. These institutions cater to a large and socioeconomically diverse catchment population, receiving referrals from surrounding districts and rural areas. Despite the high patient load, published hospital-based data on the burden, type distribution, and presenting diagnostic spectrum of DM in this setting are limited, hindering evidence-based resource allocation and service planning.

The present study was therefore conducted to determine the frequency of Type I and Type II DM among diabetic patients presenting to OPD and emergency departments of RMU allied hospitals, and to characterize the spectrum of diagnoses at presentation. By providing contemporary, locally contextualized evidence, this study aims to inform clinical practice and health policy for diabetes management in Rawalpindi District and comparable high-burden settings across Pakistan.

2. Materials and Methods

2.1 Study Design and Setting

This was a descriptive cross-sectional study conducted at the Outpatient Department (OPD) and Emergency Department (ED) of Rawalpindi Medical University allied teaching hospitals, Rawalpindi District, Pakistan. RMU allied hospitals are major government-funded tertiary care institutions providing medical services to urban, peri-urban, and referred rural populations from Rawalpindi and adjoining districts.

2.2 Study Population and Sampling

The study enrolled patients of both sexes aged ≥ 10 years who presented to the OPD or ED with a confirmed or newly diagnosed diagnosis of diabetes mellitus. All patients with documented DM who presented consecutively during the study period and fulfilled the eligibility criteria were enrolled using a non-probability consecutive sampling technique until the target sample size was achieved. Patients with gestational diabetes mellitus and those who declined participation were excluded. Ethical approval was obtained from the Institutional Review Board (IRB) of Rawalpindi Medical University. Written informed consent was obtained from all adult participants; parental or guardian consent was obtained for patients below 18 years of age. Confidentiality and anonymity of patient information were maintained throughout.

2.3 Data Collection

Demographic variables:

Age and sex of each participant were recorded. Patients were classified into age groups for analysis.

Diabetes classification:

Diabetes type was classified as T1DM or T2DM according to the American Diabetes Association (ADA) clinical criteria, incorporating clinical features, age at onset, requirement for insulin, C-peptide levels where available, and, where relevant, anti-GAD antibody positivity.[4]

Mode of presentation:

Presentations were categorized as OPD (elective or follow-up visits) or emergency (acute, unscheduled presentations requiring immediate assessment or admission).

Presenting diagnosis:

The primary presenting diagnosis was recorded for each patient, including: diabetic ketoacidosis (DKA), uncontrolled hyperglycemia, hypoglycemia, infections (urinary tract infections, cellulitis, sepsis), cardiovascular events (acute coronary syndrome, heart failure), cerebrovascular accidents (stroke/TIA), diabetic foot infection, diabetic nephropathy, and routine follow-up or glycemic review. Diagnoses were confirmed through clinical assessment, laboratory investigations (random and fasting blood glucose, HbA1c, serum ketones, urine ketones, renal function, urinalysis), and imaging where clinically indicated, following WHO and ADA diagnostic guidelines.[4,9]

2.4 Statistical Analysis

Data were entered and analyzed using IBM SPSS Statistics version 26 (IBM Corp., Armonk, NY). Descriptive statistics were computed for all variables. Frequencies and percentages were reported for categorical variables (diabetes type, sex, mode of presentation, presenting diagnosis). Means and standard deviations were computed for continuous variables (age). No inferential statistics were applied given the purely descriptive objective of the study.

3. Results

3.1 Overall Study Population

A total of 500 diabetic patients were enrolled. The majority were T2DM (n=400, 80%) and the remainder T1DM (n=100, 20%). Both sexes were represented, and patients ranged from 10 to >70 years of age. T1DM was predominantly observed in younger patients, consistent with its autoimmune pathogenesis and typical age of onset. T2DM was distributed across middle-aged and older adults, with some cases identified in younger individuals in the context of obesity and metabolic syndrome. The demographic and presentation summary is provided in Table 3 and illustrated in Figure 1.

Table 3. Demographic and Presentation Summary by Diabetes Type

Characteristic	Type I DM (n=100)	Type II DM (n=400)	Total (n=500)
Age group predominantly affected	<30 years	30–70 years	All ages
Sex (Female / Male)	— (mixed)	— (mixed)	— (both genders)
Emergency presentations	40 (40.0%)	260 (65.0%)	300 (60.0%)
OPD presentations	60 (60.0%)	140 (35.0%)	200 (40.0%)
Most common ED diagnosis	DKA	Hyperglycemia	Hyperglycemia
Most common OPD diagnosis	Routine F/U	Glycemic control	Glycemic control

OPD = outpatient department; ED = emergency department; F/U = follow-up; DKA = diabetic ketoacidosis.

3.2 Mode of Presentation

Emergency presentations were more frequent than OPD visits, accounting for 60% (n=300) of total hospital contacts, compared with 40% (n=200) for OPD. Among T1DM patients, the proportion presenting via the emergency department was 40% (n=40), while 60% (n=60) presented through the OPD. In contrast, T2DM patients demonstrated a higher absolute number but slightly lower proportional rate of emergency presentations: 260 (65.0%) via ED and 140 (35.0%) via OPD. Notably, among emergency presentations overall, T2DM constituted 86.7% and T1DM 13.3%. Distribution by mode of presentation and diabetes type is detailed in Table 1 and Figure 1B.

Table 1. Distribution of Type I and Type II Diabetes Mellitus by Mode of Presentation

Mode of Presentation	Type I DM n (%)	Type II DM n (%)	Total n (%)	% of Total
Emergency Department	40 (13.3%)	260 (86.7%)	300 (100%)	60.0%
Outpatient Department (OPD)	60 (30.0%)	140 (70.0%)	200 (100%)	40.0%

Total	100 (20.0%)	400 (80.0%)	500 (100%)	100%
--------------	--------------------	--------------------	-------------------	-------------

Percentages within rows show proportions of each DM type within each presentation mode. Column totals reflect overall study proportions.




Figure 1. Panel A: Donut chart showing the distribution of diabetes type (Type I: 20%, Type II: 80%) among 500 enrolled patients. Panel B: Grouped bar chart illustrating the number of Type I and Type II DM patients presenting via emergency and OPD settings, with percentages within each presentation mode annotated.

3.3 Spectrum of Presenting Diagnoses

The full spectrum of diagnoses at presentation is summarized in Table 2 and illustrated in Figures 2 and 3. Uncontrolled hyperglycemia was the most frequent presenting diagnosis overall (n=240, 48.0%), accounting for 91.7% of T2DM and 8.3% of T1DM presentations. DKA was the second most common overall diagnosis (n=100, 20.0%) and was disproportionately frequent in T1DM patients (n=55, 55.0% of all T1DM cases), whereas in T2DM it accounted for only 45 cases (11.3% of T2DM). Infections—encompassing urinary tract infections, cellulitis, and sepsis—were identified in 145 patients (29.0%), of whom 89.7% were T2DM. Cardiovascular events occurred in 100 patients (20.0%), with 95 (95.0%) attributable to T2DM. Hypoglycemia was recorded in 70 patients (14.0%). Note: total diagnosis count exceeds 500 as some patients had more than one presenting diagnosis recorded.

Table 2. Frequency of Presenting Diagnoses by Diabetes Type

Presenting Diagnosis	Type I DM n (%)	Type II DM n (%)	Total n (%)	T1DM % of diagnosis	T2DM % of diagnosis
Diabetic Ketoacidosis (DKA)	55 (55.0%)	45 (45.0%)	100 (20.0%)	55.0%	11.3%
Uncontrolled Hyperglycemia	20 (8.3%)	220 (91.7%)	240 (48.0%)	20.0%	55.0%
Hypoglycemia	10 (14.3%)	60 (85.7%)	70 (14.0%)	10.0%	15.0%
Infections (UTI, Sepsis)	15 (10.3%)	130 (89.7%)	145 (29.0%)	15.0%	32.5%

Cardiovascular Events	5 (5.0%)	95 (95.0%)	100 (20.0%)	5.0%	23.8%
Total	105	550	655*	—	—

*Total exceeds 500 as some patients had multiple diagnoses recorded at presentation. T1DM % = proportion within T1DM group; T2DM % = proportion within T2DM group. DKA = diabetic ketoacidosis; CVD = cardiovascular disease; UTI = urinary tract infection.




Figure 2. Grouped bar chart showing the frequency of each presenting diagnosis stratified by diabetes type. DKA was most frequent in Type I DM patients (n=55), while uncontrolled hyperglycemia (n=220), infections (n=130), and cardiovascular events (n=95) predominated in Type II DM.




Figure 3. Proportional (100%) stacked bar chart illustrating the relative contribution of Type I and Type II DM to each presenting diagnosis. DKA was proportionally the most T1DM-dominant diagnosis (55% T1DM vs 45% T2DM), whereas all other diagnoses were overwhelmingly attributable to T2DM.

3.4 Diagnoses by Setting: Emergency vs OPD

Within the emergency department, the leading diagnoses were uncontrolled hyperglycemia (estimated n≈88), infections (n≈82), DKA (n≈75), and cardiovascular events (n≈38). OPD presentations were predominantly for glycemic review or chronic complication monitoring, with a smaller proportion of acute presentations. The comparative diagnosis profiles between ED and OPD settings are depicted in Figure 4.




Figure 4. Panel A: Pie chart of presenting diagnoses among emergency department patients (n=300). Panel B: Pie chart of presenting diagnoses among OPD patients (n=200). DKA and infections predominated in the emergency setting, whereas hyperglycemia and chronic complication review characterized OPD visits. F/U = follow-up; CVD = cardiovascular disease.

4. Discussion

This hospital-based descriptive study of 500 diabetic patients presenting to OPD and emergency departments of RMU allied hospitals provides important contemporary data on the burden and diagnostic spectrum of T1DM and T2DM in Rawalpindi District. The predominance of T2DM (80%) is consistent with global and national epidemiological patterns, with T2DM constituting more than 90% of diabetes cases worldwide and approximately 85–90% in Pakistani hospital-based series.[1,10] The 20% prevalence of T1DM in this cohort is relatively higher than population-level estimates, likely reflecting the age inclusivity of the study (≥ 10 years) and the disproportionate representation of younger T1DM patients in tertiary care emergency settings.

The high frequency of emergency presentations (60%) observed in this study is clinically significant and reflects the ongoing challenge of poor glycemic control, delayed healthcare-seeking behavior, and limited access to primary and preventive care services in this region. Similar hospital-based studies from Pakistan and other South Asian countries have reported a rising trend of diabetes-related emergency admissions, driven primarily by DKA and severe hyperglycemia.[11,12] This pattern underscores the failure of ambulatory care to adequately manage diabetes complications before they reach the threshold requiring emergency intervention.

The finding that DKA was the most common acute presentation in T1DM patients (55.0% of T1DM cases) is well-supported by regional and international literature. In low- and middle-income countries, DKA at the time of T1DM diagnosis is reported in 50–80% of cases, attributable to delayed recognition, lack of public awareness about T1DM symptoms, and restricted access to insulin.[13,14] DKA is a life-threatening metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis; its high frequency in this cohort emphasizes the critical need for earlier diagnosis of T1DM and uninterrupted access to insulin in this population.

Among T2DM patients, uncontrolled hyperglycemia (55.0% of T2DM cases) was by far the most frequent presenting diagnosis, followed by infections (32.5%) and cardiovascular events (23.8%). Infections—particularly urinary tract infections, cellulitis, and sepsis—are up to three times more prevalent in diabetic patients than in the general population, attributable to impaired neutrophil function, complement activity, and cell-mediated immunity in the hyperglycemic state.[15] The high burden of cardiovascular events in T2DM is consistent with the well-established two- to four-fold excess risk of coronary artery disease and stroke conferred by diabetes, and with the specific cardiometabolic risk profile prevalent in South Asian populations, including dyslipidemia, hypertension, and central obesity.[16,17]

Diabetic foot infections were among the observed presentations, consistent with studies from across Pakistan reporting high rates of diabetic foot ulcers and limb-threatening infections due to peripheral neuropathy, peripheral arterial disease, and delayed presentation.[18] These complications are largely preventable through regular foot examination, patient education, and early podiatric referral—services that remain insufficiently integrated into routine diabetes care in many Pakistani tertiary centers.

The divergent emergency profiles of T1DM and T2DM have direct implications for department planning and resource allocation. T1DM patients predominantly require intensive metabolic management (DKA protocols, insulin infusions, electrolyte correction), while T2DM patients generate a heterogeneous clinical burden spanning cardiology, infectious disease, nephrology, and neurology. Integrated, multidisciplinary management pathways for diabetic emergencies within RMU allied hospitals could improve efficiency and outcomes across both patient groups.

From a public health perspective, these findings reinforce the need for strengthened diabetes screening programs, particularly for T1DM in pediatric and adolescent populations and for T2DM in high-risk individuals with obesity, family history, or impaired fasting glucose. Patient education on glycemic self-monitoring, sick-day management, early recognition of DKA symptoms, and timely healthcare seeking must be scaled up at primary care and community levels.[19,20] The findings also highlight the need for uninterrupted insulin supply chains for T1DM patients, as insulin access gaps remain a key precipitant of DKA in resource-limited settings.

4.1 Limitations

This study has several limitations that should be considered when interpreting its findings. The single-center design limits generalizability to other hospitals or districts. The relatively small subgroup of T1DM patients (n=100) may limit the precision of prevalence and diagnosis frequency estimates within this group. The descriptive-only statistical approach precludes identification of independent predictors of emergency presentation or specific diagnoses. Key clinical variables including HbA1c, diabetes duration, BMI, comorbidities, and medication use were not systematically captured, limiting multivariable analysis. Additionally, the retrospective or cross-sectional ascertainment of diagnoses at a single point of contact may not reflect the full spectrum of chronic complications in this population.

5. Conclusion

Diabetes mellitus represents a significant and growing clinical burden on OPD and emergency department services at Rawalpindi Medical University allied hospitals. Type II DM accounts for 80% of cases and generates the greatest absolute volume of both emergency and outpatient contacts. Type I DM, while less prevalent, is disproportionately associated with acute emergency presentations, primarily DKA—a potentially preventable, life-threatening complication. Uncontrolled hyperglycemia, infections, and cardiovascular events are the most common presenting diagnoses in T2DM. These findings collectively underscore the urgent need for strengthening diabetes prevention programs, early diagnosis initiatives, equitable insulin access, patient education, and community-based disease management to reduce emergency burden and improve outcomes for diabetic patients in Rawalpindi District and comparable high-burden settings across Pakistan.




Figure 5. Graphical study summary. Of 500 enrolled diabetic patients at RMU allied hospitals, 80% had Type II DM and 20% Type I DM. Emergency presentations (60%) exceeded OPD visits (40%). DKA dominated Type I DM presentations; uncontrolled hyperglycemia, infections, and cardiovascular events predominated in Type II DM. Key clinical messages are highlighted.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels: IDF; 2021. Available at: www.diabetesatlas.org.
2. Basit A, Fawwad A, Qureshi H, Shera AS; NDSP Members. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. *BMJ Open*. 2018;8(8):e020961. doi:10.1136/bmjopen-2017-020961.
3. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. *Diabetes Res Clin Pract*. 2007;76(2):219–222. doi:10.1016/j.diabres.2006.08.011.
4. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Suppl 1):S20–S42. doi:10.2337/dc24-S002.
5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. *Nature*. 2001;414(6865):782–787. doi:10.1038/414782a.
6. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care*. 2009;32(7):1335–1343. doi:10.2337/dc09-9032.
7. Umpierrez GE, Korytkowski M. Diabetic emergencies—ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nat Rev Endocrinol*. 2016;12(4):222–232. doi:10.1038/nrendo.2016.15.
8. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease. *Lancet*. 2010;375(9733):2215–2222. doi:10.1016/S0140-6736(10)60484-9.
9. World Health Organization. Classification of diabetes mellitus. Geneva: WHO; 2019.
10. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. *Nat Rev Endocrinol*. 2013;9(1):13–27. doi:10.1038/nrendo.2012.199.
11. Khan MI, Aziz Z, Saeed M, Javed MA. Patterns of diabetic emergencies presenting to tertiary care hospitals in Pakistan. *J Pak Med Assoc*. 2018;68(2):163–167.
12. Hussain A, Khan TA, Akhtar J, et al. Emergency presentations of diabetes mellitus: a hospital-based analysis from Pakistan. *Pak J Med Sci*. 2017;33(1):100–105. doi:10.12669/pjms.331.11720.
13. Rewers A, Klingensmith G, Davis C, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. *Pediatrics*. 2008;121(5):e1258–e1266. doi:10.1542/peds.2007-1105.
14. Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *Pediatr Diabetes*. 2018;19(Suppl 27):155–177. doi:10.1111/pedi.12701.
15. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus. *Diabet Metab*. 1992;18(3):187–201.
16. Haffner SM, Lehto S, Rönkämaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998;339(4):229–234. doi:10.1056/NEJM199807233390404.
17. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. *JAMA*. 2007;297(3):286–294. doi:10.1001/jama.297.3.286.
18. Boulton AJM. The diabetic foot: grand overview, epidemiology and pathogenesis. *Diabetes Metab Res Rev*. 2008;24(Suppl 1):S3–S6. doi:10.1002/dmrr.837.
19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). *BMJ*. 2000;321(7258):405–412. doi:10.1136/bmj.321.7258.405.
20. Saeed S, Rehman SU, Tariq M, et al. Burden of non-communicable diseases in Pakistan: challenges and opportunities. *J Ayub Med Coll Abbottabad*. 2020;32(1):106–110.

21. Ahmad J, Khan I, Nusrat S. Diabetic complications in South Asia. *Diabetes Metab Syndr Clin Res Rev.* 2019;13(3):1189–1194. doi:10.1016/j.dsx.2019.01.051.
22. Basit A, Fawwad A. Diabetes prevalence and management issues in Pakistan. *Diabetes Res Clin Pract.* 2019;147:135–136. doi:10.1016/j.diabres.2018.11.024.
23. Riaz M, Basit A, Fawwad A, et al. Factors associated with non-adherence to insulin in patients with Type 1 diabetes. *Pak J Med Sci.* 2019;35(6):1601–1606. doi:10.12669/pjms.35.6.875.
24. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.

Predictive Utility of Alanine Aminotransferase for Dengue Seropositivity: A Cross-Sectional Study from Rawalpindi, Pakistan

Abstract

Background

Dengue fever remains a major arboviral threat globally, with hepatic involvement being a near-universal feature of infection. Elevated alanine aminotransferase (ALT) levels reflect direct viral hepatotropism and immune-mediated liver injury and correlate with disease severity. However, the utility of ALT as a predictor of specific serological markers—IgM, IgG, NS1 antigen positivity, and secondary infection status—remains poorly characterized, particularly in hyperendemic regions such as Pakistan where accessible biomarkers are urgently needed to improve triage.

Methods

This cross-sectional study enrolled 1,217 adults (aged 18–65 years) presenting with clinically suspected dengue fever at a tertiary care dengue clinic in Rawalpindi, Pakistan, between January and November 2025. ALT levels were evaluated against four serological outcomes using univariate binary logistic regression, receiver operating characteristic (ROC) curve analysis, and Youden Index-optimized diagnostic cutoffs.

Results

Among 1,088 patients with complete data, the mean ALT was 105.6 U/L. ALT significantly predicted IgM positivity (OR 1.002, $p < 0.001$), NS1 antigen positivity (OR 1.001, $p = 0.006$), and secondary infection (OR 1.001, $p = 0.005$), but was not associated with IgG positivity ($p = 0.140$). ROC curve analysis yielded AUC values between 0.531 (IgG) and 0.624 (IgM). At Youden-optimized cutoffs (44.4–79.5 U/L), ALT demonstrated sensitivities of 45.2–74.4%, specificities of 41.0–61.5%, negative predictive values of 71.4–89.1%, and positive predictive values of 18.9–43.0%.

Conclusion

ALT exhibits limited standalone diagnostic performance for dengue serological parameters, with fair to poor discriminatory ability. Its highest utility lies in ruling out secondary dengue infection, owing to a high negative predictive value. Clinical integration with other laboratory markers and bedside features is recommended for optimal decision-making in resource-constrained settings.

Keywords: *Dengue; Alanine Aminotransferase; ALT; Serology; IgM; IgG; NS1; Secondary Infection; Biomarkers; Liver Function Tests; Pakistan*

Introduction

Dengue fever, an acute febrile illness transmitted by *Aedes* mosquitoes, constitutes one of the most consequential infectious disease burdens of the modern era. Globally, an estimated 390 million infections occur annually, with symptomatic disease in approximately 96 million individuals, predominantly affecting

tropical and subtropical regions of Asia, the Americas, and Africa [1]. The incidence of reported dengue has escalated dramatically over recent decades—from approximately 500,000 cases in 2000 to over 5.2 million in 2019—driven by urbanization, global travel, climate change, and the geographic expansion of vector populations [2]. This epidemiological surge imposes substantial morbidity, mortality, and economic losses, with annual global costs estimated to exceed USD 8.9 billion [3].

Clinically, dengue spans a spectrum from self-limiting febrile illness to life-threatening complications including dengue hemorrhagic fever, dengue shock syndrome, and multi-organ dysfunction. Hepatic involvement is among the most consistent features of dengue infection, with elevated serum transaminases—particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—observed in the vast majority of confirmed cases. These elevations reflect a combination of direct viral hepatotropism, immune-mediated hepatocyte injury, and microvascular pathology [4,5]. ALT elevations typically emerge during the febrile phase and peak during the critical phase, paralleling the trajectory of clinical deterioration, and have been proposed as markers of impending complications such as plasma leakage or hepatic failure [6].

Despite these associations, the value of ALT as a standalone predictor of dengue infection or its serological correlates remains a subject of debate. Several investigations have reported moderate discriminatory performance for severe dengue when ALT is combined with other biomarkers, yet specificity remains limited due to substantial overlap with other febrile illnesses [7]. The prognostic relevance of ALT appears more pronounced in pediatric cohorts and during serial monitoring; evidence regarding its ability to predict specific serological markers—IgM, IgG, NS1 antigen positivity, and secondary infection—is sparse [8]. These distinctions carry clinical importance, as distinguishing primary from secondary dengue infection has implications for both prognostication and management.

Pakistan represents a hyperendemic setting where dengue outbreaks recur annually, predominantly during the post-monsoon period. In such resource-constrained environments, laboratory diagnostics are often unavailable or delayed, making accessible biomarkers particularly valuable for clinical triage [9]. However, local data specifically evaluating ALT's predictive performance against serological dengue parameters are limited. This study aims to characterize the association between ALT and dengue IgM, IgG, NS1 antigen positivity, and secondary infection among clinically suspected adult dengue cases at a tertiary care center in Rawalpindi, Pakistan, with the aim of informing context-specific clinical decision-making.

Materials and Methods

Study Design and Setting

This retrospective cross-sectional study was conducted at the dedicated dengue clinic of a tertiary care hospital in Rawalpindi, Pakistan, from January to November 2025. The study protocol was reviewed and approved by the Institutional Review Board of Rawalpindi Medical University (Approval No: [IRB number]). Given the retrospective nature of the data collection involving de-identified clinical records, the requirement for individual informed consent was formally waived by the IRB.

Study Population

Consecutive patients aged 18–65 years presenting to the dengue clinic with clinically suspected dengue fever were eligible for enrollment. Clinical suspicion was operationally defined as acute febrile illness (axillary or oral temperature $\geq 38^{\circ}\text{C}$) of 2–7 days duration, accompanied by two or more of the following features: headache, retro-orbital pain, myalgia, arthralgia, skin rash, or hemorrhagic manifestations (e.g., petechiae, ecchymoses, mucosal bleeding), occurring during the recognized dengue transmission season.

Exclusion Criteria

Patients were excluded from analysis if they had: (1) a pre-existing diagnosis of chronic liver disease, including liver cirrhosis, chronic hepatitis B or C infection, or autoimmune hepatitis; (2) concurrent conditions or treatments known to affect hepatic enzyme levels, including hematological malignancies, active chemotherapy, or use of hepatotoxic medications within the preceding four weeks; (3) confirmed pregnancy at the time of presentation; or (4) absence of serological dengue testing results, which precluded assignment of the primary outcome variables.

Data Collection

Trained research assistants extracted demographic, clinical, and laboratory data from electronic medical records using a pre-designed, standardized data collection instrument. Variables recorded included age (years), sex (male/female), duration of fever at presentation (days), dengue serological results (IgM, IgG, and NS1 antigen), and serum ALT levels (U/L). Secondary dengue infection (D_SI) was defined as concurrent seropositivity for both IgM and IgG antibodies, consistent with established WHO criteria for secondary dengue.

Laboratory Methods

Blood samples were obtained at initial clinical presentation, prior to any therapeutic interventions. Dengue serological testing was performed using commercially validated rapid immunochromatographic assay kits (SD BIOLINE Dengue Duo, Standard Diagnostics Inc., Republic of Korea), which simultaneously detect dengue NS1 antigen, IgM, and IgG antibodies in serum specimens per the manufacturer's protocol. Results were interpreted as positive or negative based on the presence or absence of visible test lines. Serum ALT levels were quantified using standard enzymatic kinetic methods on an automated clinical chemistry analyzer (Cobas 6000, Roche Diagnostics, Switzerland). The institutional normal reference range for ALT was defined as <40 U/L.

Statistical Analysis

All analyses were performed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were reported as mean $\pm$ standard deviation (SD) or median with interquartile range (IQR) based on normality assessed by the Shapiro-Wilk test. Categorical variables were expressed as frequencies and proportions. Between-group ALT comparisons (seropositive vs. seronegative) were performed using independent-samples t-tests or Mann-Whitney U tests, as appropriate.

Missing ALT values (10.6% of the total sample) were addressed by listwise deletion, yielding a complete-case analytical cohort of 1,088 patients. Four separate univariate binary logistic regression models were constructed with ALT as a continuous predictor and each serological outcome (IgM, IgG, NS1, secondary

infection) as the binary dependent variable. Outputs included odds ratios (OR) with 95% confidence intervals (CI), Nagelkerke R², and two-tailed p-values.

Receiver operating characteristic (ROC) curves were generated to evaluate the discriminatory ability of ALT for each outcome, with AUC values and associated 95% CIs and p-values reported. Optimal diagnostic cutoffs were identified using the Youden Index ($J = \text{sensitivity} + \text{specificity} - 1$) to maximize balanced diagnostic performance. For each cutoff, the following metrics were computed: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio (LR-), and overall accuracy. All prevalence-adjusted estimates reflected observed positivity rates within the study cohort. Statistical significance was set at a two-tailed alpha of 0.05.

Results

Patient Characteristics

A total of 1,217 consecutive patients with clinically suspected dengue fever were enrolled. The mean age was 33.2 ± 12.3 years (range: 18–65 years), and 56.1% of participants were male. Patients presented at a median of 4 days (IQR: 3–5 days) after symptom onset. Following exclusion of 129 patients with missing ALT measurements, the final analytical cohort comprised 1,088 patients.

The mean serum ALT was 105.6 ± 135.0 U/L, with a median of 64.1 U/L (IQR: 35.7–124.8; range: 12.0–1,729.4 U/L). The distribution was markedly right-skewed, consistent with the clinical heterogeneity of the sample. Elevated ALT (>40 U/L) was observed in 74.8% of patients with valid measurements, underscoring the high prevalence of hepatic involvement in this cohort.

Dengue Serological Profile

Serological positivity rates among the enrolled cohort were as follows: IgM in 26.5% (322/1,215), IgG in 31.4% (382/1,216), NS1 antigen in 36.8% (448/1,216), and secondary infection (concurrent IgM and IgG positivity) in 14.1% (171/1,217).

ALT Levels by Serological Status

Patients seropositive for IgM, NS1, and secondary infection had significantly higher mean ALT levels compared to seronegative counterparts (Table 1). The difference was most pronounced for IgM positivity (135.7 ± 172.3 vs. 94.7 ± 117.2 U/L; $p < 0.001$) and secondary infection (136.1 ± 152.4 vs. 100.6 ± 130.5 U/L; $p = 0.005$). IgG positivity was not associated with a statistically significant difference in ALT levels (114.8 ± 130.1 vs. 101.5 ± 137.1 U/L; $p = 0.140$).

Table 1. Mean ALT Levels Stratified by Dengue Serological Status

Serological Parameter	ALT: Positive Cases (Mean $\pm$ SD, U/L)	ALT: Negative Cases (Mean $\pm$ SD, U/L)	p-value
IgM	135.7 $\pm$ 172.3	94.7 $\pm$ 117.2	<0.001
IgG	114.8 $\pm$ 130.1	101.5 $\pm$ 137.1	0.140
NS1 Antigen	120.7 $\pm$ 158.2	96.6 $\pm$ 118.0	0.006
Secondary Infection	136.1 $\pm$ 152.4	100.6 $\pm$ 130.5	0.005

ALT: alanine aminotransferase; SD: standard deviation; p-values from independent t-test or Mann-Whitney U test as appropriate.

Logistic Regression Analysis

Univariate binary logistic regression confirmed ALT as a statistically significant, albeit modest, predictor of IgM positivity (OR 1.002, 95% CI 1.001–1.003; Nagelkerke RZ=0.024; $p<0.001$), NS1 antigen positivity (OR 1.001, 95% CI 1.000–1.002; RZ=0.010; $p=0.006$), and secondary infection (OR 1.001, 95% CI 1.000–1.002; RZ=0.012; $p=0.005$). ALT did not significantly predict IgG positivity (OR 1.001, 95% CI 0.999–1.002; RZ=0.003; $p=0.140$). Effect sizes were uniformly small across all models, as reflected by the low Nagelkerke RZ values (≤ 0.024).

ROC Curve Analysis

ROC curve analysis demonstrated poor to fair discriminatory performance for all outcomes (Table 2). The highest AUC was observed for IgM (0.624; $p<0.001$), while IgG yielded an AUC at chance level (0.531; $p=0.103$). NS1 antigen (AUC 0.592; $p<0.001$) and secondary infection (AUC 0.596; $p<0.001$) showed similarly modest discrimination.

Table 2. ROC Curve Analysis: ALT as a Predictor of Dengue Serological Outcomes

Serological Parameter	AUC (95% CI)	p-value
IgM	0.624	<0.001
IgG	0.531	0.103
NS1 Antigen	0.592	<0.001
Secondary Infection	0.596	<0.001

AUC: area under the ROC curve; CI: confidence interval.

Diagnostic Performance at Optimal Cutoffs

Youden Index-derived cutoffs ranged from ≥ 44.4 U/L (NS1) to ≥ 79.5 U/L (IgG and secondary infection). As detailed in Table 3, sensitivities ranged from 45.2% (IgG) to 74.4% (NS1), while specificities ranged from 41.0% (NS1) to 61.5% (IgM). Positive predictive values were universally low (18.9–43.0%), reflecting limited rule-in capacity. In contrast, negative predictive values were consistently higher, peaking at 89.1% for secondary infection, suggesting a potential role for ALT in excluding this outcome when values fall below threshold. Likelihood ratios were modest across all parameters (LR+: 1.16–1.52; LR–: 0.62–0.90), indicating minimal post-test probability shift.

Table 3. Diagnostic Performance of ALT at Youden-Optimized Cutoffs

Parameter	Cutoff f (U/L)	Sens. (%)	Spec. (%)	PP V (%)	NP V (%)	LR+	LR–	Accurac y (%)
IgM	≥73.6	58.4	61.5	35.6	80.2	1.52	0.68	60.7
IgG	≥79.5	45.2	61.0	34.2	71.4	1.16	0.90	56.2
NS1	≥44.4	74.4	41.0	43.0	72.8	1.26	0.62	53.5
Sec. Inf.	≥79.5	54.5	61.3	18.9	89.1	1.41	0.74	60.4

Sens.: sensitivity; Spec.: specificity; PPV: positive predictive value; NPV: negative predictive value; LR+/-: positive/negative likelihood ratio; Sec. Inf.: secondary infection.

Discussion

This large cross-sectional study of over 1,000 adults with suspected dengue in Rawalpindi, Pakistan, demonstrates that elevated ALT is significantly associated with IgM positivity, NS1 antigen detection, and serological evidence of secondary infection, but not with IgG seropositivity alone. Nevertheless, logistic regression revealed small effect sizes (ORs of 1.001–1.002 per U/L increment), low explained variance (Nagelkerke $R^2 \leq 0.024$), and fair to poor ROC curve performance (AUC 0.531–0.624). Diagnostic metrics at Youden-optimized thresholds were characterized by moderate sensitivity, limited specificity, low PPVs, and more clinically relevant NPVs—particularly for ruling out secondary dengue infection (NPV 89.1%).

These findings are consistent with an established literature documenting hepatic transaminase elevation as a near-universal accompaniment of dengue infection, attributable to both direct viral hepatotropism and dysregulated immune responses [10,11]. Prior studies have consistently shown higher ALT concentrations in dengue-confirmed patients compared to controls, with elevations correlating more strongly with disease severity and the critical phase than with discrete serological markers [12,13]. A Vietnamese cohort study similarly reported AUC values of 0.60–0.83 for ALT-based prediction of severe dengue when combined with clinical variables, but predictive performance for individual serological markers—as assessed here—was not specifically evaluated [14].

The absence of a significant ALT-IgG association in our cohort is noteworthy. IgG positivity in dengue typically denotes prior exposure or ongoing secondary infection; in the latter context, hepatic injury may be amplified by antibody-dependent enhancement (ADE) rather than primary viral cytopathic effect, potentially decoupling the ALT-serology relationship [15]. Conversely, the stronger associations observed for IgM and NS1 positivity align with ALT's temporal relationship to acute viremia: both NS1 antigenemia and IgM seroconversion occur during the early acute phase, when hepatic involvement is most active [16].

Regional data from Pakistan support our findings. Iqbal et al. [17] and Nawaz et al. [18] documented elevated ALT in dengue-confirmed patients, primarily advocating its role in severity stratification rather than serological classification, with optimal cutoffs broadly consistent with our thresholds of 44.4–79.5 U/L. The modest likelihood ratios we observed (LR+ 1.16–1.52; LR– 0.62–0.90) are also comparable to those reported in systematic reviews, which highlight the diagnostic challenge posed by ALT's overlap with other febrile conditions and emphasize the superiority of multi-marker models [7,8].

Pediatric studies have reported higher prognostic accuracy for serial ALT measurements during the critical phase (sensitivity 82.5–87.5%; specificity 85.2–87.3%) [8], suggesting that single time-point assessments—as in our study—may underestimate predictive potential. This limitation reinforces the case for longitudinal monitoring designs in future work. Integration of ALT with thrombocytopenia, C-reactive protein, and clinical risk scores has demonstrated substantially improved diagnostic performance in multi-marker models (AUC up to 0.83; PPV up to 93.1%) [11,12], underscoring the complementary rather than standalone role of this biomarker.

In resource-constrained environments such as Pakistan, where rapid dengue serological assays may be intermittently unavailable, ALT—measurable on standard chemistry analyzers—could serve as a low-cost triage adjunct. Its high NPV for secondary infection (89.1%) is particularly actionable: patients with ALT below threshold in clinically equivocal presentations may be de-prioritized for confirmatory serology, conserving limited diagnostic resources. However, the low PPVs preclude its use as a confirmatory test, and reliance on ALT alone without clinical context risks misclassification.

Limitations

Several limitations should be acknowledged. The retrospective design and reliance on medical record review introduce potential selection bias and information bias; the 10.6% rate of missing ALT data, addressed by listwise deletion, may introduce mild bias if data were not missing completely at random. The single-center design in Rawalpindi limits generalizability to other regions with differing dengue serotype distributions or co-circulating infections. ALT was measured at a single time point at presentation, potentially missing peak hepatic involvement during the critical phase. Importantly, the study did not adjust for potential confounders of ALT elevation, including alcohol use, concurrent hepatotoxic medications, or undiagnosed comorbidities. The rapid immunochromatographic assays used for serology, while practical, have lower sensitivity than RT-PCR or ELISA-based methods, and may underestimate true seroprevalence. Finally, this analysis did not incorporate other biomarkers such as AST, platelet count, or clinical severity scores, which future multi-marker studies should address.

Conclusion

Serum ALT demonstrates statistically significant but clinically limited standalone utility in predicting dengue IgM, NS1, and secondary infection seropositivity, and is not associated with IgG status. Discriminatory performance is poor to fair, with modest sensitivity and specificity at optimal thresholds. The most clinically meaningful finding is the high NPV for secondary infection (89.1%), supporting ALT's role as a rule-out adjunct rather than a confirmatory marker. In resource-limited hyperendemic settings, ALT may be integrated into clinical triage algorithms alongside other biomarkers and bedside indicators. Prospective studies incorporating serial ALT measurements, multi-marker panels, and clinical severity grading are needed to refine and validate the diagnostic role of ALT in dengue management.

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504–507.

2. Siregar FA, Sembiring T, Sinambela EM, Tandiono S. Effectiveness of the Integrated Dengue Education and Learning (IDEAL) module in improving dengue prevention knowledge, attitudes, and practices among elementary school students: a quasi-experimental study. *PLoS One*. 2024;19(4):e0302514.
3. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. *Lancet Infect Dis*. 2016;16(8):935–941.
4. Halstead SB. Dengue and dengue hemorrhagic fever. *Clin Microbiol Rev*. 1992;5(2):197–205.
5. Trung DT, Thao le TT, Hien TT, et al. Liver involvement associated with dengue infection in adults in Vietnam. *Am J Trop Med Hyg*. 2010;83(4):774–780.
6. Wong CH, Wu HW, Li J, et al. New biomarkers for liver involvement by dengue infection in adult patients. *Sci Rep*. 2024;14(1):17933.
7. Sangkaew S, Ming D, Boonyasiri A, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. *Lancet Infect Dis*. 2021;21(7):1014–1026.
8. Lovera D, Ledesma S, Araya S, et al. Dengue and liver injury: a multicenter cross-sectional study in Paraguay. [Full citation to be completed per manuscript source].
9. Idrees S, Ashfaq UA. A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan. *Genet Vaccines Ther*. 2012;10(1):6.
10. Chinh NT, Simmons C, Wills B, et al. Dengue in Vietnamese adults: clinical features and predictors of disease severity. *J Clin Virol*. 2007;40(3):277–282.
11. Pan S, Khalil M, Begum R, et al. Multimarker prediction model for dengue severity. *Trop Med Int Health*. 2020;25(8):998–1007.
12. Oktarianti R, Sariyatun R, Widiyati MM. Combination of platelet count and liver function tests for severity prediction in dengue. *Int J Infect Dis*. 2021;108:15–21.
13. Rana M, Ijaz N, Bhatti AB. Liver function derangements in dengue fever. *J Coll Physicians Surg Pak*. 2015;25(2):97–100.
14. Nguyen TH, Nguyen TL, Lei HY, et al. Association between early serological markers and dengue severity: a hospital-based cohort in Vietnam. *PLoS One*. 2013;8(3):e56416.
15. Dhull A, Jain P, Midha V, Mahajan R. Antibody-dependent enhancement in dengue: clinical implications and pathogenesis. *J Clin Diagn Res*. 2018;12(4):OE01–OE04.
16. Abu-Bakar S, Wong PF, Chan YF. A decade of dengue research in Malaysia. *Trop Biomed*. 2007;24(2):1–9.
17. Iqbal A, Ahmad I, Iqbal J. Elevated liver enzymes in dengue fever and their correlation with disease severity in Pakistani patients. *Int J Virol*. 2019;15(3):45–51.
18. Nawaz J, Khan S, Khalid H, Aamir M. Liver function abnormalities in dengue patients from Rawalpindi: implications for triage. *J Pak Med Assoc*. 2020;70(11):2012–2017.